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Abstract
The present studies were performed to investigate the effects of endotoxemia on
glucose and insulin dynamics, and to examine their relationship to laminitis in horses.
The frequently sampled intravenous glucose tolerance test was evaluated and refined for
use in horses. A new FSIGTT was developed, consisting of 100 mg/kg dextrose followed
by 20 mU/kg insulin 20 min later. This new test was used in subsequent experiments to
assess glucose and insulin dynamics while minimizing urine glucose spillover. Serum Cpeptide concentrations were measured in horses to investigate pancreatic function and
this work revealed a decrease in C-peptide-to-insulin ratio after dextrose challenge,
suggesting reduced hepatic insulin extraction. Administration of endotoxin both as an
intravenous bolus and 8-hour continuous rate infusion significantly lowered insulin
sensitivity and increased the acute insulin response to glucose. The effects of resting
insulin sensitivity on the magnitude of insulin resistance induced by endotoxin
administration were subsequently investigated.

Resting insulin sensitivity was

successfully reduced by oral administration of 20 mg dexamethasone, but levothyroxine
sodium failed to improve insulin sensitivity. However, endotoxemia-induced insulin
resistance was ameliorated by pretreatment with levothyroxine sodium. Administration
of endotoxin alone, oligofructose alone, or endotoxin followed by oligofructose resulted
in the development of Obel grade ≥ 2 laminitis in 0/8, 1/8 and 5/8 horses, respectively,
indicating a significant association between endotoxemia and laminitis. In summary,
results show that endotoxemia exerts an adverse effect on glucose and insulin dynamics
and plays an important role in the development of laminitis in horses. Pretreatment with
levothyroxine sodium prevented insulin resistance associated with endotoxemia, so this
treatment warrants further investigation.
Keywords: horse, insulin resistance, endotoxemia, laminitis
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CHAPTER 1
Literature review
1.1

Carbohydrate metabolism – the role of insulin

1.1.1

Carbohydrate digestion:
Carbohydrate (CHO) provides the majority of dietary energy for horses, with

cereal grains, grain by products, and forage being the primary sources (Geor 2006).
Generally, the carbohydrate content of the feed is divided into nonstructural
carbohydrates (NSC) and neutral detergent fiber (NDF; Hoffman et al. 2001). The NSC
content can be calculated using the following equation:
NSC = 100 - (water + ash + fat + crude protein + NDF)
Alternatively, NSC content can be divided into ethanol- and water-soluble CHOs, with
the former containing mono- and di-saccharides and some low molecular weight
oligosaccharides, and the latter comprising mostly fructans and some high molecular
weight oligosaccharides (Virgona and Barlow 1991). Nevertheless, these groups relate
better to ruminant than equine digestive physiology.

Based on the primary site of

digestion in the equine gastrointestinal tract Hoffman et al. (2001) divided the dietary
CHO content into three groups: hydrolysable, rapidly fermented, and slowly fermented
CHOs. Hydrolysable CHOs, including hexoses, disaccharides, oligosaccharides, and
non-resistant starches are digested in the small intestine yielding glucose. If hydrolysable
CHOs are delivered to the hindgut, they undergo rapid fermentation. Digestion of slowly
and rapidly fermented CHOs occurs in the equine hind gut by enzymes secreted by
resident microbes. Rapidly fermented CHOs, comprising resistant starches of galactoand fructo-oligosaccharides, are readily fermented in the large intestine. Hemicellulose,
cellulose and ligno-cellulose form the fraction of slowly fermented CHOs which
primarily produce the volatile fatty acid acetate when fermented in the large intestine
(Geor 2006; Hoffman et al. 2001).

1

Digestion of the hydrolysable CHO content of the feed is catalyzed by enzymes
either acting within the lumen of the gastrointestinal tract or on the surface of mucosal
epithelial cells (Herdt 2002). During the luminal phase of digestion, polysaccharides
leaving the stomach are further metabolized by pancreatic α-amylase in the duodenum
and proximal jejunum. Intraluminal digestion of carbohydrates yields polysaccharides of
intermediate chain length, known as dextrines, which are then further broken down into
maltose and maltotriose. Intraluminal digestion of amylopectin yields α-limit-dextrines
containing α[1-6] linkages that are not hydrolyzed by α-amylase (Herdt 2002). During
the membraneous phase of digestion, substrate-specific enzymes bound to the brush
border of the enterocytes hydrolyze di- and tri-saccharides into monosaccharides
(glucose, galactose, and fructose). Enteral absorption of monosaccharides occurs in two
steps via secondary active transport.

The first step involves the sodium-glucose

transporter (SGLT) 1, which facilitates glucose uptake on the luminal side of the
enterocyte (Bell et al. 1993). The second step occurs at the basolateral membrane where
glucose exits the enterocyte through glucose transporter (GLUT) 2 proteins (Gould and
Bell 1990). The abundance of SGLT1 in the equine small intestine is highest in the
duodenum and then decreases towards the ileum, indicating that the majority of glucose
absorption occurs in the proximal to mid small intestine (Shirazi-Beechey 2008). Horses
on a concentrate diet have a 2 – 5 fold increase in SGLT1 protein expression in the mid
and distal small intestine, compared to horses kept on pasture, which enhances their
ability to absorb monosaccharides (Shirazi-Beechey 2008).
Fructans are a group of fructose oligosaccharides which are produced as storage
CHO in plants (Bailey et al. 2007).

Their general structure consists of a glucose

molecule linked to varying numbers of fructose molecules (van Eps and Pollitt 2006).
Degradation of fructans entering the equine gastrointestinal tract starts with microbial
fermentation and acid hydrolysis within the stomach and small intestine, however, it is
likely that the bulk of fructans reach the hindgut where they undergo microbial
fermentation (Coenen et al. 2006; Longland and Byrd 2006). Absorption of fructose in
the small intestine occurs via facilitated diffusion primarily through GLUT5 molecules
expressed on the brush border membrane of the villus enterocytes (Merediz et al. 2004).
2

Transport of fructose out of the enterocytes across the basolateral membrane occurs via
the facilitative transporter GLUT2 (Drozdowski et al. 2004). Absorbed monosaccharides
then enter the portal system and are transported to the liver (Fonyo 2003).
Degradation of dietary pectin, cellulose, and hemicellulose is mediated by
anaerobic bacteria, protozoa, and fungi present in the equine hindgut (Shirazi-Beechey
2008). Anaerobic metabolism of these fermented CHOs through the Embden-Meyerhoff
pathway leads to the formation of pyruvate and subsequently the volatile fatty acids,
acetate, propionate, and butyrate, as well as the gases carbon dioxide (CO2), methane
(CH4), and hydrogen (Shirazi-Beechey 2008). Under normal circumstances only a small
amount of lactate is formed. Volatile fatty acids are absorbed from the large intestine
through a monocarboxylate/H+ symporter, and supply 45 to 82 % of the absorbed energy
depending on the composition of the diet (Shirazi-Beechey 2008; Vermorel et al. 1997).
Excessive intake of hydrolysable and/or rapidly fermentable CHO may result in
their delivery to the hindgut where they undergo rapid bacterial fermentation (Longland
and Byrd 2006). The presence of large amounts of starch and fructan in the hindgut
facilitates the proliferation of streptococci and lactic acid-producing bacteria (Elliott and
Bailey 2006; Milinovich et al. 2007).

Decreased intraluminal pH, associated with

increased lactic acid production, not only triggers the death of resident Gram-negative
bacteria but also increases the permeability of the wall of the large intestine (Garner et al.
1978; Weiss et al. 2000).

Due to this altered permeability of the large intestine,

endotoxins released upon the death of Gram-negative bacteria, as well as biologically
active amines present in the intestinal lumen, enter the systemic circulation and may
contribute to the development of laminitis (Elliott and Bailey 2006).

1.1.2

Insulin and insulin secretion:
The role of the pancreas in the development of diabetes was first demonstrated by

German scientists Minkowski and Von Mering in 1889 (Wilcox 2005). Three decades
later in 1921, insulin was isolated and experiments were begun in dogs (Wilcox 2005).
In their studies, Banting, Best, and McLeod successfully lowered blood glucose
3

concentrations in dogs that had been rendered diabetic by pancreatectomy by
administering them chilled saline extracts of pancreas. Successful human experiments
were completed in 1922, earning Banting and McLeod the Nobel Prize in 1923 (Wilcox
2005).
Insulin is a protein hormone coded on the short arm of chromosome 11 in
humans, and is produced by the β-cells of the islets of Langerhans within the pancreas
(Wilcox 2005). Insulin is produced as preproinsulin in the ribosomes of the rough
endoplasmic reticulum. Proinsulin is formed following the cleavage of a signal sequence
responsible for the intracellular transport of the molecule. Secretory vesicles transfer
proinsulin into the Golgi apparatus. As immature vesicles form within the Golgi, a
peptide chain referred to as connecting-peptide (C-peptide) is removed from the
proinsulin molecule, transforming it into insulin. Thus, serum C-peptide concentrations
reflect insulin secretion, and unlike insulin, C-peptide undergoes very little first-pass
clearance by the liver after secretion from the pancreas (Johnson et al. 2005). The
structure of insulin consists of two peptide chains connected by disulfide bonds. Six of
these insulin molecules complex with zinc to form insoluble hexamers within mature
granules (Wilcox 2005).
Insulin secretion is modulated by blood concentration of various nutrients, most
importantly glucose (Wilcox 2005). Glucose enters the β-cells via GLUT2 proteins,
which have a low glucose affinity at physiological blood glucose levels (Gould and Bell
1990). Once inside the cell, glucose is phosphorylated by the enzyme glucokinase to
glucose-6-phosphate, which is subsequently oxidized to generate ATP. An increased
intracellular ATP/ADP ratio then results in the closure of ATP-sensitive potassium
channels, causing membrane depolarization, which in turn opens voltage-dependent
calcium channels. Insulin release is stimulated by this increase in intracellular Ca2+
concentration (Bratanova-Tochkova et al. 2002; Wilcox 2005).
Glucose-mediated insulin secretion is augmented by both ATP-sensitive
potassium channel-independent calcium-dependent and ATP-sensitive potassium
channel-independent calcium-independent pathways. Enhanced insulin secretion also
occurs in response to activation of phospholipases and protein kinase C (PKC), triggered
4

by acetylcholine.

Other mediators that facilitate insulin release include vasoactive

intestinal peptide and glucose-dependent insulinotropic polypeptide. These hormones act
through the G-protein coupled mechanisms to activate adenyl cyclase and protein kinase
A (PKA), and thereby potentiate insulin secretion (Bratanova-Tochkova et al. 2002).
Glucagon-like peptide 1 exerts its effect on insulin secretion by inhibiting ATP-sensitive
potassium channels and enhancing currents through voltage-dependent calcium channels
via cAMP/PKA dependent pathways, as well as by inhibiting currents through voltage
dependent K+ channels (MacDonald et al. 2002). Arginine, a positively charged amino
acid that enters the β-cells via cationic amino acid transporters, triggers depolarization of
cell membrane and gating of voltage-dependent calcium channels, causing insulin
excretion (Bratanova-Tochkova et al. 2002; Soria et al. 2004). In contrast, somatostatin
produced by the δ-cells of the islets of Langerhans and catecholamines acting through α2adrenoreceptors inhibit insulin release (Wilcox 2005).
In humans, basal insulin secretion accounts for 50% of total daily insulin
secretion, and 60% of insulin secreted into the portal vein is subsequently removed by the
liver (Wilcox 2005).

In the basal state, insulin secretion into the portal vein is

characteristically pulsatile due to coordinated secretory bursts from islet cells (Porksen et
al. 2002). In cases of type 2 diabetes mellitus (type 2 DM), pulsatile insulin secretion
may be impaired (Porksen et al. 2002). Restoration of oscillatory insulin secretion in
type 2 DM improves insulin action in liver, muscle, and adipose tissues (Porksen et al.
2002). Insulin secretion from the β-cells in response to sustained glucose stimulation is
characteristically biphasic, with the first phase occurring promptly after exposure to
glucose, followed by a decrease to a nadir, and then a prolonged second phase
(Bratanova-Tochkova et al. 2002; Wilcox 2005). The first rapid phase of insulin release
is attributed to the secretion of readily releasable pool of secretory granules (BratanovaTochkova et al. 2002; Soria et al. 2004). The second phase requires the amplifying
action of glucose, increasing the efficacy of Ca2+ on exocytosis of insulin granules
(Henquin et al. 2002), and is preceded by the mobilization of granules from a reserve
pool to the readily releasable pool (Bratanova-Tochkova et al. 2002).
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1.1.3

Insulin signal transduction:
Effects of insulin are mediated by membrane bound insulin receptors. The insulin

receptor is a heterotetrameric membrane glycoprotein containing 2 α and 2 β subunits
linked together by disulfide bonds (Kido et al. 2001). Insulin binding to the extracellular
α subunits results in a conformational change that enables ATP binding to the
intracellular domain of the β subunits, resulting in autophosphorylation, which in turn
triggers its tyrosine kinase activity. In addition to binding insulin, the insulin receptor
also binds insulin-like growth factor (IGF; Kido et al. 2001).
Signal transduction through the insulin receptor can be divided into
phosphatidylinositol 3 (PI3)-kinase dependent and independent pathways (Chang et al.
2004; Kido et al. 2001; Watson and Pessin 2001). In the PI3-kinase dependent pathway,
the autophosphorylated insulin receptor phosphorylates intracellular substrate proteins
known as insulin receptor substrates (IRS). There are four closely related members of
the IRS family and a more distantly related homolog, Gab-1 (Kido et al. 2001). Tyrosine
phosphorylation of IRS-1 can be mediated by the receptors of insulin and IGF-1 (Withers
and White 2000). Insulin receptor substrate-1 is most abundantly expressed in skeletal
muscle and primarily mediates mitogenic effects and insulin-stimulated peripheral
glucose uptake (Kido et al. 2001; Withers and White 2000). Deletion of IRS-1 in mice
leads to significant growth retardation, a twofold increase in β-cell mass, and an 80
percent decrease in the response to insulin in muscle (Burks and White 2001). However,
only mild insulin resistance is detected and insulin signaling within the liver remains
close to normal (Burks and White 2001). The relatively normal glucose homeostasis
exhibited by IRS-1 knockout mice may be due to compensatory hyperinsulinemia and to
the near normal response to insulin in the liver, primarily mediated by IRS-2 (Burks and
White 2001).
In addition to its important role in the liver, IRS-2 is also important for the normal
growth of pancreatic β-cells (Kido et al. 2001). Insulin receptor substrate-2 knockout
mice show profound insulin resistance primarily affecting the liver, and their β-cell mass
is approximately 50% lower compared to healthy controls (Burks and White 2001).
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Carbohydrate metabolism is significantly altered in these animals. In IRS-2 knockout
mice, the inhibitory effect of insulin on hepatic gluconeogenesis is weak and the
glycogen content of the liver is low, but insulin action in skeletal muscle and adipose
tissue remains close to normal (Burks and White 2001). Mice deficient in IRS-2 become
overtly diabetic by 12 weeks of age, and if untreated, die from dehydration and
hyperosmolar coma (Burks and White 2001).
Insulin receptor substrate-3 is located within adipose tissue, β-cells, and the brain,
whereas IRS-4 is found in thymus, brain, and kidney (Withers and White 2000). Insulin
receptor substrates 3 and 4 appear to play redundant roles in the IRS signaling system
(Sesti et al. 2001). In adipocytes obtained from IRS-1 knockout mice, approximately
50% of GLUT4 translocation was preserved by a signaling pathway involving IRS-3
(Sesti et al. 2001).

In vivo studies found no major physiologic role of IRS-4 in

controlling growth or metabolism in mice (Sesti et al. 2001).
The carboxy (COOH) terminus of each IRS protein contains a set of tyrosine
phosphorylation sites that regulate different downstream signaling proteins. Each site
binds and activates specific effector proteins including adapter proteins and enzymes,
such as PI3-kinase (Withers and White 2000). The p85 regulatory subunit of PI3-kinase
recognizes the phosphorylated insulin receptor substrate molecules and brings the p110
catalytic subunit of the heterodimer enzyme to the vicinity of its physiological substrate,
phosphatidylinositol (4,5) bisphosphate (Lizcano and Alessi 2002; Shepherd and Kahn
1999). Phosphatidylinositol (4,5) bisphosphate is subsequently phosphorylated in the D3
position generating phosphatidylinositol (3,4,5) trisphosphate (PIP3; Lizcano and Alessi
2002). A key effector of PIP3 is protein kinase B (PKB), which is also known as Akt
(Lizcano and Alessi 2002). PIP3 mediated recruitment of PKB from the cytosol brings it
closer to another protein kinase termed phosphoinositide-dependent protein kinase-1
which contributes to the activation of PKB (Lizcano and Alessi 2002; Watson and Pessin
2001).

Protein kinase B phosphorylates and thereby inactivates glycogen synthase

kinase-3 (GSK3; Lizcano and Alessi 2002). Inactivation of GSK3 leads to disinhibition
of glycogen synthase. Insulin-mediated glycogen synthesis is therefore facilitated by the
activation of PKB. Protein kinase B also phosphorylates cyclic AMP phosphodiesterase7

3-B (PDE3B) and the increased activity of this enzyme lowers intracellular cAMP
concentrations within adipocytes, which prevents the activation of PKA. In the absence
of active PKA, hormone sensitive lipase remains inactive, which therefore explains the
inhibitory effect of insulin on lipolysis (Salway 2004).

Atypical protein kinase C

(PKCζ/λ) is also activated by phosphoinositide-dependent protein kinase-1, downstream
of PI 3-kinase (Chang et al. 2004).
A PI3-kinase independent insulin signaling pathway also exists within cells. This
pathway is localized in lipid raft microdomains, which are specialized regions of the
plasma membrane (Chang et al. 2004). Activation of the insulin receptor in these plasma
membrane subdomains leads to the recruitment and phosphorylation of the adaptor
protein called associated protein substrate (APS), which in turn facilitates the
phosphorylation of the proto-oncogene Cbl (Chang et al. 2004). Next, the Cbl associated
protein (CAP) is recruited with Cbl to the insulin receptor:APS complex (Chang et al.
2004). At this point, the CAP-Cbl complex dissociates from the insulin receptor:APS
complex and interacts with the lipid raft domain protein, flotillin (Chang et al. 2004).
Tyrosine-phosphorylated Cbl then interacts with CrkII, a protein constitutively associated
with C3G, resulting in their translocation to the lipid raft (Chang et al. 2004). Upon its
translocation to lipid raft, C3G can catalyze the activation of the small G-proteins TC10α
and TC10β, which triggers GLUT4 translocation through interaction with a number of
potential effector molecules (Chang et al. 2004).
Recruitment of PKCζ/λ, an enzyme downstream of PI3-kinase, to lipid rafts in a
TC10-dependent manner, represents a point of convergence for the PI3-kinase dependent
and PI3-kinase independent pathways (Chang et al. 2004).
The mitogen activated protein kinase (MAPK; also known as extracellular signalregulated kinase) cascade is also involved in the insulin signal transduction (Saltiel and
Kahn 2001). This pathway involves the tyrosine phosphorylation of IRS proteins which
subsequently interact with the adapter protein Grb2, recruiting the Son-of-sevenless
exchange protein to the plasma membrane for activation of Ras.

After its Son-of-

sevenless-mediated activation, Ras operates as a molecular switch stimulating stepwise
activation of Raf, mitogen activated protein kinase kinase, and MAPK. Activated MAPK
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translocates to the nucleus, where it catalyses the phosphorylation of transcription factors
initiating cellular differentiation or proliferation (Saltiel and Kahn 2001).

A src-

homology-2 domain containing protein called SHC, which is another substrate of the
insulin receptor, is also capable of activating the Ras/MAPK pathway through the adapter
protein Grb2, independent of IRS-1 (Figure 1.1; Bevan 2001).
Shortly after insulin binding, the insulin receptor-insulin complex is internalized
into endosomes (Bertacca et al. 2007; Bevan 2001). The endocytosis of the activated
receptor-insulin complex enables phosphorylation of substrate molecules that are
spatially distinct from those accessible at the plasma membrane (Bevan 2001).
Acidification of the endosomal lumen results in the dissociation and degradation of
insulin from the insulin receptor (Bevan 2001). This loss of the ligand receptor complex
attenuates any further insulin receptor rephosphorylation (Bevan 2001). The receptor is
recycled back to the plasma membrane (Bertacca et al. 2007), while the insulin is
degraded by the endosomal acidic insulinase (Bevan 2001). Tyrosine phosphatases also
play an important role in termination of the signal generated by insulin by
dephosphorylating the insulin receptor and its targets (Kido et al. 2001). Mice lacking
protein tyrosine phosphatase 1b have significantly enhanced insulin-stimulated whole
body glucose disposal. Interestingly, increased insulin sensitivity in these mice was
found to be tissue specific, occurring mainly in skeletal muscle (Klaman et al. 2000).
The insulin signaling pathway has a negative feed-back loop, which is activated
by insulin and involved in the inhibition or termination of the metabolic branch of the
insulin receptor pathway (Ye 2007). Inducible Ser/Thr phosphorylation of IRS-1 leads to
the inhibition of IRS-1 function and also contributes to the development of insulin
resistance (Ye 2007). Several of the serine kinases capable of inhibiting IRS-1 are
activated by insulin, including PI3-kinase, MAPK, PKB, and PKC, forming the negative
feedback loop in the insulin receptor signaling pathway (Ye 2007).
Insulin-stimulated glucose uptake is mediated by translocation of GLUT4 from
the intracellular pool to the plasma membrane (Kido et al. 2001). A synaptic vesicle
model has been proposed to explain how GLUT4 molecules dock and fuse with the
plasma membrane (Kido et al. 2001).
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Figure 1.1 – Signal transduction in insulin action. The insulin receptor is a tyrosine
kinase which undergoes autophosphorylation after ligand binding and catalyzes
phosphorylation of cellular proteins eventually resulting in alterations in glucose
transport, gene expression and metabolic pathways.
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1.1.4

Glucose transporters:
Since glucose does not diffuse readily through plasma membrane, its entry into

cells is carried out by proteins belonging to two distinct molecular families (Shepherd
and Kahn 1999). Energy independent transport of glucose is mediated by members of
facilitative glucose transporter family of glucose carriers (Gould and Holman 1993).
This type of glucose transport is saturable, bidirectional, and stereoselective (Bell et al.
1993). The second family is represented by the sodium-linked glucose transporters,
which are largely restricted to the kidneys and intestines (Shepherd and Kahn 1999).
They utilize the electromechanical Na2+ gradient to actively transport glucose and
galactose against their concentration gradient (Bell et al. 1993).
The current model of GLUT proteins includes 12 membrane-spanning α-helical
segments, connected by short, hydrophilic chains of 7 to 14 amino acids, with a large
intracellular loop connecting transmembrane segments 6 and 7 (Bell et al. 1993). The 12
α-helices are combined to form a central aqueous pore, with up to 8 of the 12 helices
contributing to parts of the surface lining of the pore (Manolescu et al. 2007). Both the
COOH and amino (NH2) terminals of the molecule are located on the intracellular side of
the plasma membrane. The NH2 half of the protein appears to have a role in correctly
inserting the molecule into the plasma membrane, while the COOH terminus is involved
in sugar transport itself (Bell et al. 1993). It is currently thought that glucose transport
occurs by a mechanism in which the transporter alternates between two conformational
states, with the substrate-binding site facing in either an extracellular or intracellular
direction (Bell et al. 1993). It is believed that GLUT1 exists in tetramers increasing its
catalytic activity 2-8 fold (Bell et al. 1993). Recent sequencing of the human genome
identified 14 members of the solute carrier family 2 (SLC2) genes, which are known to
encode GLUT proteins (Manolescu et al. 2007). Sequence alignments indicate that the
14 GLUT proteins encoded by these genes can be clustered into three families or
subclasses I, II, and III (Manolescu et al. 2007).
Glucose transporter 1 is the erythrocyte type glucose transporter. It is an integral
membrane protein that can be found in erythrocytes, fetal tissues, kidney, liver, colon,
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and brain (Fonyo 2003). This transporter is also expressed in most cultured cells (Gould
and Bell 1990; Gould and Holman 1993).
Glucose transporter 2 is preferentially expressed in the liver, on the basolateral
membrane surface of kidneys and small intestinal epithelia, and in the insulin-producing
β-cells of the pancreas (Bell et al. 1993; Gould and Bell 1990). This glucose transporter
has a high Kmax value of 42 mmol/L for glucose (Shepherd and Kahn 1999), providing a
rationale for its localization to those tissues that are involved in the net release of glucose
during fasting (liver), glucose sensing (β-cells of the pancreas), and transepithelial
transport of glucose (kidney and small intestine; Gould and Holman 1993). The high
Kmax of GLUT2 prevents its saturation at physiological glucose concentrations, therefore
glucose

flux

through

GLUT2

changes

in

an

almost

linear

fashion

with

intracellular/extracellular glucose concentrations (Gould and Holman 1993).
Messenger RNA coding the glucose transporter 3 has been found in most tissues,
but is most abundant in kidney, brain, placenta, and platelets (Gould and Bell 1990;
Heijnen et al. 1997). Using immunocytochemical methods, GLUT3 has been localized to
the α-granule membrane in resting platelets, and it is from this location that it moves to
the cell surface following thrombin stimulation (Heijnen et al. 1997). Elevated GLUT3
mRNA levels have also been detected in the hippocampus of diabetic rats, likely
representing a compensatory mechanism to increase glucose utilization during diabetes
(Reagan et al. 1999).
Adipose tissue and muscle possess a unique, insulin-sensitive glucose transporter
designated as GLUT4 (Gould and Holman 1993). Immunoblot analysis has been used to
characterize GLUT4 protein in equine skeletal and cardiac muscle suggesting a mean
theoretical value of 53.3 ± 0.5 kDa for equine GLUT4 (Lacombe et al. 2003). Further
investigation revealed that the molecule contains 509 amino acids, which are coded by a
DNA segment measuring 1,623 base pairs in length, including 1530 base pairs of open
reading frame (Jose-Cunilleras et al. 2005). Glucose transporter 4 protein expression was
demonstrated to be higher in equine skeletal muscle fiber type 2B than in types 1 or 2A
using indirect immunofluorescence assays (van Dam et al. 2004). Insulin facilitates
translocation of GLUT4 from the intracellular pools to the cell membrane in adipose and
12

muscle tissue, thereby increasing glucose uptake across the plasma membrane within
minutes (Gould and Bell 1990). Interestingly, insulin also causes a 3-fold increase in the
number of GLUT1 molecules on the surface of adipocytes (Gould and Bell 1990).
Studies examining rats made diabetic by streptozocin treatment have shown significant
reduction in GLUT4 mRNA within muscle tissue and adipocytes, suggesting that insulin
not only plays a role in the translocation of GLUT4 from the intracellular pools to the cell
membrane, but also influences GLUT4 synthesis (Garvey et al. 1989).
In skeletal muscle, both insulin stimulation and increased muscle activity cause
translocation of GLUT4 from the intracellular pool to the cell surface, with the exercisesensitive pool associated with an endosomal transferrin receptor (van Dam et al. 2004).
Indeed, two distinct pools of GLUT4 molecules have been identified in rat skeletal
muscle (Aledo et al. 1997). One fraction is highly enriched with transferrin receptor and
annexin II, characteristic for the early endosome compartment, whereas the other fraction
is proven to be insulin sensitive (Aledo et al. 1997). In rats, exercise not only enhances
GLUT4 translocation but also influences GLUT4 expression at both the transcriptional
and translational level (Dohm 2002). Skeletal muscle GLUT4 gene expression was also
found to be increased in horses following exercise (Jose-Cunilleras et al. 2005; Lacombe
et al. 2003). Conversely, McCutcheon et al. (2002) demonstrated no significant change
in equine skeletal muscle GLUT4 content in samples collected from horses within 2
minutes after cessation of exercise. Ingestion of starch-rich meals did not influence
GLUT4 gene expression in horses compared with the consumption of isocaloric fiberrich meals or feed withdrawal following exercise (Jose-Cunilleras et al. 2005).
Administration of dexamethasone also failed to induce a significant change in equine
skeletal muscle GLUT4 protein content (Tiley et al. 2008).
Glucose transporter 5 is expressed at high levels in human small intestine(Gould
and Bell 1990), and plays an important role in fructose transport (Manolescu et al. 2007;
Merediz et al. 2004). This protein has a 42%, 40%, 39% and 42% homology with
glucose transporters 1, 2, 3, and 4, respectively (Gould and Bell 1990). In the equine
small intestine, GLUT5 is expressed on the brush-border membrane of the villous
enterocytes with its levels decreasing from the duodenum towards the ileum (Merediz et
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al. 2004). The presence of GLUT5 in the equine small intestine suggests the capacity of
equine small intestine to absorb fructose.

Kinetic studies suggest that the GLUT5

molecules are low affinity and high capacity transporters (Merediz et al. 2004).
Glucose transporter 6 mRNA is principally expressed in the spleen, brain, and
peripheral leukocytes and appears to be a low affinity facilitator (Joost and Thorens
2001). Both glucose and fructose are proposed substrates for glucose transporter 7,
which is primarily expressed in the apical membrane of the enterocytes of the small
intestine and colon, although its mRNA has been detected in the testes and prostate as
well (Cheeseman 2008).
Glucose transporter 8 (formerly designated as GLUTX1), like GLUT6, belongs to
the class III sugar transport facilitators because it contains the characteristic glycosylation
motif in loop 9 (Joost and Thorens 2001). It is expressed in the heart, skeletal muscle,
brain, spleen, prostate and intestine, with the highest level of expression in the testis (Kim
and Moley 2007).

Expression of GLUT8 has also been demonstrated to play an

important role in blastocyst survival (Kim and Moley 2007).
Glucose transporter 9 is a high affinity glucose transporter which also transports
fructose (Kim and Moley 2007). Human GLUT9 is expressed in the kidney, liver, heart
and adrenal gland. In mice, GLUT9 has two splice variants: GLUT9a, which is a long
form that has 12 transmembrane segments, and GLUT9b that has a deletion resulting in
the loss of 2 transmembrane spanning domains (Kim and Moley 2007).
Both GLUT10 and GLUT11 were identified using homology-based searches of
expressed sequence tag databases (Doege et al. 2001; McVie-Wylie et al. 2001).
Northern blot analysis revealed that GLUT10 is expressed at the highest levels in the
liver and pancreas, and a lower level of expression was detected in heart, brain, placenta,
lung, skeletal muscle and kidneys (McVie-Wylie et al. 2001). Glucose transporter 11 has
also been detected exclusively within heart and skeletal muscle in humans. It appears to
transfer fructose with comparable affinity for glucose, which is consistent with its
sequence similarity to GLUT5 (Doege et al. 2001).
A novel glucose transporter-like protein, GLUT12, was found in MCF-7 breast
cancer cells (Rogers et al. 2002). Immunoblotting also demonstrated its presence in
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adipose tissue, skeletal muscle, and small intestine (Rogers et al. 2002). It was located
inside the cell in the perinuclear region in the absence of insulin, suggesting that it may
play a role in insulin-mediated glucose uptake (Rogers et al. 2002).
The only glucose transporter demonstrated to use a proton gradient to energize the
movement of substrate is the GLUT13 (H+/myoinositol transporter), which is a proton
coupled myo-inositol transporter (Manolescu et al. 2007).

Glucose transporter 14

appears to have resulted from a gene duplication of GLUT3 (Manolescu et al. 2007; Wu
and Freeze 2002). It has two alternatively spliced forms, which are both specifically
expressed in the testes. The mRNA level of GLUT14 in testicular tissue is approximately
four times higher than that of GLUT3 (Wu and Freeze 2002).

1.1.5

Physiologic role of insulin:
Insulin is of paramount importance in controlling metabolism by regulating

cellular energy supply, macronutrient homeostasis, and anabolic processes (Wilcox
2005).

At the cellular level, insulin influences carbohydrate, lipid, and amino acid

metabolism as well as mRNA transcription and translation. Insulin exerts its action in
concert with other counter regulatory hormones that influence metabolism, including
glucagon, glucocorticoids, and catecholamines.

Insulin-mediated growth hormone

secretion also helps to prevent insulin-induced hypoglycemia (Wilcox 2005).
Insulin profoundly influences glucose uptake into skeletal muscle by facilitating
GLUT4 translocation to the sarcolemma from intracellular pools (Shepherd and Kahn
1999). Muscle tissue accounts for 60 to 70 % of insulin-mediated whole body glucose
disposal (Fonyo 2003). In the fed state, insulin activates glycogen synthase and promotes
glycogen synthesis, while also suppressing catabolic processes and maintaining muscle
mass (Fonyo 2003; Wilcox 2005). In skeletal muscle, GLUT4 translocation into the
plasmalemma is also facilitated by exercise (van Dam et al. 2004).
Basal glucose uptake of adipose tissue is mediated via GLUT1, whereas insulinmediated glucose transport occurs via both GLUT1 and GLUT4 molecules (Tafuri 1996).
In rat adipose tissue, insulin produces an approximately 20- to 30-fold increase in glucose
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uptake, whereas in human adipocytes only a 2- to 4-fold increase is demonstrated (Gould
and Holman 1993). It has been estimated that adipose tissue accounts for 10 % of
insulin-stimulated whole body glucose disposal (Wilcox 2005). Insulin also increases fat
stores by promoting lipid synthesis and inhibiting lipolysis (Saltiel and Kahn 2001).
Insulin-mediated glucose uptake and the presence of free fatty acids (FFA) are both
necessary for triglyceride (TG) synthesis in adipose tissue. The most available source of
FFAs is triglyceride carried within lipoproteins that is metabolized by lipoprotein lipase
(LPL) bound to the endothelial surface of capillaries (Adam 2004). Insulin stimulates
gene transcription and synthesis of LPL in adipocytes (Salway 2004).

Insulin also

enhances the activity of enzymes involved in lipogenesis within adipose tissues,
including pyruvate dehydrogenase, fatty acid synthase, and acetyl-CoA-carboxylase
(Saltiel and Kahn 2001). Protein kinase A-mediated activation of hormone sensitive
lipase, and therefore lipolysis, is inhibited by insulin (Fonyo 2003; Saltiel and Kahn
2001; Wilcox 2005). This occurs through insulin-mediated activation of PDE3B and
lowers intracellular cAMP levels, which prevents the activation of PKA (Salway 2004).
One of the most important effects of insulin is to control glucose homeostasis by
regulating metabolic processes in the liver (Guyton and Hall 2006).

Although

hepatocellular glucose transport occurs via insulin-independent GLUT2 molecules
(Wilcox 2005) insulin still increases hepatic glucose uptake by facilitating intracellular
glucose trapping through glucokinase-mediated phosphorylation (Guyton and Hall 2006).
Insulin inhibits the production and release of glucose by blocking gluconeogenesis and
glycogenolysis within the liver (Saltiel and Kahn 2001). Transcription of gluconeogenic
genes encoding phosphoenolpyruvate-carboxykinase, fructose 1,6-bisphosphatase, and
glucose 6-phosphatase are reduced under the influence of insulin (Salway 2004). Insulin
also inhibits glycogenolysis by interfering with the PKA-mediated activation of glycogen
phosphorylase (Salway 2004).

Insulin generated signals are also important in the

activation of the enzyme protein phosphatase-1G, which is capable of dephosphorylating,
and thereby activating, the enzyme glycogen synthase.

This facilitates glycogen

synthesis (Salway 2004).
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Insulin administration has also been shown to stimulate glycolysis by increasing
the rate of pyruvate kinase synthesis in the liver (Miyanaga et al. 1982). The ketone
bodies β-hydroxy-butyrate and acetic acid are synthesized from FFAs in the liver. Insulin
prevents ketogenesis by lowering the amount of available FFAs (Fonyo 2003).
Mitogenic effects of insulin and growth hormone are mediated by hepatic production of
IGFs (Wilcox 2005).
Insulin deficiency is permissive of protein catabolism, releasing amino acids
which are subsequently utilized for gluconeogenesis (Wilcox 2005). Insulin is anabolic
in conjunction with IGF-1 in the presence of amino acids by modulating the
phosphorylation status of intermediates in the protein synthetic pathway (Wilcox 2005).
In addition to its essential metabolic actions, insulin has important vascular
actions as well. It stimulates the production of nitric oxide (NO) via the PI3-kinasedependent pathway in endothelial cells leading to vasodilatation and increased blood flow
(Kim et al. 2006). Insulin also facilitates the secretion of the vasoconstrictor endothelin1 (ET-1) from endothelia (Kim et al. 2006). Effects of insulin on the vascular system are
discussed in greater detail below.
Although neuronal glucose uptake is not dependent upon insulin, the hormone
acts as a neuropeptide, and insulin is involved in satiety and the regulation of appetite
(Wilcox 2005).

In the anterior pituitary gland, insulin stimulates growth hormone

secretion, which in turn promotes IGF-1 production by the liver (Wilcox 2005).

1.1.6

Insulin resistance:
Insulin resistance (IR) is defined as a state in which normal concentrations of

insulin fail to elicit the expected physiological response (Hoffman et al. 2003; Kahn
1978). Insulin sensitivity is influenced by certain physiological and pathological factors
such as diet. Consumption of a diet rich in sugar and starch lowered insulin sensitivity in
Thoroughbred geldings, compared to a diet containing primarily fat and fiber (Hoffman
et al. 2003). In men, glucose, fatty acids, and dietary fiber are all known to upregulate
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glucagon-like peptide 1 and by doing so improve insulin sensitivity (MacDonald et al.
2002).
Pregnancy is another physiologic factor associated with insulin resistance (Butte
2000). In women, insulin action is 50-70% lower than normal during late pregnancy, and
both basal and 24h mean insulin concentrations show a two-fold increase (Butte 2000).
Postprandial glucose concentration, basal endogenous hepatic glucose production, and
total gluconeogenesis are also increased during late pregnancy. These alterations are
most likely due to the rising concentrations of prolactin, cortisol, and glucagon that serve
to ensure continuous delivery of nutrients to the growing fetus (Butte 2000).
Hyperinsulinemia, enhanced β-cell sensitivity to endogenous and exogenous glucose,
increased degradation of insulin and decreased insulin sensitivity have also been
demonstrated in pregnant mares (Fowden et al. 1984).
Stressors activating the hypothalamus-pituitary-adrenal axis cause increased
secretion of counter-regulatory hormones such as catecholamines and glucocorticoids,
resulting in decreased insulin sensitivity (Rosmond 2005). Conditions associated with
elevated glucocorticoid levels are characterized by increased glucose production in the
liver and decreased peripheral glucose transport and utilization, leading to IR (Ruzzin et
al. 2005; Saad et al. 1993). A study performed on rat skeletal muscle revealed that
dexamethasone treatment lowered insulin-stimulated glucose uptake, glycogen synthesis,
and glycogen synthase fractional activity (Ruzzin et al. 2005). It was also demonstrated
that chronic dexamethasone treatment impairs insulin-mediated PKB activation, so the
enzyme is unable to inactivate GSK3 via phosphorylation. Glycogen synthase kinase-3,
in its active form, phosphorylates and thereby inactivates glycogen synthase, interfering
with glycogen synthesis (Ruzzin et al. 2005). The authors speculated that the decreased
PKB activity is due to a dexamethasone-mediated increase in the expression of the p85α
subunit of the upstream enzyme PI3-kinase, which may act as a competitive antagonist of
the p85α-p110 heterodimer in IRS-1 binding (Ruzzin et al. 2005).
Another study identified lower activity of PI3-kinase in rat liver and skeletal
muscle following dexamethasone administration (Saad et al. 1993). Pretreatment with
glucocorticoids decreased insulin-stimulated glucose uptake in rat adipocytes, but uptake
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was restored by preincubation with conventional PKC inhibitors (Kawai et al. 2002).
These results indicate that PKC plays an important role in glucocorticoid-induced IR.
Using the minimal model analysis of the frequently sampled intravenous glucose
tolerance test (FSIGTT), Tiley et al. (2007) established that insulin sensitivity decreases
in horses receiving 0.08 mg/kg bodyweight (bwt) dexamethasone intravenously every
other day for 3 weeks.
Epinephrine was demonstrated to raise plasma glucose concentrations in humans
by reducing peripheral glucose clearance and increasing hepatic glucose production via
gluconeogenesis or glycogenolysis (Nonogaki 2000; Vicini et al. 2002). Epinephrine, but
not norepinephrine, also inhibits insulin-stimulated glucose uptake in skeletal muscle
(Nonogaki 2000). An in vivo study of human subjects revealed that elevated epinephrine
concentrations significantly delay the inhibitory action of insulin on hepatic glucose
production without influencing the maximal inhibitory effect of insulin (Vicini et al.
2002). Similarly, physiologic epinephrine concentrations were demonstrated to reduce
muscle glucose uptake activated by a moderate, but not high, physiological insulin
concentration through the suppression of IRS-1 associated PI3-kinase activation (Hunt
and Ivy 2002).

Endocrinopathies, such as pheochromocytomas and pituitary pars

intermedia dysfunction (PPID) have also been associated with IR in horses (Cefalu 2001;
Garcia and Beech 1986).
There are several pathologic processes associated with reduced insulin sensitivity.
In humans, obesity and IR are significantly related (Garca-Estevez et al. 2004). The
degree of IR increases along with increasing body mass index (BMI; Garca-Estevez et al.
2004). However, the decrease in insulin sensitivity was blunted above a BMI value of 30
kg × m-2 (Garca-Estevez et al. 2004; Kern et al. 2001). Chronic, low grade inflammation
associated with obesity is an important factor in the development of decreased insulin
sensitivity (de Luca and Olefsky 2008). Increased tumor necrosis factor α (TNFα)
secretion by adipocytes and higher circulating plasma interleukin (IL)-6 levels were
demonstrated in obese subjects (Kern et al. 2001).

Both of these factors were

significantly associated with IR, and therefore implicated in its development (Kern et al.
2001).

Tumor necrosis factor α lowers insulin sensitivity by enhancing lipolysis
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(Trayhurn and Wood 2005), by decreasing LPL activity (Kern et al. 1995), and by
inhibiting insulin receptor signaling within adipocytes (Borst 2007). Impaired insulin
signaling and increased hepatic glucose production have been demonstrated in
association with IL-6 (Borst 2007). Resistin, an adipokine expressed predominantly in
adipose tissue, provides another link between obesity and IR (Shuldiner et al. 2001). In
obese, insulin-resistant mice, injection of antibodies raised against resistin decreased
blood glucose concentrations and improved insulin sensitivity (Shuldiner et al. 2001).
Leptin, a different adipokine secreted by adipocytes, exerts its effect through activation of
leptin receptors in the hypothalamus (Borst 2007). The primary role of leptin is to
decrease food intake and increase energy expenditure through uncoupling proteins,
present in mitochondria. Leptin is also an insulin sensitizing hormone, therefore reduced
leptin responsiveness associated with obesity is likely to contribute to the development of
insulin resistance (Borst 2007).

Adiponectin, a hormone produced exclusively by

adipocytes also enhances insulin sensitivity, but in contrast to leptin, its concentration is
low in obese people and increases after weight loss (Borst 2007).
Elevated FFA concentrations contribute to IR in people by hampering glycogen
synthesis in skeletal muscle via inhibition of transmembrane glucose transport (Shulman
2004). It was demonstrated that the FFA-mediated decrease in transmembrane glucose
transport is associated with abolished insulin-stimulated, IRS-1-associated PI3-kinase
activity (Shulman 2004). It is hypothesized that increased amounts of fatty acid-derived
metabolites (e.g. fatty acyl-CoA, diacylglycerol) activate PKC leading to inhibition of
IRS-1 by Ser/Thr phosphorylation (Shulman 2004). Additionally, elevated plasma FFA
concentrations have also been shown to cause IR by increasing insulin concentrations
within the blood (Ye 2007). There are three proposed mechanisms explaining FFAmediated beta cell activation. The G-protein coupled receptor 40 is a molecule that is
abundantly expressed on the surface of pancreatic beta cells and is capable of amplifying
the glucose signal, which enhances insulin secretion.

This occurs when G-protein

coupled receptor 40 is activated by its ligand, long-chain fatty acids. Derivates of FFAs
such as long chain acyl-CoA and malonyl CoA may directly promote the beta cell
response as well. Finally, FFA activates G-protein coupled receptor 120 in the intestinal
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tract, stimulating glucagon-like peptide 1 secretion which in turn enhances insulin release
(Ye 2007).

Chronic hyperinsulinemia induces IR primarily involving the glycogen

synthetic pathway and by increasing lipogenesis (Koopmans et al. 1999).

Indeed,

induction of chronic, physiologic hyperinsulinemia in rats resulted in an impairment of
insulin’s ability to suppress plasma FFA levels, as well as reduced whole body insulin
mediated glucose uptake by 38% (Koopmans et al. 1999).
Defective muscle glycogen synthesis is also important in the development of IR
(Shulman 2004). In skeletal muscle, control of glucose uptake is distributed among three
steps: delivery, transmembrane transport, and phosphorylation of glucose (Wasserman
and Ayala 2005). Exercise facilitates muscle glucose uptake by modulating all three
steps of the control mechanisms.

Exercise and insulin not only stimulate GLUT4

translocation to the sarcolemma, but also cause marked hyperemia and capillary
recruitment in muscle, thereby facilitating glucose delivery. Additionally, both insulin
and exercise have been suggested to increase the rate of intracellular glucose
phosphorylation by causing hexokinase to bind to mitochondria, providing it easy access
to ATP, a substrate necessary for the glucose-6-phosphate synthesis.

Disturbances

affecting any of these three steps of muscle glucose uptake could result in the
development of IR (Wasserman and Ayala 2005).

Using magnetic resonance

spectroscopy, Shulman et al. (2004), demonstrated that the insulin-stimulated change in
intracellular concentration of glucose-6-phosphate, an intermediate metabolite between
glucose transport and glycogen synthesis, is blunted in human patients with type 2 DM.
This observation suggests that either decreased glucose transport or decreased hexokinase
activity is the cause of IR within the skeletal muscle of these patients.

Further

experiments performed in humans with type 2 DM have revealed that intracellular
glucose concentrations are far lower than would be expected if hexokinase were the
primary rate-limiting enzymatic step for insulin-mediated glycogen synthesis (Shulman
2004). Therefore, it appears that impaired insulin-mediated glucose uptake plays the
central role in the defective muscle glycogen synthesis in cases of type 2 DM.
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1.1.7

IR in Horses
Horses and ponies are affected by IR with obesity being one of the most important

predisposing factors for this condition (Frank et al. 2006; Hoffman et al. 2003; Jeffcott et
al. 1986).

Oral glucose tolerance tests revealed impaired glucose tolerance and

hyperinsulinemia in ponies that were obese or had previously suffered from laminitis
(Jeffcott et al. 1986). The presence of IR was confirmed by the failure of exogenous
insulin to lower serum glucose concentrations when these animals were compared with
healthy nonobese ponies and Standardbred horses (Jeffcott et al. 1986). Similarly, a
study by Powell et al. (2002) demonstrated that horses with a body condition score <5
were less insulin resistant than horses with a body condition score >8. Decreased insulin
sensitivity was also detected in obese Thoroughbred geldings when compared to their
nonobese counterparts (Hoffman et al. 2003). Resting insulin concentrations and leptin
levels, along with plasma VLDL, HDL-cholesterol, and nonesterified fatty acid
concentrations were significantly elevated in obese horses with IR compared to their
healthy counterparts (Frank et al. 2006). In this study, insulin resistance was defined as
maintenance of plasma glucose concentrations above the pre-injection concentration for ≥
45 minutes during a combined glucose-insulin test (Frank et al. 2006). The same study
revealed that neck circumference, as well as resting insulin and leptin concentrations,
were helpful in identifying horses with IR (Frank et al. 2006). In another study of 60
horses, increased obesity was associated with elevated plasma concentrations of TNFα
protein and enhanced blood mRNA expression of IL-1 and TNFα (Vick et al. 2007).
Furthermore, body condition score and plasma TNFα concentrations were inversely
related to insulin sensitivity. These findings suggest that increased concentrations of
inflammatory cytokines contribute to the development of IR in obese horses, which is
consistent with findings in other species (Kern et al. 1995; Trayhurn and Wood 2005;
Vick et al. 2007). Negative correlation between percent body fat and plasma adiponectin
concentrations, demonstrated in mature mares and weanling fillies (Kearns et al. 2006)
may provide further explanation for the decreased insulin sensitivity registered in obese
horses.
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Insulin sensitivity in horses is profoundly influenced by diet, in part by affecting
body weight and body condition score (Vick et al. 2006). In obese mares, feed restriction
resulted in a significant decrease in body weight, percentage body fat and circulating
concentrations of leptin and insulin, accompanied by a significantly increased insulin
sensitivity, relative to obese mares fed ad libitum (Vick et al. 2006). Insulin sensitivity
was also found to be significantly lower in Thoroughbred geldings fed a diet rich in sugar
and starch when compared to geldings eating forage and a supplement rich in fat and
fiber (Hoffman et al. 2003). Consumption of pasture grass containing large amounts of
NSC is associated with high glycemic and insulinemic responses, likely contributing to
the exacerbation of IR (Longland and Byrd 2006). In humans, increased consumption of
fructans has been associated with enhanced de novo lipogenesis and triglyceride synthesis
in the liver, which contributes to the development of IR (Basciano et al. 2005). Serum
insulin concentration measurements were used to investigate the effects of fructan
supplementation on insulin sensitivity in ponies (Bailey et al. 2007). After the addition
of inulin to a basal hay diet, serum insulin concentrations were significantly increased in
laminitis-predisposed ponies, and a similar, albeit not significant, increases in insulin
levels were also demonstrated in healthy ponies, suggesting exacerbation of IR. Plasma
TG concentrations were higher, but not significantly increased, in laminitis-predisposed
ponies when consuming basal hay diet supplemented with fructans relative to basal hay
diet alone (Bailey et al. 2007).
Genetic factors also seem to play a role in the development of IR in horses
(Johnson et al. 2004). Specific breeds that have been associated with the occurrence of
IR include Morgan horses, domesticated Spanish mustangs, European Warmbloods,
American Saddlebreds, and different pony breeds (Johnson 2002; Johnson et al. 2004).
A higher degree of IR was also noted in healthy ponies relative to Dutch Warmblood
horses (Rijnen and van der Kolk 2003). The presence of a certain level of insulin
insensitivity in ponies has been suggested to originate from natural selection, facilitating
survival under harsh circumstances (Jeffcott et al. 1986).

Thus, ponies may have

developed a highly efficient metabolism, with a degree of IR in the muscle, enhancing
CHO delivery to the liver where coexistent hyperinsulinemia promotes lipid synthesis
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(Jeffcott et al. 1986).

Genetic variability with respect to insulin action has been

implicated in the development of equine Cushing’s syndrome as well (Johnson et al.
2004).
Equine Cushing’s disease and IR are commonly registered as comorbid conditions
in horses, suggesting associations between these conditions (Johnson et al. 2004).
Resting hyperinsulinemia, a nonspecific indicator of IR (Kronfeld et al. 2005a), was
detected in horses with pituitary adenoma (Garcia and Beech 1986). Insulin resistance
was confirmed in these horses by a subsequent intravenous glucose tolerance test
demonstrating prolonged hyperglycemia (Garcia and Beech 1986). However, the lack of
correlation between plasma cortisol and glucose concentrations in horses suffering from
hyperadrenocorticism suggests that cortisol is not the only factor influencing the
development of IR in these cases (van der Kolk et al. 1995). Additionally, serum insulin
concentrations have been successfully used as a prognostic indicator for survival in
horses with equine Cushing’s disease (McGowan et al. 2004). Insulin resistance is also a
hallmark feature of equine metabolic syndrome (EMS), or “peripheral Cushing’s
syndrome” (Johnson 2002). Horses suffering from EMS are characteristically obese,
prone to develop laminitis, aged between 8-18 years, often have a cresty neck, and are
described by their owners as “easy keepers”, implying that it is difficult to reduce the
weight of these horses (Johnson 2002).
Lower insulin sensitivity has been described in pregnant mares, likely
representing a physiologic adaptation process aimed at enhancing nutrient delivery to the
developing fetus (Fowden et al. 1984). Reduced insulin sensitivity was implied by the
significantly higher insulin concentrations seen in mares less than 270 days pregnant than
in non-pregnant animals or in mares nearer to term. Increased insulin concentrations
were attributed to the enhanced responsiveness of pancreatic β-cells to glucose.
Additionally, exogenous insulin infusion decreased plasma glucose concentrations to a
lesser degree in mares more than 270 days pregnant than in non-pregnant animals,
providing corroborative evidence of IR in pregnant mares (Fowden et al. 1984).
In weanlings with osteochondritis dissecans, plasma insulin and glucose
concentrations were significantly greater 2 hours after feeding a concentrate meal,
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relative to unaffected foals, indicating insulin resistance, although insulin/glucose ratios
were not significantly different between groups (Pagan 2001).

Higher basal IGF-I

concentrations were also observed in Thoroughbred weanlings rendered insulin resistant
by feeding them a diet rich in sugar and starch (Treiber et al. 2005a). Increased IGF-I
may be a risk factor for osteochondrosis dissecans, explaining the association between
high CHO diets, IR and osteochondrosis dissecans (Treiber et al. 2005a). Similar to
humans (Reaven 2003), IR has been associated with elevated blood pressure in a group of
laminitis prone ponies (Bailey et al. 2008).

1.1.8

Factors enhancing insulin sensitivity in horses:
There are a number of factors known to enhance insulin sensitivity in humans

including exercise, weight reduction, a calorie restricted diet and pharmacologic
interventions (Cefalu 2001). Exercise has been demonstrated to enhance GLUT4 gene
transcription and translation in rats, as well as translocation of GLUT4 molecules from
the intracellular pools to the sarcolemma (Dohm 2002). The effect of submaximal
treadmill exercise prior to and following 6 weeks of exercise training was examined on
equine skeletal muscle GLUT4 protein content and on glucose transport in muscle
membrane vesicles (McCutcheon et al. 2002). Middle gluteal muscle GLUT4 protein
content increased 2- to 3-fold by the end of the training program relative to values
measured at the initiation of the study. Conversely, GLUT4 content was not different at
the end of the 60 min submaximal exercise period from values measured preceding it.
Following treadmill exercise, increased glucose transport was demonstrated in the muscle
membrane vesicles; however, this response was blunted by 6 weeks of training,
suggesting a reduction in the extent of translocation of GLUT4 to the sarcolemma in
trained muscle (McCutcheon et al. 2002). Another study in horses has demonstrated that
6 weeks of exercise training lowers glucose production and whole body glucose disposal
by approximately 22%, relative to pre-training values, when the same absolute workload
is used (Geor 2006). No significant change was registered when the same relative
workload was applied after completion of training. During submaximal exercise, insulin
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concentrations decreased whereas glucagon concentrations increased. Training blunted
these alterations during submaximal exercise at the same absolute, but not relative,
workload (Geor et al. 2002). In another study, euglycemic hyperinsulinemic clamp
(EHC) procedures performed 24 hours after the completion of 7 consecutive days of light
exercise revealed 60 and 48% increases in insulin sensitivity in obese and lean horses,
respectively, relative to sedentary controls (Powell et al. 2002).

Insulin sensitivity

returned to pre-exercise values 9 days following the cessation of the exercise program
(Powell et al. 2002).
A study investigating the role of obesity and diet on glucose and insulin dynamics
in horses revealed that obese Thoroughbred geldings were significantly less insulin
sensitive than nonobese ones, and a diet rich in fat and fiber enhanced insulin sensitivity
relative to a feed rich in starch and sugar (Hoffman et al. 2003). A study by Vick et al.
(2006) has confirmed that feed restriction in obese mares significantly decreases body
weight and improves IR compared to results obtained from obese mares fed ad libitum.
Short and long term oral administration of levothyroxine sodium has been
demonstrated to increase insulin sensitivity in horses (Frank et al. 2008; Frank et al.
2005b).

Levothyroxine sodium was speculated to enhance insulin sensitivity by

increasing abundance of glucose transporter proteins in adipose tissue and skeletal
muscle (Casla et al. 1990; Matthaei et al. 1995; Romero et al. 2000; Weinstein et al.
1994), as well as by increasing GLUT1 gene expression and the partitioning of glucose
transporters into the cell membrane within hepatocytes (Haber et al. 1995). From the
variety of medications available for the management of IR in humans, only the biguanide
metformin and the sulfonylurea glyburide have been evaluated for use in horses (Durham
et al. 2008; Johnson et al. 2005; Vick et al. 2006). In a Spanish Mustang suffering from
diabetes mellitus, with the diagnosis based on the concurrent presence of
hypoinsulinemia and hyperglycemia, treatment was attempted using glyburide and
metformin (Johnson et al. 2005). This treatment successfully lowered the interstitial
glucose concentration to physiologic levels within 4.5 h (Johnson et al. 2005). Oral
metformin treatment at a dosage of 15 mg/kg twice daily significantly improved insulin
sensitivity in horses and ponies with a history of laminitis, with the magnitude of effect
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greatest early in the course of treatment (Durham et al. 2008).

Similarly, insulin

sensitivity increased significantly only at the end of the first 30 day treatment period
when mares were treated with 1.5, 3, and 4.5 g metformin twice daily for successive
periods of 30 days (Vick et al. 2006).
Oral administration of chromium L-methionine has been shown to decrease
postprandial insulin secretion without affecting plasma glucose concentrations in aged
mares, suggesting enhanced insulin sensitivity (Ralston 2002). These findings, however,
were not substantiated by performing an intravenous glucose tolerance test (Ralston
2002).

Studies performed in mice demonstrated that chromium supplementation

enhances insulin sensitivity by facilitating tyrosine-phosphorylation and inhibiting serinephosphorylation of IRS-1, the latter occuring through the downregulation of C-Jun NH2terminal kinase (JNK; Chen et al. 2008). Furthermore, addition of chromium to the diet
also significantly reduced TNFα and IL-6 in the serum of diabetic mice (Chen et al.
2008).

1.1.9

IR and laminitis:
Laminitis refers to inflammation of the lamellae within the hoof capsule that can

result in the failure of the attachment between the distal phalanx (coffin bone) and the
inner hoof wall (Fagliari et al. 1998). The distal phalanx is suspended within the hoof
capsule by a resilient lamellar apparatus containing the primary epidermal lamellae,
which form the hard keratinized backbone to which the semi-keratinized secondary
epidermal lamellae attach. The primary and secondary epidermal lamellae interdigitate
with the primary and secondary dermal lamellae that are attached to the periosteum of the
third phalanx. A basement membrane (BM), found at the basal side of the epidermal
basal cells separates the epidermal compartment of the hoof from the dermal
compartment (French and Pollitt 2004a; Johnson et al. 1998; Mungall and Pollitt 2001;
Pollitt 1994).
When laminitis occurs, attachment of the BM at the dermo-epidermal junction
fails, and the distal phalanx separates from the hoof capsule (French and Pollitt 2004a).
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Epidermal basal cells are attached to the BM by electron dense plaques called
hemidesmosomes (HD).

The major components of the HD intracellular plaque are

plectin, BP230, BP180, and integrin α6β4. Anchoring filaments connect the HD to the
lamina densa of the basement membrane.

Intermediate filaments of the basal cell

cytoskeleton insert into the HD connecting the cytoskeleton to the plasmalemma (French
and Pollitt 2004a).
There are at least two mechanisms proposed to explain why separation occurs at
the dermo-epidermal junction during laminitis (French and Pollitt 2004a). In the absence
of glucose, the number of HDs decline and the intermediate filaments of the cytoskeleton
lose their attachment to the intracellular dense plaque of the HD.

This results in

weakening of the connection between the germinal cells and basement membrane.
Failure of the cytoskeleton also causes basal cell nuclei to become rounded and then more
spindle shaped; they are positioned more basally instead of apically (French and Pollitt
2004a). The second mechanism involves matrix metalloproteinases (MMP). Cultured
equine hoof explants secrete the inactive pro-enzymes MMP-2 and MMP-9 which are
activated by a multistep process when they are needed (Mungall and Pollitt 2002; Pollitt
1996). Mononuclear phagocytes present in higher concentration within laminitic hooves
are also a potential source of MMPs (French and Pollitt 2004a; Pollitt and Daradka
1998). Activation of MMPs results in the destruction of the anchoring filaments, but
HDs remain unaffected (French and Pollitt 2004a). The importance of MMPs in the
development of laminitis is emphasized by the fact the connective tissue samples
obtained from laminitic horses have significantly greater MMP activity (Johnson et al.
1998). Bacterial proteases such as thermolysin are also capable of activating MMPs
(Mungall and Pollitt 2001).
Impaired glucose delivery to the laminar keratinocytes in horses suffering from IR
may contribute to the development of laminitis. Healthy laminar keratinocytes express
GLUT1, GLUT4 and epithelial sodium channel (ENaC; Mobasheri et al. 2004). The
presence of GLUT4 suggests that these cells are metabolically active and their glucose
uptake is stimulated by insulin. In severe cases of laminitis, immunostaining of GLUT1,
GLUT4, and the α-subunit of ENaC markedly decrease, suggesting necrotic death of
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resident laminar keratinocytes (Mobasheri et al. 2004).

However, insulin mediated

glucose uptake into equine lamellar tissues has been questioned by Asplin et al. (2007a),
who failed to demonstrate increased glucose uptake in lamellar explants after insulin
stimulation. Furthermore, the same study demonstrated no evidence of GLUT4 gene
expression in laminar tissues, suggesting that glucose uptake in the hoof occurs thorough
the insulin independent GLUT1 molecules which are expressed in the coronary band and
lamellar tissues (Asplin et al. 2007b).
The importance of IR in the development of pasture associated laminitis has been
emphasized by Treiber et al. (2006b), because this group was able to identify ponies
suffering from prelaminitic metabolic syndrome (PLMS) with 74% sensitivity and 79%
specificity using three or more of the following characteristics: IR, compensatory β-cell
response, hypertriglyceridemia, or obesity. The same study revealed that ponies with
PLMS have an odds ratio of 10 for the development of pasture associated laminitis when
compared to ponies without PLMS (Treiber et al. 2006b). Further evidence for the role
of IR in the development of laminitis is provided by results of a study in which prolonged
hyperinsulinemia was induced by application of an EHC for up to 72 h, which led to the
development of Obel grade 2 laminitis in clinically normal ponies (Asplin et al. 2007b).
Changes in the digital vasculature are also proposed to occur during the acute
stage of equine laminitis, with shunting of blood away from lamellar capillaries via
arteriovenous anastomoses (Pollitt and Molyneux 1990). If this phenomenon lasts for
long enough, lamellar ischemia is thought to develop, which results in ischemic necrosis
of digital lamellae (Pollitt and Molyneux 1990).

During the prodromal stages of

laminitis; lamellar microvascular blood flow fluctuates. The blood flow decreases in the
first 2 hours and then returns to near baseline value before finally decreasing again 8
hours after administration of black walnut extract (Adair et al. 2000). Insulin resistance
may also contribute to the vascular changes preceding laminitis.

Inhibited insulin

signaling via the PI3-kinase pathway, involved in NO synthesis, was demonstrated during
IR, whereas the Ras/MAPK pathway mediated production of ET-1 remained undisturbed
(Jiang et al. 1999; Kim et al. 2006). The additive effect of these mediators likely leads to
pathologic vasoconstriction (Kim et al. 2006). The dyslipidaemia that develops in insulin
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resistant patients plays a central role in diabetic microangiopathy (Jenkins et al. 2004a;
Jenkins et al. 2004b). Microvascular changes demonstrated in diabetic patients may
occur in the laminar vessels of horses with chronic IR and contribute to the development
of laminitis.
Accumulation of platelets in the equine hoof wall distal to the coronary band
occurs at the onset of laminitis, implicating microvascular thrombosis and systemic
coagulopathy in the development of CHO induced laminitis (Weiss et al. 1994).
Elevated fasting insulin levels, a characteristic feature of IR (Cefalu 2001), have been
associated with impaired fibrinolysis and hypercoagulability in people (Meigs et al.
2000).

In human subjects, a strong positive association was demonstrated between

fasting insulin concentrations and levels of plasminogen activator inhibitor 1, fibrinogen,
von Willebrand factor, and factor VII (Meigs et al. 2000).
Destruction of the basement membrane between the dermal and epidermal
compartment of the hoof by MMPs is often implicated in the development of laminitis
(Kyaw-Tanner et al. 2008; Souza et al. 2006). Increased MMP-1 and MMP-2 protein
levels, as well as increased MMP-2 activity, were registered in human umbilical vein
endothelial cell culture media following exposure to high (25 nM) glucose concentrations
for 48 h (Death et al. 2003). Furthermore, the mRNA, protein, and activity levels of
MMP-9 were all significantly higher in human monocyte-derived macrophages exposed
to a high glucose concentration, compared with cells exposed to either a normal glucose
concentration or a high concentration of mannitol (Death et al. 2003). Thus, IR and
accompanying hyperglycemia likely plays an integral role in the development of laminitis
by activating MMPs (Treiber 2005).

1.1.10 Nonspecific indicators of IR in horses:
Measurement of basal hyperglycemia is one of the most common screening tests for
diabetes mellitus in human beings, but it does not differentiate between inadequate
insulin secretion by pancreatic β-cells and the reduced ability of peripheral tissues to take
up glucose (Firshman and Valberg 2007; Kronfeld et al. 2005a). It has been applied to
30

horses as well, albeit in conjunction with intravenous glucose tolerance testing (Jeffcott et
al. 1986). The primary advantage of using basal hyperglycemia as an indicator of IR is
the ease of sample collection and measurement of plasma glucose concentrations. On the
other hand, the nonspecific nature of this test as an indicator for IR is an important
drawback. Glucose responses vary significantly even when measured 5-6 h after feeding
and are influenced by the type of feed provided (Ralston 2002).

If basal glucose

measurements are taken, samples should be chilled after collection, and plasma glucose
concentrations should be determined promptly, to prevent registering false-low results
due to glucose consumption by red blood cells (Christopher and O'Neill 2000). Stressinduced variations in cortisol may also influence findings, so stress should be minimized
prior to sample collections (Ralston 2002).
Fasting hyperinsulinemia has also been used as an indicator of IR (Kronfeld et al.
2005b). Hyperinsulinemia develops to compensate for IR but declines if compensation
becomes inadequate (Firshman and Valberg 2007; Kronfeld et al. 2005a). False negative
responses may therefore occur during impending type 2 DM, a decompensation that is
common in human beings but rare in horses (Kronfeld et al. 2005a). Enhanced β-cell
sensitivity to glucose has been implicated in the development of basal hyperinsulinemia
during pregnancy in mares (Fowden et al. 1984). Advantages of measuring fasting
insulin concentrations to establish IR include uncomplicated sample collection and
inexpensive sample processing. The primary disadvantage of this method is its low
accuracy, because insulin secretion and clearance are profoundly influenced by a
multitude of factors including diet, duration of fasting, diurnal variations, and stressinduced alterations in cortisol concentrations (Ralston 2002). The nonspecific character
of this test has been demonstrated in horses, and only a trend (P = 0.065) for higher basal
insulin concentrations was registered in geldings fed diets high in sugar and starch
relative to geldings consuming feed rich in fat and fiber (Treiber et al. 2005a). On the
other hand, the minimal model analysis of FSIGTT demonstrated a (P = 0.007)
significant difference in insulin sensitivity for the same groups of horses (Treiber et al.
2005a).
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Glucose tolerance is assessed by the plasma glucose response to oral or intravenous
glucose administration (Firshman and Valberg 2007; Kronfeld et al. 2005a). The oral
glucose tolerance test is used to evaluate small intestinal absorption, hepatic glucose
uptake, and the endocrine function of the pancreas (Firshman and Valberg 2007). The
intravenous glucose tolerance test on the other hand, provides information about the
functional turnover rate of glucose, a measure of insulin sensitivity (Firshman and
Valberg 2007).

Marked or prolonged elevation of plasma glucose levels may be

attributable to impaired insulin secretion or decreased insulin sensitivity (Kronfeld et al.
2005a). The intravenous glucose tolerance test has been used in horses to evaluate the
effects of diet and pituitary pars intermedia dysfunction on glucose and insulin responses
(Garcia and Beech 1986).
The insulin tolerance test measures the blood glucose response to an exogenous
insulin challenge (Firshman and Valberg 2007). The inability of exogenous insulin to
elicit a decrease in blood glucose levels is suggestive of insulin resistance. It has been
successfully applied to horses and ponies to assess insulin sensitivity (Jeffcott et al.
1986).

However, glycemic responses to exogenous insulin are confounded by

endogenous insulin secretion (Kronfeld et al. 2005a). In healthy horses, completion of an
insulin tolerance test, comprising the administration of 0.1 U/kg insulin intravenously,
resulted in hypoglycemia that reached a nadir at approximately 40 min with blood
glucose concentrations then returning to baseline values by 130 min (Eiler et al. 2005).
The combined glucose-insulin test (CGIT) provides more information than either
the glucose tolerance test or insulin tolerance test alone (Eiler et al. 2005). During the
test, insulin and glucose are administered concurrently as a bolus at the initiation of the
study, then successive blood samples are collected for 150 minutes. For the CGIT,
insulin resistance is defined as maintenance of blood glucose concentrations above the
baseline level for ≥ 45 min (Frank et al. 2006). Frank et al. (2006) applied the CGIT
method to define insulin resistance in obese horses. The advantages of this procedure
include its simplicity to perform and the low number (n=14) of blood samples collected
during the test, which makes it a useful clinical diagnostic test (Eiler et al. 2005).
Although in its current form no quantitative measures of glucose and insulin dynamics
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are obtained from this procedure, calculations of area under the glucose (AUCg) and
insulin (AUCi) curves may remedy this deficiency. Nevertheless, administration of
exogenous insulin at the initiation of the procedure interferes with the evaluation of
endogenous insulin response.
In human subjects, glucose-to-insulin ratios correlate positively with insulin
sensitivity, whereas the insulin-to-glucose ratio correlates with insulin secretion
(Kronfeld et al. 2005a).

An initial decrease in the insulin-to-glucose ratio during

intravenous glucose tolerance test in horses with pituitary adenoma indicated an impaired
insulin response to acute hyperglycemia (Garcia and Beech 1986).
Surrogates for quantitative methods have been developed for screening IR in people
and horses as well (Kronfeld et al. 2005a). The quantitative insulin sensitivity check
index (QUICKI) estimates insulin sensitivity in human beings from fasting insulin (I0)
and glucose (G0) concentrations using the following formula: QUICKI = 1/[log(I0) +
log(G0)] (Katz et al. 2000). In people, the correlation between QUICKI and EHC was
stronger than the correlation between EHC and minimal model analysis of glucose and
insulin dynamics (Katz et al. 2000).
Two proxies, the reciprocal of the square root of insulin (RISQI) and the modified
insulin-to-glucose ratio (MIRG), were developed by Treiber et al. (2005b) for the
prediction of insulin sensitivity and beta cell responsiveness, respectively. Beta cell
responsiveness represented by the MIRG is similar to the acute insulin response to
glucose [AIRg], obtained via minimal model analysis of frequently sampled intravenous
glucose tolerance test (FSIGTT) data (Treiber et al. 2005b). Resting glucose and insulin
concentrations are measured for the calculations. Insulin sensitivity is derived using the
following formula:
Insulin sensitivity = 7.93 × (RISQI) – 1.03
where RISQI is the reciprocal of the square root of basal insulin concentration. Acute
insulin response to glucose can be calculated by using the following equation:
AIRg = 70.1 × (MIRG) – 13.8
where MIRG = [800 - 0.3 × (basal insulin concentration - 50)2] / (basal glucose
concentration – 30) (Treiber et al. 2006b). These proxies compared favorably with
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proxies used successfully in human studies when comparisons were made with insulin
sensitivity and AIRg values obtained from the minimal model. The combined use of
RISQI and MIRG facilitates distinction between compensated and uncompensated IR in
horses (Treiber et al. 2005b). The aforementioned proxies were used in a study to
establish metabolic predispositions and nutritional risk factors for development of
pasture-associated laminitis in ponies (Treiber et al. 2006b). However, one disadvantage
of using proxy measurements is that factors other than insulin sensitivity affect fasting
insulin concentrations. Furthermore, if RISQI values of < 0.32 mU/L0.5 are used to define
IR, as suggested by Treiber et al. (2006b), any horse with a fasting insulin concentration
≥ 10 mU/L would be classified as insulin resistant, even though fasting insulin
concentrations of 5 to 20 mU/L are usually considered normal in horses (Ralston 2002).

1.1.11 Quantitative methods for the evaluation of IR:

In contrast to nonspecific indications of insulin resistance, the euglycemichyperinsulinemic clamp technique allows the quantification of insulin sensitivity (Rijnen
and van der Kolk 2003). During the EHC, euglycemia and hyperinsulinemia are induced
by the concurrent infusion of glucose and insulin. Blood samples are collected during the
procedure to confirm that blood glucose concentrations are maintained on a constant,
euglycemic level, which is achieved by the adjustment of the glucose infusion rate. In a
successful clamp, the rate of glucose infusion used to maintain euglycemia equals cellular
glucose uptake mediated by the exogenously administered insulin. The glucose disposal
rate is usually calculated from the mean glucose infusion rate used during the last 60
minutes of the 120- or 180-minute test. Arterial samples are preferable because insulin
administration increases differences between arterial and venous blood glucose
concentrations. Disadvantages of the method include its labour intensive nature and the
use of supraphysiologic insulin concentrations (Kronfeld et al. 2005a).

The EHC

technique was successfully applied to determine reference range values indicative of
insulin sensitivity in horses and ponies (Rijnen and van der Kolk 2003). Vick et al.
(2008) also used the EHC technique in horses to demonstrate that lipopolysaccharide
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administration induces a transient increase in insulin sensitivity followed by a reduction
in insulin sensitivity at 24h. The effects of short term exercise training and the influence
of dexamethasone administration on insulin sensitivity in horses have also been
investigated using the EHC technique (Powell et al. 2002; Tiley et al. 2008).
The insulin suppression test is another quantitative method that has been used in
people to measure the ability of a fixed rate insulin infusion to dispose of a glucose load
(Kronfeld et al. 2005a). Endogenous insulin secretion is suppressed by administration of
somatostatin or octreotide, and infusion rates are controlled to yield a relatively steady
level of insulin and glucose concentration during the last 60 minutes of the test. The
steady state plasma glucose concentration is determined as the mean glucose
concentration of 6 blood samples obtained every 10 minutes during the last hour of the
test. It reflects insulin-mediated glucose disposal which is directly related to IR. The
limiting factors of this method are the adverse effects of insulin suppressant drugs,
inconsistency of the steady-state, and an elevated steady-state glucose concentration
which exceeds the renal threshold (Kronfeld et al. 2005a). To date, there are no reports
detailing the use of this method in horses.
The minimal model of glucose-insulin dynamics has been used to interpret data from
the FSIGTT. The minimal model partitions glucose disposal into glucose-dependent and
insulin-dependent parts by fitting a nonlinear model to the data obtained from the
FSIGTT. In the model, the glucose-time curve is described by two differential equations,
one represents glucose-mediated glucose uptake, whereas the other explains insulinmediated glucose disposal.

The insulin modified FSIGTT involves the intravenous

administration of a glucose bolus (300mg/kg of bwt) at 0 min followed by a bolus
infusion of insulin (30 mU/kg of bwt) at 20 min (Kronfeld et al. 2005a). Over the course
of the test, 31 blood samples are obtained at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16,
19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150 and 180 min relative
to glucose infusion, to determine glucose and insulin concentrations. The FSIGTT has
sometimes been extended to 240 min. Insulin sensitivity (SI) is calculated using the
following equations:

35

X’(t) = -p2 × X(t) + (p3 × [I(t) – Ib])
SI = p3/ p2
Where X’(t) (min-2) represents the change in insulin action over time; parameter p2
represents the rate (min-1) of decline of insulin action; X(t) is insulin action (min-1) (i.e.
the acceleration of glucose disposal at time t associated with insulin concentration above
basal); parameter p3 represents the rate (min-1) of introduction of insulin into the
interstitial space; I(t) represents the insulin concentration (mU/L) at time t; and Ib
represents basal insulin concentration (mU/L). Assumptions were X(0) = 0 and {I(t)-Ib}
= 0 if I(t) < Ib. Besides the SI value, the minimal model analysis of the FSIGTT also
provides a measure of glucose effectiveness (Sg), a value representing the net fractional
glucose clearance independent of insulin. The equation used to calculate Sg is:
G’(t) = -(X+Sg) × G(t) + (Sg × Gb)
Where G’(t) represents the rate of glucose clearance from plasma; X represents insulin
action; G(t) represents plasma glucose concentration at time t with G(0) being the
theoretical glucose concentration at time 0, as calculated using the minimal model; and
Gb represents basal glucose concentration (Hoffman et al. 2003). Further variables
provided by minimal model analysis of the insulin modified FSIGTT data include AIRg
and the disposition index (DI; Kronfeld et al. 2005a). The AIRg is the increase in plasma
insulin concentrations above baseline levels integrated from 0 to 10 min after glucose
administration (Treiber et al. 2005a).
AIRg = ∫ [I(t) –Ib] × dt
Where I(t) and Ib represents insulin concentrations at time t and baseline, respectively.
This variable therefore characterizes the responsiveness of pancreatic β-cells to a glucose
load. The DI represents the ability of the pancreatic β-cells to compensate for decreased
insulin sensitivity and it is derived from the minimal model by multiplying AIRg with SI
(Bergman 2005). The minimal model analysis of the insulin modified FSIGTT has been
successfully used to investigate the effects of obesity and diet on insulin sensitivity in
horses (Hoffman et al. 2003). Tiley et al. (2008) also applied the minimal model to
establish the effects of dexamethasone on insulin sensitivity and glucose dynamics in
Standardbreds. A study examining the repeatability of EHC versus minimal model
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analysis of FSIGTT data demonstrated that EHC results were more repeatable under the
experimental conditions used (Pratt et al. 2005). Further disadvantages of this technique
include the potential loss of glucose into the urine during the FSIGTT, which is not
accounted for in minimal model analysis. The AIRg values, which are calculated from
insulin concentrations measured in the peripheral blood, are also confounded by hepatic
insulin extraction and by the whole body insulin clearance rate (Toffolo et al. 1999). In
human subjects, these confounding factors are controlled by using C-peptide
measurements for the assessment of pancreatic β-cell function (Toffolo et al. 1999).

1.2

Endotoxin – endotoxemia:

1.2.1

Structure of the endotoxin:
Endotoxin is a heat stable macroamphiphile lipopolysaccharide (LPS) molecule

found in the cell membrane of Gram-negative bacteria, which may cause severe
physiological derangements when it enters the circulation in mammals (Rietschel et al.
1994). It constitutes approximately three quarters of the outer leaflet of the bacterial cell
membrane and functions as a protective layer inhibiting the entry of toxic compounds. It
is also important in the transport of nutrients, so it is essential for bacterial viability
(Rietschel et al. 1994).
Lipopolysaccharide is composed of a hydrophilic heteropolysaccharide and a
covalently bound lipid component, termed lipid-A. In certain bacteria, such as members
of the Enterobacteriaceae genus, the heteropolysaccharide can be further divided into the
O-specific chain and the core oligosaccharide (Rietschel et al. 1994). The O-specific
chain is a polymer of oligosaccharides, containing one to eight glycosyl residues. The
structure of the repeating units creates considerable variability between strains.

It

determines the serological specificity of the LPS and thus, functions as an important
surface antigen (Rietschel et al. 1994).
The core region consists of a heterooligosaccharide which can be further divided
into outer (O-specific chain proximal) and inner (lipid-A proximal) portions (Rietschel et
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al. 1994). The outer core in Salmonella spp. and Escherichia coli serotypes contains
hexoses such as D-glucose, D-galactose and N-acetyl-D-glucosamine, while the inner
core is composed of heptoses and 3-deoxy-D-manno-octulosonic acid. Most of the
structural diversity of the core region is related to the outer core while the innermost part
appears to be highly conserved amongst Gram-negative bacteria (Rietschel et al. 1994).
Lipid-A constitutes the toxic and immunomodulating principle of LPS and it is
the most conserved region of the endotoxin molecule.

Chemically, it is a

phosphoglycolipid containing D-gluco-configurated pyranosidic hexosamine residues
present as a β-linked homo- or heterodimer. Changes in its hydrophilic backbone (ie,
omission of phosphoryl groups) or addition of a fatty acid to its hydrophobic region both
significantly reduce the bioactivity of lipid-A. Full endotoxic activity is expressed by a
molecule containing two hexosamine residues, two phosphoryl groups and six fatty acids
including 3-acyloxylacyl groups (Reed 2003; Rietschel et al. 1994).

1.2.2

Cellular recognition and signal transduction of endotoxin:
After endotoxin is released into the systemic circulation, it is recognized by the

innate immune system, including macrophages and monocytes (Chow et al. 1999;
Werners et al. 2005). The effects of LPS on macrophages are markedly enhanced by the
presence of a protein called lipopolysaccharide-binding protein (LBP; Martin 2000;
Werners et al. 2005). Lipopolysaccharide-binding protein mainly functions as a transport
protein which disaggregates LPS and transfers it to targets on cellular membranes and to
lipoproteins in solution. Lipopolysaccharide molecules bound to and transported by HDL
are biologically inactive, therefore HDL binding provides a mechanism for detoxification
of LPS in the plasma (Martin 2000). Lipopolysaccharide-binding protein is a 50-kDa
polypeptide that is glycosylated and secreted as a 60-kDa glycoprotein primarily by the
liver and lungs (Martin 2000; Wan et al. 1995). As a type I acute phase response protein,
LBP mRNA expression is stimulated by LPS, IL-1, IL-6 and TNFα in primary rat
hepatocyte cultures (Wan et al. 1995).

Lipopolysaccharide-induced LBP mRNA

expression was markedly enhanced in hepatocytes isolated from rats previously injected
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with LPS, suggesting the existence of a priming mechanism which facilitates a more
rapid and vigorous response to a subsequent challenge (Wan et al. 1995).
The LPS-LBP complexes are transported to the cluster-of-differentiation antigen
14 (CD14), a molecule existing in two forms (Werners et al. 2005). A tail composed of
glycosylphosphatidylinositol may anchor CD14 molecules to the cell membrane or they
may be present in a soluble form that lacks the glycosylphosphatidylinositol tail (Martin
2000; Werners et al. 2005).

Binding of LPS-LBP complexes to CD14 present on

monocytes, macrophages and neutrophil granulocytes leads to cellular activation and
production of proinflammatory cytokines (Downey and Han 1998; Werners et al. 2005).
Soluble CD14 receptors are also capable of binding LPS-LBP complexes and facilitate
LPS-dependent activation of some CD14 negative cells such as endothelial, epithelial,
and smooth muscle cells (Downey and Han 1998).
Once it was determined that CD14 lacks a cytoplasmic domain (Werners et al.
2005), it was then found that LPS-stimulated signal transduction occurs through Toll-like
receptors (TLR; Chow et al. 1999). Lipopolysaccharide signaling through the TLR4
receptor, however, also requires the presence of myeloid differentiation factor 2, a protein
physically associated with TLR4 on the cell surface (Shimazu et al. 1999; Werners et al.
2005; Yang et al. 2000). To date, at least 11 different TLRs have been cloned in
mammalian species (Werners et al. 2005). Both TLR2 and TLR4 appear to play a role in
LPS-induced signal transduction (Chow et al. 1999; Kirschning et al. 1998). Human
embryonic kidney 293 cells transiently transfected with human TLR4 or TLR2 cDNA
demonstrated a significantly increased responsiveness to LPS in the presence of CD14 as
measured by the activation of nuclear factor κB (NF-κB; Chow et al. 1999).
After ligand binding, TLR4 dimerizes and undergoes a change in conformation
that is necessary to initiate intracellular signaling events (Werners et al. 2005). The best
characterized LPS-induced pathways are the NF-κB pathway and three MAPK-associated
pathways (Yang et al. 2000):
• MAPK (extracellular signal regulated kinase)
• C-Jun NH2-terminal kinase 1 and 2
• p38 MAPKs (Downey and Han 1998).
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Endotoxin-induced activation of NF-κB via TLR4 is initiated by the association of the
TLR4 receptor with myeloid differentiation protein. This protein stimulates the IL-1
receptor-associated kinase which in turn facilitates recruitment of TNF receptor
associated factor-6 (Yang et al. 2000).

The activation of these proximal signaling

molecules leads to stimulation of members of the MAPK kinase kinase family that
activate inhibitory kappa B kinases.

Inhibitory kappa B kinases phosphorylate the

inhibitory kappa B proteins, which are subsequently degraded resulting in the liberation
of NF-κB and its translocation to the nucleus (Yang et al. 2000). Almost all genes
important in the pathogenesis of LPS-induced systemic inflammation contain promoter
elements for NF-κB such as TNFα, IL-1β, IL-6, IL-8, inducible nitric oxide synthase and
cyclo-oxygenase (COX) -2 (Downey and Han 1998). In addition to the aforementioned
cellular activation mechanisms, PKC and SRC family kinases were also found to be
activated following LPS stimulation (Downey and Han 1998).

1.2.3

Pathogenesis of endotoxemia:
Endotoxin is liberated from the outer membrane of the cell wall of Gram-negative

bacteria upon rapid proliferation or lysis of the organisms (Werners et al. 2005), thus the
equine intestinal tract contains large amounts of LPS (Morris 1991). Normally there are
three mechanisms preventing the access of LPS to the peripheral circulation: the mucosal
cell barrier of the intestines, the ability of bile acids to bind LPS, and the clearance of
LPS from the blood by the Kupffer cells of the liver (Hardie and Kruse-Elliott 1990a;
Morris 1991). In order to cause disease, large amounts of endotoxin must be absorbed
from the gastro-intestinal tract and then overwhelm the liver’s detoxifying ability, or the
number of Kupffer cells in the liver must be reduced due to pathologic processes (Hardie
and Kruse-Elliott 1990a; Morris 1991).
In cases of endotoxemia the source of endotoxin can be endogenous or
exogenous. The gastro-intestinal tract is an endogenous source and endotoxin release
occurs during acute abdominal disease. In contrast, the source of endotoxin is exogenous
in cases of metritis, pleuropneumonia, or neonatal septicemia (Werners et al. 2005). The
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interaction of LPS with mononuclear phagocytes, and subsequent activation of these cells
are pivotal early events in the pathogenesis of endotoxemia (MacKay 2001). Activated
macrophages possess an increased ability of adherence and pseudopod formation (Morris
1991). Most importantly, activated macrophages secrete a wide variety of inflammatory
mediators, such as cytokines, lipid mediators, and free oxygen radicals, which play a
central role in the pathogenesis of endotoxemia (Hardie and Kruse-Elliott 1990a; Morris
1991; Werners et al. 2005). The most extensively studied cytokines, IL-1, IL-6, and
TNFα are all pyrogens, and are capable of stimulating acute phase protein production by
the liver (Werners et al. 2005).
Tumor necrosis factor-α is a polypeptide produced by activated macrophages,
vascular smooth muscle cells, blood leukocytes, and mesothelial cells (Barton and
Collatos 1999; Detmer et al. 2001; Hardie and Kruse-Elliott 1990a). The plasma half life
of TNFα is short (approximately 6 min), and it rapidly binds to specific receptors in
target tissues, such as lungs, kidneys, and liver (Hardie and Kruse-Elliott 1990a). As a
proximal mediator of LPS effects, TNFα is important in neutrophil activation and
adherence, alterations to the vascular endothelium, and decreased LPL synthesis (Hardie
and Kruse-Elliott 1990a). This cytokine also enhances the synthesis of class I major
histocompatibility complex antigen and triggers the secretion of the second wave of
inflammatory cytokines, including IL-6 and granulocyte-monocyte colony stimulating
factor (Hardie and Kruse-Elliott 1990a; MacKay 2001).

In humans and mice,

intravenous infusion of endotoxin induces a marked increase in TNFα concentrations at 2
hours, followed by a return to baseline levels by 4 hours post-infusion (Copeland et al.
2005). Stimulation with LPS significantly increased TNFα production in blood from 10
horses, however the magnitude of this response showed wide inter-animal variation
(Werners et al. 2006).
Interleukin-1 plays a central role in the control of fever, neutrophil and T
lymphocyte chemotaxis, expression of intracellular adhesion molecules in vascular
endothelium, and also triggers an increase in the number of circulating immature
neutrophils (Hardie and Kruse-Elliott 1990a). Macrophages and vascular smooth muscle
cells secrete IL-1 in response to bacterial LPS or TNFα (Detmer et al. 2001; Hardie and
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Kruse-Elliott 1990a). Increased plasma concentrations of IL-1β were detected in mice at
multiple time points following intravenous LPS administration whereas in people, no
circulating IL-1 was detected following endotoxin challenge (Copeland et al. 2005; van
Deventer et al. 1990). Exposure to Escherichia coli O111:B4 LPS has also been shown
to increase IL-1β mRNA expression in equine monocytes (Figueiredo et al. 2008).
Interleukin-6, a phosphoglycoprotein produced by fibroblasts, mononuclear, and
endothelial cells, stimulates the final differentiation of B-lymphocytes into plasma cells
and induces production of acute phase proteins by hepatocytes (Morris 1991). In mice
and people, endotoxin administration increased IL-6 concentration with a peak registered
2 h after endotoxin infusion (Copeland et al. 2005).

Van Deventer et al. (1990)

demonstrated that release of IL-6 was delayed approximately 15 minutes relative to
TNFα in human subjects receiving an LPS infusion, indicating that TNFα may stimulate
the release of IL-6 from the monocyte/macrophage compartment, or alternatively, from
endothelial cells.

Interleukin-6 secretion was also registered in equine monocytes

exposed to LPS (Figueiredo et al. 2008).
Lipopolysaccharide binding also destabilizes cell membranes and activates the
nearby phospholipases A2, C, and D (Stief 2007).

Phospholipase A2 cleaves the

membrane phospholipids in the sn-2 position, thereby generating lysophospholipids and
arachidonic acid (Stief 2007), with the latter further converted into leukotrienes via the 5lipoxygenase pathway or into prostanoids via the COX pathway (Hardie and KruseElliott 1990a). Thromboxane-A2 is a COX end-product that causes vasoconstriction
during endotoxemia and induces platelet aggregation (Morris 1991). Prostacyclin is
another arachidonic acid derivate that is often released more gradually, and causes
vasodilatation and inhibition of platelet aggregation (Morris 1991).
different leukotrienes released during endotoxemia.

There are four

Of these, leukotriene-C4,

leukotriene-D4, and leukotriene-E4 are potent bronchoconstrictors and vasoconstrictors
that also increase capillary permeability of postcapillary venules, whereas leukotriene-B4
promotes neutrophil-endothelial adherence and is a potent chemoattractant for
neutrophils (Hardie and Kruse-Elliott 1990a). Exposure to endotoxin has been shown to
increase the expression of COX-2 protein and mRNA in equine digital vein endothelial
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cells and equine digital artery smooth muscle cells, respectively (Menzies-Gow et al.
2008; Rodgerson et al. 2001).
Platelet activating factor is another important molecule mediating LPS effects
(Carrick et al. 1993). It is synthesized by leukocytes, platelets, and endothelial cells
through phospholipase A2-mediated hydrolysis. Its biological effects include platelet and
neutrophil activation and aggregation, bronchoconstriction, pulmonary hypertension, and
increased vascular permeability (Carrick 1989; Carrick et al. 1993). Although treatment
with a platelet activating factor receptor antagonist delayed the onset of fever,
tachycardia, and leukopenia in horses that received endotoxin, the drug failed to change
any of the clinical or laboratory data (Carrick et al. 1993).

1.2.4

Clinical conditions related to endotoxemia:
Endotoxin-induced systemic inflammatory response syndrome causes profound

derangements in whole body homeostasis that ultimately affect multiple organ systems
(Morris 1991).

Endotoxemia most commonly occurs following gastro-intestinal

compromise because of an increase in the permeability of the intestinal mucosa.
Ischemic insults and severe bowel inflammation therefore facilitate endotoxin absorption
from the lumen (Morris 1991). Absorbed endotoxin itself has a pronounced effect on the
gastrointestinal tract. Lipopolysaccharide delays gastric emptying, decreases gastric acid
output, and increases gastric pH (Doherty et al. 2003; Valk et al. 1998).
Platelet counts were lower and there was a trend towards increased coagulation
times (thrombin time, prothrombin time and activated partial thromboplastin time) in
ponies that received endotoxin intravenously (Fessler et al. 1982). Interestingly, the
decline in platelet counts was more pronounced in ponies given flunixin meglumine,
perhaps because this drug reduces the release of prostacyclin, which is known to inhibit
platelet aggregation (Fessler et al. 1982). An endotoxin-induced elevation in fibrinogen
concentration was also detected in ponies, which was prevented by the administration of
dexamethasone, prednisolone succinate, or flunixin meglumine (Ewert et al. 1985).
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One of the most characteristic consequences of endotoxemia is neutropenia. Tumor
necrosis factor, IL-1, and LPS itself stimulate the expression of adhesion molecules such
as p- and e-selectins on endothelial cells, and stimulates neutrophil adhesion (MacKay
2001; Morris 1991). Profound granulocytopenia was registered in human subjects 60
minutes after IV administration of LPS, which then shifted to granulocytosis two hours
after infusion (Richardson et al. 1989). Granulocytosis persisted for 4 hours and returned
to baseline levels by 24 hours. Rebound neutrophilia is attributed to an increase in
colony stimulating factors released by macrophages following TNFα exposure (Morris et
al. 1990). Endotoxin-induced monocytopenia and lymphopenia are also detected in
humans (Richardson et al. 1989). Monocytopenia persists longer than neutropenia and
lasts for up to 6 hours (Pernerstorfer et al. 1999).

Significant lymphocytopenia is

observed for 1 to 6 hours after endotoxin infusion (Richardson et al. 1989).
In a study of anesthetized ponies that received 0.2 mg/kg bwt endotoxin IV,
multiple derangements in hemogram and blood-gas parameters were observed (Bottoms
et al. 1981; Fessler et al. 1982). During the first 4 hours, there was a marked decrease in
white blood cell count (WBC) due to a reduction in the number of neutrophils (Fessler et
al. 1982). Significantly elevated packed cell volume (PCV) values were also detected in
animals receiving LPS, which was likely to have been a consequence of catecholaminemediated splenic contraction (Fessler et al. 1982). Higher circulating catecholamine
concentrations have been previously detected in humans and laboratory animals with
endotoxemia (Hinchcliff et al. 2005).

Respiratory acidosis detected during the

experiment was related to general anesthesia, however, significantly elevated blood
lactate levels and lower venous pH values were suggestive of a shift from aerobic to
anaerobic metabolism (Fessler et al. 1982).

Flunixin meglumine administration

ameliorated this shift to anaerobic metabolism, presumably by maintaining better
peripheral blood flow, as demonstrated in a previous study (Bottoms et al. 1981; Fessler
et al. 1982).
Circulating endotoxin has a direct toxic effect on tissues and initiates an
exaggerated inflammatory response which causes vascular dysfunction (Hardie and
Kruse-Elliott 1990a). This can result in distributive shock, multiple organ failure and
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ultimately death. Toxic radicals released upon activation of leukocytes also contribute to
cellular death (Hardie and Kruse-Elliott 1990a). Changes in blood biochemical values
can reflect deteriorating organ function. Blood biochemical parameters were examined in
anesthetized ponies receiving a lethal dose of endotoxin (Ewert et al. 1985). Elevated
creatinine kinase activities were detected in all groups, but ponies that received
dexamethasone, prednisolone succinate, or flunixin meglumine were less affected.
Lactate dehydrogenase levels increased gradually during the shock period, with the
highest levels detected in the group of ponies that did not receive anti-inflammatory
drugs (Ewert et al. 1985).
Endotoxemia causes profound hemodynamic changes culminating in endotoxic
shock, which is classified as a distributive shock (Muir 1998). Exposure of endothelial
cells, neutrophils, and macrophages to LPS activates their inducible nitric oxide synthase
enzyme leading to excessive generation of NO (Muir 1998).

Nitric oxide causes

vasodilatation, hypotension, and possibly arteriovenous shunting. Cardiac output is often
elevated during the early phases of endotoxemia, which causes injected, warm mucous
membranes.

However, when endotoxin shock develops, arterial blood pressure and

cardiac output decrease, resulting in reduced peripheral perfusion indicated by pale, cold
mucosal membranes (Muir 1998). Compensatory responses include tachycardia and
peripheral vasoconstriction mediated by thromboxane-A2, ET-1, arginine-vasopressin,
and angiotensin II. As the disease progresses, decompensation becomes apparent by
progressive systemic hypotension, which is confounded by direct myocardial suppression
of NO, and increased vascular permeability.

Increased plasma concentrations of

prostacyclin, prostaglandin-E2, and bradykinin are often detected during the
decompensation phase (Reed 2003). Increased blood levels of ET-1 have also been
detected in various species during endotoxemia (Wanecek et al. 2000). Endothelin-1 is
produced by vascular endothelial cells, mast cells, macrophages, and smooth muscle cells
and is involved in the regulation of vascular tone. It causes concentration-dependent
vasoconstriction which is mediated by endothelin-A and endothelin-B2 receptors
(Wanecek et al. 2000). During endotoxemia, ET-1 contributes to endotoxin-induced
coronary

vasoconstriction,

late

phase

pulmonary

hypertension,

splanchnic
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vasoconstriction, and acute renal failure (Wanecek et al. 2000).

Endothelin-1

concentrations were elevated in laminar connective tissue collected from horses with
laminitis, suggesting that ET-1 plays a role in the pathogenesis of this disease (Katwa et
al. 1999).

1.2.5

Endotoxemia and IR:
In a study by Fessler et al. (1982), plasma insulin and glucose concentrations were

evaluated following endotoxin administration. Ponies receiving endotoxin demonstrated
an initial hyperglycemia without any alterations in insulin level, followed by
hypoglycemia accompanied by transient hyperinsulinemia (Fessler et al. 1982). It was
concluded that early hyperglycemia facilitated insulin release, which triggered
subsequent rebound hypoglycemia (Fessler et al. 1982).
Endotoxemia caused whole body insulin resistance in rats with a 37% decrease in
glucose disposal (Virkamaki and Yki-Jarvinen 1994).

The decrease was partially

attributed to a defect in muscle glycogen synthesis (Virkamaki and Yki-Jarvinen 1994).
The same study examined the effects of α- and β-adrenergic blockade on glucose
metabolism during endotoxemia. Although α- and β-blockade abolished the transient
hyperglycemia observed after endotoxin administration, it failed to normalize glucose
disposal or skeletal muscle glycogen synthesis, so LPS-induced insulin resistance was not
corrected during the late (6-8 hrs) phase (Virkamaki and Yki-Jarvinen 1994). Continuous
LPS infusion significantly decreased the number of insulin receptors, insulin-stimulated
tyrosine phosphorylation of insulin receptors, abundance of IRS-1 molecules, and
tyrosine phosphorylation of IRS-1 molecules in rat liver tissue, whereas only tyrosine
phosphorylation of IRS 1 molecules was significantly affected in skeletal muscle
(McCowen et al. 2001). The effect of endotoxin on IRS-1 is mediated by TNFα, which
activates C-Jun NH2-terminal kinase and I kappa B kinase resulting in the inhibition of
IRS-1 signaling through serine307 phosphorylation (Aguirre et al. 2000; de Luca and
Olefsky 2008).
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In a prospective study of apparently healthy, middle aged women, elevated levels of
the systemic inflammatory markers IL-6 and C-reactive protein were found to be
determinants of risk for type 2 DM (Pradhan et al. 2001). In horses, Vick et al. (2008)
investigated the effects of systemic inflammation on insulin sensitivity using the EHC
method. Systemic inflammation induced by intravenous administration of 0.045 μg/kg
bwt lipopolysaccharide induced a transient increase in insulin sensitivity followed by
profound IR at 24 h (Vick et al. 2008). The IR that develops during the systemic
inflammatory response likely aims to provide high glucose flow to cells involved in
immune and inflammatory reactions and other non insulin-dependent cells (Fitzgerald
2004). In a study of humans where the EHC method was used to asses glucose dynamics
during endotoxemia, LPS administration resulted in a biphasic response in glucose
utilization, similar to that registered in horses (Agwunobi et al. 2000; Vick et al. 2008).
The glucose infusion rate had to be increased 120 minutes after LPS administration, after
which time it had to be progressively lowered. By the 420 minute time point, the glucose
infusion rate was significantly lower in the group receiving LPS compared to control,
indicating that insulin resistance had developed (Agwunobi et al. 2000). The difference
in glucose infusion rate was attributed to alterations in nonoxidative glucose disposal.
After an initial rise in glucose storage rate, it started to decline progressively and then
reached statistical significance 420 minutes after LPS administration (Agwunobi et al.
2000). Endotoxin-mediated activation of TLR-4 receptors in 3T3-L1 adipocytes has also
been shown to provoke insulin resistance (Song et al. 2006).

1.2.6

Endotoxemia and laminitis:
In horses, approximately 75% of acute laminitis is preceded by alterations

involving the gastrointestinal system (Weiss et al. 1998). Changes in the caecal flora,
including a concomitant increase in the number of lactic acid producing bacteria and
reduction in the Gram-negative bacterial population, were demonstrated during the onset
of acute laminitis induced by CHO overload in horses (Garner et al. 1978). These
findings were further substantiated by registering that fecal and caecal bacterial
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populations also change during oligofructose-induced laminitis from a predominantly
Gram-negative population to one dominated by Gram-positive bacteria (Milinovich et al.
2007; Milinovich et al. 2006). Specifically, Streptococcus lutetiensis, a member of the
Streptococcus bovis/equinus complex, demonstrated a marked population increase
between 8 and 16h after OF administration (Milinovich et al. 2006). A sharp decline in
the number of OF-utilizing organisms occurred between 16 and 24 hours and this was
accompanied by a sharp decline in fecal pH, followed by the development of clinical
laminitis between 24 and 32h (Milinovich et al. 2006). The lower pH likely contributes
to the transient increase in intestinal mucosal permeability registered during the
prodromal stages of alimentary laminitis (Weiss et al. 1998).

Altered intestinal

permeability allows endotoxin absorption into the circulation, as demonstrated by the
elevated endotoxin levels registered in 11/13 horses developing Obel grade 3 laminitis
following CHO overload (Sprouse et al. 1987).

The role of endotoxemia in the

development of laminitis has been further supported by results of a study investigating
factors associated with the development of laminitis in hospitalized horses (Parsons et al.
2007). This study revealed that horses suffering from clinically evident endotoxemia
have an odds ratio of 5 to develop laminitis when compared with horses that have no
clinical signs of endotoxemia (Parsons et al. 2007). Additionally, an in vitro study
implicated the streptococcal pyrogenic exotoxin B in the development of laminitis by
demonstrating its ability to trigger laminar separation in equine hoof explants (Mungall et
al. 2001).
The expression of extracellular MMPs, notably MMP-2 and MMP-9, is
significantly higher in hoof laminar tissues obtained from laminitic horses versus hoof
laminar tissues obtained from non-laminitic animals (Johnson et al. 1998). Endotoxin or
inflammatory cytokine mediated activation of these gelatinases may further explain the
strong association between endotoxemia and laminitis (Bailey et al. 2004; Johnson et al.
1998).
The vascular theory suggests that laminitis is a consequence of digital ischemia
and subsequent reperfusion (Adair et al. 2000; Menzies-Gow et al. 2005). Equine digital
smooth muscle cells exposed to endotoxin demonstrated an increased expression of
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COX-2 mRNA (Rodgerson et al. 2001). Vasoactive prostanoids, produced via the COX2 pathway, may be important in the vasoconstrictive events preceding laminitis
(Rodgerson et al. 2001). Concentrations of ET-1, a potent vasoconstrictor, were also
increased in laminar connective tissue of horses suffering from laminitis (Katwa et al.
1999). Decreased digital blood flow and high plasma ET-1 concentrations were found in
horses with severe endotoxemia as well, providing yet another example of how
endotoxemia and laminitis may be interconnected (Menzies-Gow et al. 2005).
Microvascular thrombosis, demonstrated in ponies with carbohydrate-induced laminitis,
likely contributes to alterations in digital blood flow (Weiss et al. 1994).
Lipopolysaccharide-mediated activation of phospholipase A2 increases cell membrane
perturbation causing cell fragmentation (Stief 2007). These cell fragments subsequently
activate the intrinsic (contact) pathway of the coagulation cascade by facilitating the
conversion of prekallikrein to kallikrein (Stief 2007). Endotoxin has been shown to
enhance tissue factor expression on equine peritoneal macrophages, which activates the
extrinsic pathway of the coagulation cascade (Barton et al. 1996).

In conclusion,

endotoxin-mediated activation of both arms of the coagulation cascade is likely to
contribute to the development of laminitis by altering digital blood flow.

1.2.7

Endotoxin tolerance and endotoxin hyporesponsiveness:
Repeated exposure to endotoxin can lead to the development of tolerance, which

is reflected by a characteristic decrease in TNFα concentration (West and Heagy 2002).
Endotoxin tolerance can be divided into early and late tolerance (Hardie and Kruse-Elliott
1990b). In one study, early endotoxin tolerance developed after lipopolysaccharide was
administered twice 24 h apart (Allen et al. 1996). After the second injection, horses
showed a decreased activity, lower concentration of TNFα, shorter duration of elevated
rectal temperature, and smaller rise in blood pressure (Allen et al. 1996). Macrophages
obtained from horses with acute gastrointestinal disease also produce significantly less
TNFα in vitro when compared with similarly treated macrophages obtained from healthy
animals (Barton et al. 1996).

Early endotoxin tolerance seems to be a plausible
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explanation for this latter phenomenon.

During early phase endotoxin tolerance,

impaired NF-κB activation and translocation, and altered IL-1 receptor-associated kinase
and MAPK functions were demonstrated, leading to reduction in TNFα, IL-6, and IL-8
levels, while prostaglandin E2 and IL-10 concentrations increased (West and Heagy
2002). LPS exposure induces translocation of p65 and p50 subunits of NFκB from the
cytosol to the nucleus in both LPS responsive and LPS tolerant THP-1 cells (Chan et al.
2005). However, NFκB p65 binding to the IL-1β promoter is rapidly and transiently
increased in LPS responsive monocytes whereas it is significantly limited in LPS tolerant
cells. Concomitant alterations in chromatin remodeling are also present in LPS tolerant
cells (Chan et al. 2005).

Endotoxin-mediated overexpression of the dual specific

phosphatase MKP-1 has been shown to contribute to the development of endotoxin
tolerance by negatively regulating the p38 MAPK, which is an enzyme that is important
for the post-transcriptional stabilization of TNFα mRNA (Nimah et al. 2005). While it
has been shown in humans that early tolerance lasts only for a few days, late tolerance
extends for several weeks (Hardie and Kruse-Elliott 1990b). Late tolerance is O-antigen
dependent and may be mediated by specific antibodies (Hardie and Kruse-Elliott 1990b).
The ability of an individual to respond to endotoxin is highly variable (Arbour et
al. 2000). Common, co-segregating missense mutations affecting the TLR4 receptor
have been shown to be responsible for differences in the response to inhaled LPS in men
(Arbour et al. 2000). Large individual differences in the response to LPS have also been
documented in peripheral blood mononuclear cells and whole blood and alveolar
macrophages obtained from horses (Werners et al. 2006). Genotyping TLR-4, myeloid
differentiation factor 2, and CD-14 receptors in 10 horses, including 3 horses with
significantly lower LPS-induced TNFα responses, revealed mutations involving the
sequence of the TLR4 receptors (Werners et al. 2006). However, these changes could
not be linked to the hyporesponsiveness to LPS (Werners et al. 2006). No mutations
were found to affect the genes coding for either the myeloid differentiation factor 2 or
CD-14 receptors, suggesting that these are more highly conserved structures (Werners et
al. 2006).
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CHAPTER 2
Effects of an intravenous endotoxin challenge on glucose and
insulin dynamics in horses
This chapter is a revised version of a paper by the same name published in the
American Journal of Veterinary Research in 2008 by Ferenc Tόth, Nicholas Frank, Sarah
B. Elliott, Raymond J. Geor and Raymond C. Boston.
Reference: Tόth, F., Frank, N., Elliott, S. B., Geor, R. J. and Boston, R.C. Effects of an
intravenous endotoxin challenge on glucose and insulin dynamics in horses. Am J Vet Res
2008;69: 82-88

2.1

Introduction
Endotoxin is a heat-stable lipopolysaccharide (LPS) located within the outer

membrane of Gram-negative bacteria that can be released as a result of rapid bacterial
growth or cell death (Morris 1991; Werners et al. 2005). In healthy animals, endotoxin is
located within the intestines and is contained there by the mucosal barrier and mucus
layer (Werners et al. 2005). If endotoxin enters the portal blood system via active
transport or passive diffusion from the intestinal tract, LPS molecules are removed from
circulation by the Kupffer cells of the liver (Morris 1991). Clinical signs of endotoxemia
develop when body defenses are compromised and blood endotoxin concentration
increases. In horses, endotoxemia is most commonly associated with gastrointestinal tract
disturbances such as colic and colitis that involve bacterial overgrowth and increased
intestinal wall permeability (French et al. 2002; Larsen 1997; Morris and Moore 1989).
Endotoxemia develops when the mucosal barrier is compromised and there is movement
of endotoxin into the blood and lymphatic system, or when endotoxin passes through the
serosa into the peritoneal cavity (French et al. 2002; Larsen 1997; Morris and Moore
1989).

Horses that develop retained fetal membranes, pleuropneumonia, wound
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infections, or Gram-negative bacteremia are also at risk for endotoxemia (Morris 1991;
Werners et al. 2005).
Insulin resistance is a state in which normal concentrations of insulin fail to elicit
a normal physiologic response (Kahn 1978), and this condition develops as a
consequence of endotoxemia in humans (Agwunobi et al. 2000) and rats (Virkamaki and
Yki-Jarvinen 1994). This disturbance in glucose metabolism in horses is a concern
because of its putative link with laminitis. Administration of a high dose of LPS (125
µg/kg) to ponies induces hyperglycemia within the first hour, followed by significant
hypoglycemia compared to values registered before endotoxin administration, but plasma
insulin concentrations remained unchanged (Ewert et al. 1985; Fessler et al. 1982).
Effects of endotoxemia on insulin sensitivity are relevant because insulin resistance (IR)
is a risk factor for pasture-associated laminitis in ponies (Treiber et al. 2006b), and there
is in vitro evidence that hoof laminar tissues require an adequate supply of glucose to
maintain structural integrity (Pass et al. 1998). If IR is an important risk factor for
laminitis, then endotoxemia may exacerbate this disturbance in glucose metabolism and
further increase the risk of disease.
Administration of exogenous LPS is used to experimentally induce endotoxemia
but does not represent development of the disease clinically, which may explain why
laminitis has not developed in LPS-treated horses (Barton et al. 2004; Doherty et al.
2003; Kiku et al. 2003; MacKay et al. 1999; Moore et al. 1981). However, endotoxemia
may still play a role in the development of laminitis, and this method allows physiologic
responses to LPS administration to be isolated and studied. Endotoxemia has been
associated with acute laminitis in two studies (Parsons et al. 2007; Sprouse et al. 1987),
although a causal relationship has not been established.

Parsons et al. (2007)

retrospectively evaluated horses that developed acute laminitis during hospitalization.
This group determined that the odds of a horse with clinical endotoxemia developing
acute laminitis during hospitalization were 5 times those of a horse with no clinical signs
of endotoxemia. However, endotoxemia was only inferred from clinical signs and not
confirmed by endotoxin assay. Sprouse et al. (1987) also reported that plasma endotoxin
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concentrations significantly increased in 11 of 13 horses that developed Obel grade 3
laminitis after alimentary carbohydrate overload.
Clinical signs consistent with endotoxemia have been observed in horses during
the development of laminitis after oligofructose administration (van Eps and Pollitt
2006). Horses that received 10 g of oligofructose/kg via intragastric administration
developed diarrhea within 12 hours and had signs of depression, inappetence, fever, and
tachycardia within the 48-h period following treatment (van Eps and Pollitt 2006). Mean
white blood cell (WBC) and neutrophil counts initially decreased, but then increased
within 48 hours of oligofructose administration. These findings suggest that endotoxemia
contributes to the development of laminitis associated with carbohydrate overload in
horses (Bailey et al. 2004). Carbohydrate overload causes an overgrowth of intestinal
bacteria that lowers the intraluminal pH and increases intestinal wall permeability (Al
Jassim et al. 2005; Elliott and Bailey 2006; Harris et al. 2006; van Eps and Pollitt 2004).
Endotoxemia detected during the development of carbohydrate-induced laminitis may
reflect this increase in intestinal wall permeability (Sprouse et al. 1987).
The purpose of the study reported here was to evaluate the effects of endotoxin
administered intravenously on glucose and insulin dynamics in horses. We hypothesized
that endotoxemia would induce alterations in glucose and insulin dynamics in horses.
The frequently sampled intravenous glucose tolerance test (FSIGTT) was elected to test
our hypothesis because data from this test can be assessed via minimal model analysis.
The minimal model of glucose and insulin dynamics is a nonlinear model that uses data
obtained from the FSIGTT to partition glucose disposal into glucose- and insulinmediated fractions (Kronfeld et al. 2005a). It provides values for glucose effectiveness
(Sg), insulin sensitivity (SI), and acute insulin response to glucose (AIRg; Hoffman et al.
2003; Kronfeld et al. 2005a; Treiber et al. 2006a). Glucose effectiveness describes the
capacity of glucose to mediate its own disposal, whereas SI represents the ability of
insulin to promote glucose disposal and decrease endogenous glucose production. The
acute insulin response to glucose is a measure of initial phase endogenous insulin
secretion in response to exogenous glucose. The ability of pancreatic beta cells to

53

increase insulin secretion in response to decreased insulin sensitivity is represented by the
DI (Bergman 2005).

2.2

Materials and Methods:
Horses – Sixteen healthy mares from the University of Tennessee teaching and

research herd were evaluated during the study period (February to June 2006). Horses
were admitted to the University of Tennessee Large Animal Hospital in pairs, and each
pair of horses remained hospitalized for 14 days. Only mares were selected to eliminate
differences attributable to sex. The horses were 4 to 12 years old (mean age, 9.1 years;
median, 9.5 years); breeds included mixed (n = 8), Quarter horse (3), Tennessee Walking
Horse (1), Appaloosa (1), and Paint (3). Horses were weighed at the time of admission;
weights ranged from 436 kg to 563 kg (mean weight, 493.6 kg; median, 498.6 kg). Body
condition score (on a scale of 1 to 9) ranged from 4 to 6 (Henneke et al. 1983). The study
protocol was approved by the University of Tennessee Institutional Animal Care and Use
Committee.
Experimental design – A randomized crossover study design with repeated
measures was used; each horse received the LPS and control treatments. Eight horses
were randomly selected to receive an injection of LPS during the first of the 2-week
period and then an injection of sterile saline (0.9% NaCl) solution (control treatment)
alone the second week; the remaining 8 horses received the LPS and control treatments in
the reverse order. Horses were weighed and physical examinations were performed on
the first day (Friday), and then each horse was housed separately in 3.7 X 3.7-m stalls
within the veterinary teaching hospital. Grass hay and water were provided ad libitum
and each horse was acclimated to its new environment for approximately 72 hours.
Horses were evaluated during each of the 2 study weeks; each week, procedures were
performed according to the same schedule. On the first day of the week (Monday), an IV
catheter was placed and a sham FSIGTT was performed. An FSIGTT was performed 24
hours before treatment (Tuesday; baseline [–24 hours]), and the infusion of LPS or saline
solution was administered between 1200 and 1230 on Wednesday (designated time = 0).
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Frequently sampled IV glucose tolerance test procedures were performed 24 (Thursday)
and 48 hours (Friday) after treatment. All FSIGTTs were performed between 12:00 and
3:00 PM. Intravenous catheters were removed at the end of each study week.
Lipopolysaccharide administration – Escherichia coli O55:B5 LPS was mixed
with 60 mL of sterile saline (0.9% NaCl) solution under a fume hood by an investigator
(SBE) wearing gloves and a respirator to minimize exposure. The LPS solution (20
ng/kg) or 60 mL of saline solution alone was infused via the IV catheter during a 30minute period.

Horses were observed for signs of colic and physical examination

variables, including rectal temperature, heart rate, respiratory rate, mucous membrane
color, and capillary refill time with the results recorded every 15 min for the first 3 h,
then every 30 min for the following 3 hours, and then every 2 hours for 18 hours.
CBC analysis – Blood was collected from the indwelling jugular catheter into
tubes containing EDTA before the LPS or saline solution infusion was initiated
(commenced at time = 0) and 3 hours later (ie, 2.5h after completing the LPS infusion).
Samples were immediately transported to the clinical pathology laboratory for complete
blood count (CBC) analysis.
FSIGTT procedure – On the first day of each study week, each horse was
weighed and a 14-gauge polypropylene catheter 1 was inserted into the left jugular vein.
During tests, the horse was allowed access to grass hay and water ad libitum. Patency of
the IV catheter was maintained between tests by injection of 5 mL of saline solution
containing heparin into the catheter every 6 hours. An injection cap and infusion set 2
(length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter. The FSIGTT
procedure first described for use in horses by Hoffman et al. (2003) was used. Briefly, a
bolus (300 mg of glucose/kg) of a 50% (wt/vol) dextrose solution 3 was administered to
each horse via the infusion line and catheter, followed by injection of saline solution
containing heparin (4 U/mL). Blood samples were collected via the catheter immediately
before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of dextrose. At

1

Abbocath-T 14G X 140 mm, Abbott Laboratories, North Chicago, Ill.
Butterfly, Abbott Laboratories, North Chicago, Ill.
3
Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill.
2
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20 min, regular insulin 4 (30 mU/kg) was administered followed by another infusion of
saline solution containing heparin. Blood samples were subsequently collected via the
catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min
after the dextrose infusion. At each time point, 3 mL of blood was withdrawn from the
infusion line and discarded. A 6-mL blood sample was then collected, followed by
infusion of 5 mL of saline solution containing heparin. Half the volume of the blood
sample was transferred to a tube containing sodium heparin, which was immediately
cooled on ice and then refrigerated. The remaining blood was transferred to a tube
containing no anticoagulant. Those samples were allowed to clot at 22oC for 1h and then
serum was harvested via low-speed (1,000 × g) centrifugation.

Plasma and serum

samples were stored at –20oC until further analyzed.
Plasma glucose and serum insulin concentrations – Plasma glucose
concentrations were measured by use of a colorimetric assay 5 on an automated discrete
analyzer 6. Serum insulin concentrations were determined by use of a radioimmunoassay 7
that has been validated for use in horses (Freestone et al. 1991). Each sample was
assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were
required for acceptance of glucose and insulin assay results, respectively.
Interpretation of FSIGTT data by use of the minimal model – Values of SI,
Sg, AIRg, and disposition index (DI) were calculated for each FSIGTT in accordance
with the minimal model (Bergman et al. 1981) by use of commercially available
software 8,9 and previously described methods (Hoffman et al. 2003). Disposition index
was calculated via multiplication of AIRg by SI.
Statistical analysis – Horses were classified as responders or nonresponders
according to their response to endotoxin, and groups were compared by use of the
nonparametric Mann-Whitney U test. Mixed-model ANOVA for repeated measures was
performed by use of statistical software 10 to determine the effects of treatment (LPS vs
4

Humulin R, Eli Lilly & Co, Indianapolis, Ind.
Glucose, Roche Diagnostic Systems Inc, Somerville, NJ.
6
Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ.
7
Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, Calif.
8
MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, Pa.
9
Stata 9.2, Stata Corp, College Station, Tex.
10
PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC.
5
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saline solution) and time (−24, 24, or 48 hours) on Sg, SI, AIRg, and DI. When a
significant treatment × time effect was detected, the Bonferroni test for multiple
comparisons was used to identify significant differences between least squares means.
Significance was defined at a value of P < 0.05.

2.3

Results
The response to endotoxin was determined via observation of signs of colic and

detection of leukopenia, which was defined as WBC count < 5.6 X 103 WBCs/µL
(Duncan et al. 1994) at 3 hours after LPS administration. Compared with horses that
were classified as nonresponders (n = 3), rectal temperature, heart rate, WBC count,
percentage decrease (from baseline) in WBC count, and neutrophil count differed
significantly in horses that were identified as responders (n = 13; Table 2.1).
In responders, signs of colic detected within 3 hours of LPS administration
included pawing, rolling, and stretching. Nonresponders did not develop signs of colic.
Frequently sampled intravenous glucose tolerance tests were successfully performed, and
mean ± SE plasma glucose and serum insulin concentrations were calculated (Figures
2.1 and 2.2). Data from a single FSIGTT performed 48 hours after LPS administration in
1 horse were excluded from the statistical analysis because the DI value was clearly an
outlier and had a studentized residual (adjusted by dividing it by an estimate of its SD ) of
7.44.
Compared with the control treatment, injection of LPS significantly decreased SI
(time × treatment; P = 0.040) and increased AIRg (time × treatment; P = 0.006) over
time (Table 2.2). Mean ± SD SI significantly decreased from 2.9 ± 1.9 × 10-4 L•min1

•mU-1 at baseline (ie, prior to LPS administration) to 0.9 ± 0.9 × 10-4 L•min-1•mU-1 after

24 hours (69% reduction); however, the value at 48 hours did not differ significantly
from the pretreatment value.

Mean AIRg significantly increased from 520 ± 196

-1

mU•min•L at –24 hours to 938 ± 620 mU•min•L-1 and 712 ± 400 mU•min•L-1 at 24 and
48 hours after LPS treatment, respectively. After LPS treatment, mean DI significantly
(time × treatment; P = 0.024) decreased from the baseline value of 14 ± 10 × 10-2 to
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Table 2.1 – Mean ± SD physical examination variable and WBC count data in 16 horses
that received Escherichia coli O55:B5 LPS in 60 mL of sterile physiologic saline (0.9%
NaCl) solution (20 ng/kg) administered IV and developed signs of colic and leukopenia
(responders) or did not respond to treatment (nonresponders).
Nonresponder

Responder group

group (n = 3)

(n = 13)

Maximal heart rate (beats/min)

49 ± 7

67 ± 17*

Maximal rectal temperature (ºC)

38.2 ± 0.6

39.1 ± 0.5*

9.4 ± 5.1

45.1 ± 11.1*

7.4 ± 1.4

4.0 ± 0.9*

5.5 ± 0.7

2.3 ± 0.8*

Variable

Decrease in WBC count at 3 hours after
treatment, compared with pretreatment
value (%)
WBC count at 3 hours after treatment
(× 103 cells/µL)
Neutrophil count (× 103 cells/µL)

Leukopenia was defined as WBC count < 5.6 × 103 WBCs/µL. Reference range for heart
rate: 28-40 beats/min. Reference range for rectal temperature: 37.8-38.8 ºC. Reference
range for neutrophil count: 2.9-8.5 × 103 cells/µL.
*For this variable, value was significantly (Mann-Whitney U test; P < 0.05) different
from that of the nonresponder group.
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Figure 2.1 – Mean ± SE plasma glucose concentrations during FSIGTTs performed in 16
horses that received an IV infusion of saline (0.9% NaCl) solution (60 mL) or
Escherichia coli O55:B5 LPS (endotoxin; 20 ng/kg) in 60 mL of saline solution during
the first study week according to a randomized crossover design. Tests were conducted
24 hours before (white circles) and 24 (black squares) and 48 hours (white triangles) after
administration of saline solution (panel A) or LPS (panel B). Values derived at 48 hours
after LPS infusion are calculated from 15 horses.
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Figure 2.2 – Mean ± SE serum insulin concentrations during FSIGTTs performed in 16
horses that received an IV infusion of saline (0.9% NaCl) solution (60 mL) or
Escherichia coli O55:B5 LPS (endotoxin; 20 ng/kg) in 60 mL of saline solution during
the first study week according to a randomized crossover design. Tests were conducted
24 hours before (white circles) and 24 (black squares) and 48 hours (white triangles) after
administration of saline solution (panel A) or LPS (panel B). Values derived at 48 hours
after LPS infusion are calculated from 15 horses.
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Table 2.2 – Mean ± SD minimal model analysis values obtained from FSIGTT data
derived from 16 horses that received an IV infusion of physiologic saline solution (60
mL; control treatment) or E coli O55:B5 LPS in 60 mL of physiologic saline solution (20
ng/kg) during each week of a 2-week study period according to a randomized crossover
design. The FSIGTTs were conducted 24 hours before and 24 and 48 hours after
administration of the injection.
Time point
Variable

Treatment

Before treatment

24 hours

48 hours *

SI

Control

3.0 ± 1.9a

2.7 ± 1.5a,b

2.7 ± 1.3a,b

× 10–4

LPS

2.9 ± 1.9a,b

0.9 ± 0.9c

1.5 ± 0.9b,c

Sg

Control

2.3 ± 0.6a

2.5 ± 0.8a

2.4 ± 0.8a

× 10–2

LPS

2.3 ± 0.6a

1.9 ± 0.6a

2.1 ± 0.7a

AIRg

Control

503 ± 260a

594 ± 319a,b

537 ± 275a,b

(mU•min•L-1)

LPS

520 ± 196a,b

938 ± 620c

712 ± 400c,b

DI

Control

13 ± 8a

14 ± 6a

13 ± 6a

× 10-2

LPS

14 ± 10a

6 ± 5b

10 ± 9a,b

(L•min-1•mU-1)

( min-1)

* Mean ± SD values for the endotoxin group are calculated from data derived from 15
horses.
a-c

For variables with significant (P < 0.05) treatment × time effects, mean values with

different superscripts differ significantly, as determined by use of an ANOVA for
repeated measures and via comparison of least squares mean values by use of a
Bonferroni adjustment. Treatment-time effects were detected for SI (P = 0.041), AIRg
(P = 0.006), and DI (P = 0.024).
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6 ± 5 × 10-2 at 24 hours after endotoxin administration. No significant treatment × time
effects were detected for Sg.
In the 3 horses that did not develop a clinical response to endotoxin
administration, mean SI increased by 12% and then decreased by 27% at 24 and 48 hours
following LPS infusion, respectively, compared with the value before treatment.
Compared with the pretreatment value, mean AIRg was decreased by 2% and increased
by 7% at 24 and 48 hours after injection, respectively; mean Sg was decreased by 36%
and increased by 14% at 24 and 48 hours after injection. The DI values did not increase
or decrease from baseline by > 1% after LPS administration. After the completion of the
study horses were returned to the University of Tennessee teaching and research herd.

2.4

Discussion
In the present study, 13 of 16 healthy horses that received Escherichia coli

O55:B5 LPS via IV infusion at a dose of 20 ng/kg developed signs of mild colic and
leukopenia (ie, WBC count < 5.6 X 103 WBCs/µL).

At 24 hours after LPS

administration, insulin sensitivity was significantly lower than the value prior to
treatment and AIRg increased to compensate for this alteration in glucose dynamics.
Signs of colic, fever, tachycardia, and leukopenia were detected in the horses that
responded to LPS in the present study, and these findings are consistent with those of
previous reports (Barton et al. 2004; Doherty et al. 2003; Kiku et al. 2003; MacKay et al.
1999; Moore et al. 1981). In 1 study (MacKay et al. 1999), IV administration of
Escherichia coli O55:B5 LPS at a dose of 30 ng/kg decreased the WBC count, compared
with baseline values, with the nadir occuring at 2 hours after infusion. Horses developed
mild restlessness, sweating, increased respiratory effort, and tachypnea in response to
LPS; mean rectal temperature increased over time, and a peak value > 39oC (102.2oF)
was detected 4 hours after initiation of the endotoxin infusion. Plasma interleukin-6 and
TNFα activities were also increased in treated horses. In another study (Barton et al.
2004), E coli O26:B5 LPS was administered to horses at the dose used in the present
study (20 ng/kg). In those horses, mean rectal temperature was approximately 39°C at 3
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hours after initiation of the LPS infusion; mean heart rate also significantly increased
from baseline values, and peaked at approximately 50 beats/min after 1.5 hours. In that
same study, neutrophil counts were assessed every 30 minutes and the lowest mean value
(< 3,000 cells/µL) was detected 1 hour after LPS infusion. However, similar to the
finding in the responder group of the present study, the mean neutrophil count remained
less than the pretreatment value for 3 hours after LPS was infused.
In the study reported here, 3 horses failed to develop signs of colic or leukopenia.
This lack of response may be attributable to circulating anti-endotoxin antibodies or
genetic polymorphism within intracellular LPS signal transduction pathways (Arbour et
al. 2000; Hardie and Kruse-Elliott 1990b). Toll-like receptor-4, myeloid differentiation
factor-2, and cluster differentiation factor-14 can all be affected (Arbour et al. 2000). In
humans, missense mutations affecting the extracellular domain of the Toll-like receptor 4
are associated with a diminished response to inhaled LPS (Arbour et al. 2000). However,
a common mutation was not identified when this hypothesis was tested in horses that had
blunted responses to LPS (Werners et al. 2006).
Glucose and insulin dynamics were assessed in horses by use of FSIGTT and
minimal model analysis procedures in the present study. These methods have been
previously used in horses and are preferred over the EHC technique, which is alternative
method of quantifying SI (Hoffman et al. 2003; Kronfeld et al. 2005a; Pratt et al. 2005).
One advantage of the minimal model is that it provides measures of the pancreatic
response (AIRg) and ability of glucose to mediate its own disposal (Sg), as well as SI
(Bergman 2005).

The DI, which represents the ability of pancreatic beta cells to

compensate for decreased insulin sensitivity, can also be calculated (Hoffman et al.
2003). Measures of AIRg, Sg, and DI are not provided by use of the EHC technique.
The EHC technique is also more difficult to perform from a technical standpoint because
an infusion line must remain connected to each horse throughout the 2- to 3-hour study
period (Pratt et al. 2004), which provides more opportunity for equipment failure and
stress.
Insulin sensitivity values prior to LPS infusion and those determined in horses
during the week that they received the control treatment compared favorably with results
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of previous studies (Hoffman et al. 2003; Treiber et al. 2005b). A mean SI value of 1.9 ×
10–4 L•min-1•mU-1 was reported for nonobese Thoroughbred geldings (Hoffman et al.
2003) and the mean value for a group of 46 horses was 2.1 × 10–4 L•min-1•mU-1 (Treiber
et al. 2005b). In contrast, lower mean SI values of 0.39 × 10–4 L•min-1•mU-1 and 0.08 ×
10–4 L•min-1•mU-1 have been detected in healthy ponies and ponies that had previously
had laminitis (Treiber 2005), which suggests that insulin sensitivity is generally lower in
ponies than horses (Jeffcott et al. 1986; Rijnen and van der Kolk 2003). Mean SI
significantly decreased following LPS administration in the horses of the present study.
At 24 hours after treatment, mean SI was significantly lower than the mean value before
LPS infusion; at 48 hours after treatment, mean SI was still lower than the mean value
before LPS infusion, but this difference was not significant. A biphasic glucose response
has been detected after LPS administration in humans (Agwunobi et al. 2000). Glucose
infusion rates during EHC procedures were significantly higher 120 minutes after LPS
was administered, compared with saline controls, but then progressively decreased and
were significantly lower than what was registered in saline controls at 420 minutes after
LPS administration.

Endotoxemia also induces IR in rats, as evidenced by a 37%

decrease in glucose disposal following LPS administration (Virkamaki and Yki-Jarvinen
1994).

At the tissue level, continuous LPS infusion significantly decreased insulin

receptor abundance, inhibited insulin-stimulated tyrosine phosphorylation of insulin
receptors, and decreased the number of IRS-1 molecules within liver tissues collected
from treated rats (McCowen et al. 2001). In contrast, only tyrosine phosphorylation of
IRS-1 molecules was significantly affected in rat skeletal muscle tissue. Results of those
studies suggest that IR can be rapidly induced through interference with tissue insulin
signaling pathways; however, in those experiments, rats received markedly larger doses
of LPS than those administered to horses in the study reported here.
Increases in serum TNFα activity have been detected in the plasma of horses
following the experimental induction of endotoxemia, and this cytokine may mediate the
development of IR in equids (Barton et al. 2004; MacKay et al. 1999; Rui et al. 2001).
Results of a study (Rui et al. 2001) involving rodents indicated that TNFα induces serine
phosphorylation of IRS-1, which disrupts the interaction of IRS-1 with the catalytic
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domain of the insulin receptor and inhibits insulin-stimulated activation of the
phosphatidylinositol 3-kinase cascade. Alternatively, IR may develop in horses after LPS
administration because of increases in circulating cortisol concentrations. Administration
of LPS significantly increases cortisol concentrations in ponies, and pretreatment of rat
adipocytes with glucocorticoids inhibits insulin-mediated glucose uptake in vitro (Ewert
et al. 1985; Fessler et al. 1982; Kawai et al. 2002).

Increased catecholamine

concentrations have also been detected in humans after injection of LPS and this response
may lower SI (Krabbe et al. 2001). In an in vitro study (Hunt and Ivy 2002) of isolated
rat muscle, physiologic concentrations of epinephrine inhibited insulin-mediated glucose
uptake into tissues by modulating activation of IRS-1–associated phosphatidylinositol 3kinase. Intravenous administration of epinephrine has also been shown to delay the
ability of insulin to inhibit endogenous glucose production in humans (Vicini et al. 2002).
Glucose effectiveness in horses was not altered by LPS administration in the
present study and values were consistent with those previously reported. In nonobese and
moderately obese Thoroughbred geldings, mean ± SE Sg values of 1.43 ± 0.16 × 10–2 and
1.59 ± 0.19 × 10–2 have been detected, respectively, and for 46 healthy horses, a 95%
confidence interval for Sg of 0.12 to 2.95 × 10–2 has been reported (Hoffman et al. 2003;
Treiber et al. 2005b). In the study reported here, mean AIRg was 83% and 45% higher
than the pretreatment value at 24 and 48 hours after LPS administration, respectively.
Before LPS infusion and during the week that horses received the control treatment,
AIRg values were higher than the mean value of 270 mU•min•L-1 detected in 46 healthy
horses, but were within the 95% reference interval of 67 to 805 mU•min•L-1 previously
reported for this variable (Treiber et al. 2005b). Minimal model analysis values may vary
between study populations because of differences in evaluation techniques and breed,
sex, age, or diet of the study horses.
The results of our study have indicated that pancreatic beta cells of horses respond
to endotoxin-induced IR by secreting more insulin. Compensated IR has been previously
described in ponies and is recognized by the presence of hyperinsulinemia in chronically
insulin-resistant animals (Treiber et al. 2006b). However, in the horses of the present
study, mean DI decreased by 57% over 24 hours in response to LPS, which suggests that
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this compensatory response was inadequate.

More time may be required for the

pancreatic beta cells to fully respond to the decrease in SI or alternatively, endotoxin may
directly inhibit pancreatic function.
The data obtained in the present study may be relevant to the pathogenesis of
laminitis because laminar keratinocytes appear to have a high requirement for glucose
(Pass et al. 1998). The presence of insulin-sensitive glucose transporter 4 protein within
equine hoof tissues suggests that insulin plays an important role in glucose uptake
(Mobasheri et al. 2004). In vitro experiments performed with freshly isolated hoof
explants have also revealed that laminae separate at the dermoepidermal junction when
glucose concentrations are decreased within the tissue culture medium (Pass et al. 1998).
Insulin resistance might also predispose horses to laminitis by inducing endothelial cell
dysfunction. This may increase endothelin-1 synthesis and cause a concurrent decrease
in nitric oxide production in the endothelium, resulting in vasoconstriction (Kim et al.
2006). It has previously been shown that endothelin-1 concentrations are higher in
laminar connective tissues from horses with laminitis (Eades et al. 2007; Katwa et al.
1999). In a recent study in horses, Eades et al. (2007) determined that digital venous
blood endothelin-1 concentrations were significantly higher than baseline values 11 hours
after carbohydrate was administered to induce laminitis.
In the present study, administration of 20 ng of E coli O55:B5 LPS/kg decreased
insulin sensitivity while enhancing the acute insulin response to glucose and did not alter
glucose effectiveness in horses.

Results suggest that endotoxemia will further

compromise glucose and insulin dynamics in chronically insulin-resistant horses, which
may place them at higher risk for development of laminitis.

2.5

Evaluation of the euglycemic hyperinsulinemic clamp procedure
The initial protocol for this study included a comparison of FSIGTT and

euglycemic hyperinsulinemic clamp (EHC) techniques. It was originally our intent to
evaluate the effects of LPS on glucose and insulin dynamics using both techniques, with
8 horses evaluated with each procedure. However, results of preliminary studies revealed
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unacceptably high coefficients of variation for consecutive EHC tests. A study was
therefore designed to test the hypothesis that the EHC has a low repeatability when
performed multiple times consecutively with only a short interval between procedures.

2.5.1

Methods
Four adult mares were evaluated and each mare underwent four EHC procedures

24 h apart. Horses were hospitalized in pairs and acclimated to their new environment
for 72 h before testing commenced. A 14-gauge intravenous catheter was inserted into
each jugular vein and a sham test was performed at the end of the acclimation period.
The sham test consisted of repeated blood sample collections according to the EHC
protocol. The first of four consecutive EHC procedures was then initiated 24 hours after
completion of the sham test. During the tests, horses remained in their stalls and were
provided with grass hay ad libitum.
During the EHC procedure, three blood samples were collected at – 10, – 5, and 0
min before initiating of the insulin and glucose infusions, to determine baseline glucose
concentrations.

At t = 0, a priming insulin dose of 0.018 IU/kg was administered

intravenously, immediately followed by the continuous rate infusion (CRI) of regular
insulin at a rate of 0.003 IU/min/kg for 3h. A CRI of 50% dextrose solution was
concurrently administered using a syringe pump through the contralateral jugular
catheter. Blood glucose concentrations were monitored every 5 min during the 3-hour
clamp using a handheld glucometer. 11 These results were used to adjust the dextrose
infusion rate to maintain euglycemia. At 15 min intervals, blood samples were collected
for measurement of serum insulin and plasma glucose concentrations. The first 150 min
period of each clamp was considered to be an equilibration period, so data from the final
30 min was used to calculate whole-body glucose uptake (M), steady state insulin
concentration (I), and their ratio (M/I), which is a measure of insulin sensitivity (Pratt et
al. 2005).

11

Steady state insulin concentrations were calculated by averaging insulin

Precision Q•I•D System, MediSense, Birmingham, UK
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concentrations measured during the last 30 min of the clamp. The M value was derived
as follows:
M = GIR – SC
where GIR is the glucose infusion rate (mmol/kg/min) and SC equals the space
correction, which is calculated using the formula:
SC = (G2 – G1) × (0.19 × bwt) / (T × bwt)
where G1 and G2 are the blood glucose concentrations at the beginning and end of each 5
min time interval (T) and (0.19 × bwt) is the glucose space in liters. Coefficient of
variation (CV) values for the M/I ratio were calculated for the 4 procedures performed in
each horse.

2.5.2

Results
No adverse effects were registered during EHC procedures; however 3 of 16 EHC

procedures were unsuccessful because steady state glucose concentrations could not be
maintained. Coefficient of variation values calculated for successful clamps in four
horses were 20.2% (n = 4), 49.6% (n = 3), 13.3% (n = 3), and 20.2% (n = 3; Table 2.3).
Mean ± SD interday CV for M/I ratios obtained from 4 horses undergoing 13 successful
EHC procedures was 25.8 ± 16.2 %.

2.5.3

Discussion
Results of this study demonstrated higher CV for the EHC procedure than the

value of 14.1 ± 5.7 % previously reported by Pratt et al. (2005). Furthermore, a steady
state glucose concentration could not be attained in 3 of 16 clamps, which represents a
19% failure rate for this procedure. Calculation of an M/I ratio was not possible in these
situations. One explanation for our results may be that Pratt et al. (2005) restrained
horses in stocks during EHC procedures, thereby limiting their activity. Conversely,
mares undergoing EHC procedures in this study were kept in stalls and their activity level
varied from standing calmly to pacing nervously in their stalls, over the course of a single
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test. Exercise enhances glucose delivery and facilitates glucose uptake in the muscle by
increasing capillary recruitment and stimulating GLUT4 translocation to the sarcolemma,
respectively (Wasserman and Ayala 2005). Therefore, altered muscle glucose delivery
and uptake associated with different levels of activity, provide a plausible explanation for
the higher CV registered in our study.

Furthermore, changes in activity frequently

observed within a single EHC procedure may explain the difficulty of attaining a steady
state glucose concentration during some of the clamps.
Based on these results, it is apparent that horses should be restrained in standing
stocks during the EHC procedure to control for alterations in glucose and insulin
dynamics associated with differences in physical activity. Additionally, horses that are
not accustomed to standing in stocks and being separated from their herd mates should be
trained to tolerate long-term confinement to standing stocks before EHC procedures are
performed in order to prevent stress-induced changes in insulin sensitivity (Harewood
2005; Irvine and Alexander 1994; Rosmond 2005). Housing the horse with a companion
during the EHC procedure may also reduce the stress associated with separation.
Results demonstrated that the EHC had a 19% failure rate and low repeatability in
our research setting, so the FSIGTT was selected to evaluate the effects of endotoxemia
on glucose and insulin dynamics in horses.
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Table 2.3 – Ratios of whole body glucose uptake and steady state insulin concentrations
(M/I) registered in four horses during four euglycemic hyperinsulinemic clamps
performed 24 h apart. Coefficient of variation values are calculated for the M/I ratios for
successful clamps. Euglycemic hyperinsulinemic clamps that failed, due to unsuccessful
clamping of blood glucose concentrations during the last 30 min of the procedures, are
indicated with the word “failed”.
Horse

M/I ratio (×10-4)

CV (%)

24h clamp

48h clamp

72h clamp

96h clamp

1

1.47

1.37

1.34

0.89

20.22

2

Failed

0.43

0.4

0.14

49.64

3

0.55

0.71

Failed

0.65

13.29

4

Failed

0.3

0.24

0.21

20.21
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CHAPTER 3
Evaluation of the insulin-modified frequently sampled
intravenous glucose tolerance test for use in horses.
3.1

Introduction
Insulin resistance (IR), is an important condition in horses, and has become a

frequent subject of publications in equine medicine in recent years (Hurley and Moore
2007). Insulin resistance is a state in which normal concentrations of insulin fail to elicit
a normal physiologic response (Kahn 1978).

Previous studies have suggested an

association between IR and various clinical conditions, including laminitis and reduced
reproductive performance (Hurley and Moore 2007; Johnson 2002; Pass et al. 1998;
Treiber et al. 2006a; Treiber et al. 2006b).
There are several methods available to evaluate glucose and insulin dynamics in
the horse.

Nonspecific indicators of IR include basal hyperglycemia, basal

hyperinsulinemia, decreased glucose tolerance and altered results of proxy measurements
(Kronfeld et al. 2005a; Treiber et al. 2005b).

Ponies suffering from prelaminitic

metabolic syndrome have been successfully identified using the modified insulin-toglucose ratio and reciprocal of the square root of insulin proxy measurements (Treiber et
al. 2006b). Data obtained from the combined glucose-insulin test (CGIT) has facilitated
the estimation of insulin sensitivity (SI), glucose effectiveness (Sg) and net insulin
response in mares (Frank et al. 2005a; Frank et al. 2005b). Nevertheless, quantitative,
specific assessment of insulin sensitivity in horses can only be achieved by using the
euglycemic hyperinsulinemic clamp (EHC), the minimal model analysis of the
frequently sampled intravenous glucose tolerance test (FSIGTT) or the insulin
suppression test (Kronfeld et al. 2005a). Although it was demonstrated in one study that
minimal modeling of the FSIGTT has lower repeatability than the EHC (Pratt et al.
2005), the minimal model provides additional information about glucose and insulin
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dynamics such as Sg and the acute insulin response to glucose (AIRg), which are not
supplied by the EHC (Kronfeld et al. 2005a).
Minimal modeling of FSIGTT data was first applied to horses by Hoffmann et al.
(2003), using the same technique utilized in man. Dosages of dextrose and insulin
administered during this established FSIGTT are identical to those used in humans
(Avogaro et al. 1996; Bergman et al. 1987; Hoffman et al. 2003; Trout et al. 2007).
However, plasma glucose concentrations above 350 mg/dL are often detected during this
established FSIGTT, which exceeds the estimated renal threshold for glucose of 160 to
180 mg/dL for horses (Carlson 2002).
If urinary glucose spilling is present during the established FSIGTT it is likely to
influence data supplied by minimal model analysis, because urinary glucose loss is not
taken into account in this model (Avogaro et al. 1996).

The extent to which this

deficiency influences minimal model indices has not yet been investigated (Avogaro et
al. 1996). Glucose concentrations exceeding the estimated renal threshold occur early in
the FSIGTT, so Sg values, calculated mainly between 8 and 20 min after glucose bolus,
are most likely to be affected (Avogaro et al. 1996). Furthermore, plasma glucose
concentrations can remain above renal threshold beyond 20 min in horses (Toth et al.
2008), which could influence SI values.
The pancreatic insulin response to different glucose loads has never been studied
in horses. Intravenous administration of 0.33 g/kg bwt dextrose to horses as a bolus
resulted in maximum glucose and insulin concentrations 1 and 2 min relative to glucose
infusion, respectively, but measurements were only performed for 30 min (Giraudet et al.
1994).

Altered pancreatic function has been associated with IR in several species,

including the horse (Brunton et al. 2006; Hoffman et al. 2003; Toth et al. 2008), which
suggests that this aspect of glucose metabolism warrants further investigation. Given that
the horse has been recently proposed as a potential model for human metabolic
syndrome, careful investigation of methods used for measuring insulin and glucose
dynamics in horses is also warranted (Hodavance et al. 2007).
In the study reported here we aimed to evaluate the effects of different dosages of
dextrose and insulin on the glycemic and insulin response in horses during the FSIGTT.
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We also aimed to develop a new FSIGTT that minimized urine glucose spillover and
compare it with the established FSIGTT and the CGIT, which is another commonly used
test for IR in horses. It was hypothesized that lowering the dextrose dosage administered
during the FSIGTT would eliminate urinary glucose spillover, while still providing
sufficient data for minimal model analysis. We also hypothesized that marked urinary
glucose spillover occurs during the established FSIGTT and CGIT.

3.2

Materials and Methods
Horses – Six mares from the University of Tennessee teaching and research herd

were evaluated during the study period (February to June 2007). Horses were admitted to
the teaching hospital in pairs. To eliminate differences attributable to sex, only mares
were selected. Horses were 6 to 13 years of age (mean age, 9.3 years; median, 9 years)
and breeds of horse included Quarter horse / Tennessee Walking horse crossbred (n = 3),
Quarter horse (2) and Standardbred (1). Horses were weighed at the time of admission;
weights ranged from 461 kg to 523 kg (mean weight, 497 kg; median, 501 kg) with body
condition scores (on a scale of 1 to 9) ranging from 4 to 6 (Henneke et al. 1983). The
study protocol was approved by the University of Tennessee Institutional Animal Care
and Use Committee.
Experimental design – Effects of six different dextrose and insulin dosages on
glucose and insulin dynamics were assessed in six mares across a 5–week period. Urine
glucose spillover was also measured during the last week of the testing period. Horses
were admitted to the hospital 3 days before the beginning of the study period to facilitate
acclimation to their new environment. Animals were weighed and physical examinations
were performed upon admission, and each horse was housed separately in 3.7-m × 3.7-m
stall. Grass hay and water were provided ad libitum over the course of the study period.
Mares were examined to ensure that they were not pregnant and 2.2 mg/mL altrenogest 1
(10mL; orally once a day) was administered throughout the study to control for the

1

Regu-Mate®, Intervet Inc, Millsboro, Del

73

confounding effects of estrus cycle. Each week during the study, an IV catheter was
placed on day 1 and left in place for 4 days.
In the first phase of the study, each horse received six different dosages of
dextrose 2 (50, 100, 150, 200, 250 or 300 mg/kg bwt) on days 2, 3, 4 of weeks one and
two, according to a Latin square design. Insulin was not administered during this phase
of the study. Blood samples were collected in accordance with the FSIGTT protocol.
During the second phase of the study, on days 2, 3, 4 of weeks three and four,
each horse was given 300 mg/kg bwt dextrose followed by a variable dosage of regular
insulin 3 (5, 10, 15, 20, 25 and 30 mU/kg bwt) 20 min later, with the order of insulin
administration determined by the Latin-square design.

Blood samples were again

collected in accordance with the FSIGTT protocol.
During the third phase of the study, on days 2, 3 and 4 of week five, each horse
was given the following three different combinations of dextrose and insulin: 300 mg/kg
bwt dextrose followed by 30 mU/kg insulin 20 min later (established FSIGTT), 100
mg/kg bwt dextrose followed by 20 mU/kg insulin 20 min later (new FSIGTT) and 150
mg/kg bwt dextrose and 100 mU/kg insulin administered sequentially at the beginning of
the test (CGIT). The sequence of treatments was determined by a crossover study design.
A 24-French Foley catheter with a 30 mL inflatable balloon was inserted into the urinary
bladder and urine samples were collected immediately before dextrose administration and
then every 10 min for 3 h thereafter. Blood samples were collected according to the
FSIGTT and CGIT protocols.

Urinary catheters were removed every day at the

conclusion of the study.
After completing the first three phases of the study an additional fourth phase was
designed to determine total urinary glucose loss during the established FSIGTT and new
FSIGTT and CGIT in two of the mares. Urine collection was achieved using the same
methodology as that described above, except that all urine produced was collected during
the procedure, including urine that was voided around the catheter.

2
3

Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill
Humulin R, Eli Lilly and Co, Indianapolis, Ind.
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FSIGTT – On the first day of each study week, horses were weighed and a 14gauge polypropylene catheter 4 was inserted into the jugular vein. Horses were given
access to grass hay and water ad libitum during the test period. Patency of the IV
catheter was maintained between tests by infusion of 5 mL of 0.9% saline solution
containing heparin (4 U/mL) every 6h. Dextrose (50% wt/vol) solution was infused
intravenously at six different dosages (50, 100, 150, 200, 250 and 300 mg of glucose/kg)
via an infusion set 5 (length, 30 cm; internal diameter, 0.014 cm) attached to the catheter,
followed by injection of saline solution containing heparin. No insulin was administered
during this part of the study. Blood samples were collected via the catheter immediately
before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16,19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70,
80, 90, 100, 120, 150, and 180 min after dextrose infusion. At each time point, 3 mL
blood was withdrawn from the infusion line and discarded. A 6 mL blood sample was
then collected, followed by infusion of 5 mL of saline solution containing heparin. Half
the volume of blood collected was transferred to a tube containing sodium heparin, which
was immediately cooled on ice and refrigerated.

The remaining blood sample was

allowed to clot at 22oC for 3h and serum was harvested via low-speed (1,000 × g)
centrifugation. Plasma and serum samples were stored at –20oC until further analysis.
During the third and fourth week of the study, a 300 mg/kg bolus infusion of
dextrose (50% wt/vol) solution was administered to each horse via the infusion line and
catheter, followed by 5 ml of saline solution containing heparin. Blood samples were
collected again via the catheter immediately before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14,
16, and 19 min after infusion of dextrose. At 20 min, regular insulin was infused
intravenously at one of six different dosages (5, 10, 15, 20, 25 and 30 mU/kg) according
to the Latin square design, and then 20 mL saline solution containing heparin was infused
to clear the catheter. Further blood samples were collected at 22, 23, 24, 25, 27, 30, 35,
40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes. Samples were handled identically
to that described above.
CGIT procedure – The method first described by Eiler et al. (2005), was used
with increased sampling frequency during the first 30 min of the procedure. At t = 0,
4
5

Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, Ill
Butterfly, Abbott Laboratories, North Chicago, Ill.
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dextrose solution (50% wt/vol) was infused intravenously at a dosage of 150 mg/kg bwt,
immediately followed by regular insulin at a dosage of 100 mU/kg bwt via the infusion
set attached to the catheter, followed by infusion of 20 mL saline solution containing
heparin. Blood samples were collected via the catheter immediately before and 1, 2, 3, 4,
5, 6, 7, 8, 10, 12, 14, 16,19, 22, 23, 24, 25, 35, 45, 60, 75, 90, 105, 120, 135, 150, 165,
and 180 min after dextrose infusion. Samples were handled identically to that described
for the FSIGTT procedure.
Urine collection – To facilitate urine collection for the third and fourth phases of
the study, a 24-French Foley catheter, with a 30 mL inflatable balloon, was inserted into
the urinary bladder, and left in-situ during the course of procedures. In the third phase,
the bladder was emptied and urine samples were collected every 10 min to measure
urinary glucose concentrations.
During the fourth phase of the study, urine production was established in two
mares by collecting all urine from the bladder every 10 min over the course of each test.
If any urine was lost due to leakage around the Foley catheter it was collected from the
floor, which was covered with a plastic sheet to facilitate collection. At the end of each
procedure, urine samples from each horse were pooled, and total urine volume and urine
glucose concentration were determined. Urinary glucose loss was calculated as the
product of urine volume and urine glucose concentration, and expressed as a percentage
of the total amount of glucose administered.
Plasma and urine glucose concentrations and serum insulin concentrations –
Glucose concentrations were measured by use of a colorimetric assay 6 on an automated
discrete analyzer (D'Agord Schaan et al. 2003). Insulin concentrations were determined
by use of a radioimmunoassay 7 that has been validated for equine insulin (Freestone et al.
1991). Each sample was assayed in duplicate and intra-assay coefficients of variation of
less than 5% or 10% were required for acceptance of glucose and insulin assay results,
respectively.
Interpretation of FSIGTT data by the minimal model – Values for SI, Sg,
AIRg, and disposition index (DI) were calculated for each FSIGTT in accordance with
6
7

Glucose, Roche Diagnostic Systems Inc, Somerville, NJ.
Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, Calif.
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the minimal model (Bergman et al. 1981) by use of commercially available software 8,9
and previously described methods (Hoffman et al. 2003).

Disposition index was

calculated by multiplying AIRg by SI.
Statistical analysis – Area under the curve for glucose (AUCg) and area under
the curve for insulin (AUCi) values were calculated for each treatment in each phase of
the study from the glucose and insulin concentrations measured during both FSIGTT
procedures and the CGIT, by use of the trapezoidal method, using commercially available
computer software (SAS 9.1) 10. During phases one and two, mixed model analysis of
variance with orthogonal polynomial contrasts was used to compare AUCi and AUCg
values as well as minimal model variables, including SI, Sg, AIRg and DI, among
treatments. To evaluate urinary glucose spilling, urinary AUCg (uAUCg) values were
calculated during the third phase of the study based on urine glucose concentrations,
using the trapezoidal method. Mixed model analysis of variance was used to evaluate the
effects of treatments on AUCi, AUCg, uAUCg, and minimal model variables. Nonnormally distributed data were log transformed for statistical analysis.

If normal

distribution could not be achieved by transformation, then the non-parametric MannWhitney U test was applied. When a significant treatment × time effect was detected, a
protected Least Significant Difference mean separation method for multiple comparisons
was used to identify significant differences between least squares means. Results are
reported as true means ± SD or medians and 25 and 75 percentiles. Correlation was
calculated for AUCi and AIRg values obtained throughout the study. Linear regression
was performed using urinary glucose measurements during the third phase of study to
predict the time when urinary glucose spillover ceased. Significance was defined at P <
0.05.

8

MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA.
Stata 9.2, Stata Corporation, College Station, TX.
10
PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC.
9
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3.3

Results
No

abnormalities

were

detected

during

daily

physical

examinations.

Experimental procedures remained well tolerated by each horse, with the exception of
one mare which showed mild signs of abdominal pain following insertion of the urinary
catheter, necessitating its removal 80 min after insertion. Collection of a urine sample
was unsuccessful at 28 of 285 time points during the study, including 10 samples lost
from the mare that did not tolerate the urinary catheter. Evaluation of baseline insulin
concentrations and SI values revealed that one horse included in the study was insulin
resistant. The mean resting insulin concentration for this horse was 58.3 μU/mL and
mean SI was determined to be 0.23 × 10–4 L•min-1•mU-1. Therefore, data from this horse
were excluded from statistical analyses and results reported here are for 5 horses.
In the first phase of the study, a significant linear relationship (P < 0.001) was
detected between the dextrose dosage administered and AUCg, AUCi, and AIRg values,
with all three variables increasing as the dextrose dosage increased (Table 3.1, Figures
3.1 and 3.2). A plateau for AUCg was detected as dextrose dosages of 200 mg/kg or
above were administered (Figure 3.3).
During the second phase of the study, a strong inverse linear relationship (P =
0.023) was apparent between insulin dosage and AUCg during the FSIGTT (Figure 3.4),
with the AUCg decreasing as the insulin dosage increased. However, altering the insulin
dosage did not significantly affect AUCi (P = 0.482), SI (P = 0.878), Sg (P = 0.460),
AIRg (P = 0.731) and DI (P = 0.948; Table 3.2).
In the third phase of the study, AUCg (P = 0.003) and AUCi (P < 0.001) differed
significantly among tests (Figure 3.5). No significant difference was registered for SI (P
= 0.424), Sg (P = 0.134), AIRg (P = 0.502) and DI (P = 0.812) when the new and
established FSIGTT were compared (Table 3.3). A strong correlation (R = 0.709, P <
0.001) was found between AUCi and AIRg values measured throughout the study.
Urine AUCg differed significantly (P < 0.001) among tests, with values of 161.4
g/dL•min, 34.2 g/dL•min and 58.9 g/dL•min detected for the established FSIGTT, new
FSIGTT, and CGIT, respectively (Figure 3.5).
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Table 3.1 – Mean ± SD AUCg and AUCi values median and 25th and 75th percentile
AIRg values, and obtained from 5 horses following intravenous administration of 50,
100, 150, 200, 250 and 300 mg/kg bwt 50% dextrose solution.

Procedures were

conducted over a period of two weeks.
Trt

Glucose dosage (mg/kg bwt)
Variable

AUCg
(g/dL•min)

AUCi
(mU/mL•min)

AIRg
(mU•min•L-1)

a-c

300

Effect
P

50

100

150

200

250

mean ±
SD

17
± 0.6 a

17.7
± 0.6 a

18.3
± 0.8 a

21.2
± 2.5 b

21.3
± 3.3 b

21.3
< 0.001
± 2.8b

mean ±
SD

3.8
± 2.5 a

4.4
± 1.6a,b

5.5
6.3
b
± 2.9 ±3.5 b,c

8.3
± 4.8 c

9.6
< 0.001
± 6.3 c

median

417a

561a

644b,c

519b,a

756c

785c

25th

409

504

614

482

543

711

75th

523

573

686

619

787

1018

< 0.001

For variables with significant (P < 0.05) treatment effects, values with different

superscripts differ significantly, as determined by use of an ANOVA and via comparison
of least squares mean values by use of a Least Significant Difference adjustment.
Nonparametric Mann-Whitney U test was used to compare AIRg values among
treatments.
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Figure 3.1 – Mean ± SE plasma glucose concentrations registered during the first phase
of the study following intravenous administration of six different dosages of 50%
dextrose solution to 5 horses. Dosages: 50 mg/kg (solid triangles), 100 mg/kg (open
circles), 150 mg/kg (solid squares), 200 mg/kg (open triangles), 250 mg/kg (solid circles)
and 300 mg/kg (open squares).
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Figure 3.2 – Mean ± SE blood insulin concentrations registered during the first phase of
the study following intravenous administration of six different dosages of 50% dextrose
solution to 5 horses. Doses included: 50 mg/kg (solid triangles), 100 mg/kg (open
circles), 150 mg/kg (solid squares), 200 mg/kg (open triangles), 250 mg/kg (solid circles)
and 300 mg/kg (open squares).
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AUCg (g/dL x min)

24

b

b

b

200

250
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22
20
18

a

a

a

16
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Figure 3.3 – Mean ± SE area under the curve for glucose (AUCg) values calculated
during the first phase of the study following intravenous administration of six different
dosages of 50% dextrose solution to 5 horses.
a-b

Values with different superscripts differ significantly (P < 0.05), as determined by

ANOVA and comparison of least squares mean values by use of a Least Significant
Difference adjustment.
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a,b

a,b
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20
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Figure 3.4 – Mean ± SE area under the curve for glucose (AUCg) values calculated in 5
horses during the second phase of the study after intravenous administration of 300
mg/kg 50% dextrose solution at t = 0 min followed by 6 different dosages of insulin (5,
10, 15, 20, 25 and 30 mU/kg) at t = 20 min.
a-b

Values with different superscripts differ significantly (P < 0.05), as determined by

ANOVA and comparison of least squares mean values by use of a Least Significant
Difference adjustment.
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Table 3.2 – Mean ± SD AUCg and AUCi values, and median and 25th and 75th percentile
minimal model analysis values from 5 horses following intravenous administration of
300 mg/kg bwt 50% dextrose solution at t = 0, followed by the administration of 5, 10,
15, 20, 25 and 30 mU/kg bwt insulin at t = 20 min.
Insulin dosage (mU/kg bwt)
5
AUCg
(g/dL•min)

AUCi
(mU/mL•min)

SI
-1

-1

(L•min •mU )
× 10–4

Sg

(min-1)
×10–2

AIRg

(mU•min•L-1)

DI

×10-2
a-c

10

15

20

25

30

20.7
± 1.5a,b

21.9
± 3.4a,b

19.9
± 3.1 b

0.026
0.482

mean ±
SD

22.5
± 2.3 a

22.9
21.5
a
± 3.3 ± 4.3a,b

mean ±
SD

12.3
± 7.2

12.1
± 4.7

10.4
± 4.5

12
± 4.6

12.6
±6

13.6
± 7.2

median

1.75

1.17

1.33

1.04

1.71

1.97

th

1.04

0.94

0.72

1.01

0.31

0.62

75th

3.22

1.7

1.68

1.17

2.74

2.32

median

0.52

2.45

2.92

2.07

1.77

1.95

25th

0.35

0.9

1.81

1.69

1.12

1.87

75th

1.49

2.64

2.93

2.15

2.21

2.41

median

25

588

651

549

646

654

732

th

551

588

547

597

594

562

th

75

751

759

712

765

719

816

median

9.63

10.44

8.36

8.59

10.18

11.09

25

7.96

3.93

7.27

6.72

2.00

4.54

75th

24.16

12.92

9.13

8.97

19.70

11.68

25

th

Trt
effect
P

0.878

0.460

0.731

0.948

For variables with significant (P < 0.05) treatment effects, mean values with different

superscripts differ significantly, as determined by use of an ANOVA and via comparison
of least squares mean values by use of a Least Significant Difference adjustment.
Nonparametric Mann-Whitney U test was used to compare SI, Sg, AIRg and DI values
among treatment groups.
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Figure 3.5 – Mean ± SE area under the curve for urinary glucose (uAUCg), area under
the curve for glucose (AUCg) and area under curve for insulin (AUCi) values calculated
for 5 horses during the third phase of the study. Each horse underwent three tests
according to a crossover study design: established FSIGTT (300 mg/kg dextrose and 30
mU/kg insulin; white column), new FSIGTT (100 mg/kg dextrose and 20 mU/kg insulin;
solid column) and the CGIT (150 mg/kg dextrose and 100 mU/kg insulin; shaded
column).
a-c

Within each variable, mean values with different superscripts differ significantly (P <

0.05), as determined by ANOVA and comparison of least squares mean values by use of
a Least Significant Difference adjustment.
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Table 3.3 – Mean ± SD urine AUCg, AUCi, AUCg and minimal model analysis values
obtained from 6 horses using the established, new FSIGTT, and CGIT method. Tests
were conducted 24h apart.
Trt

Treatment
New
FSIGTT

CGIT

P

161.4 ± 40.2a

34.2 ± 16.4 b

58.9 ± 8.6 c

< 0.001

AUCg
(g/dL•min)

20.8 ± 2.2 a

18.4 ± 1.5 b

15.7 ± 1.2 c

0.003

AUCi

12.4 ± 3.7 a

7 ± 2.7 b

18.3 ± 3.8 c

< 0.001

1.64 ± 0.92

2.02 ± 1.54

N/A

0.424

2.3 ± 0.7

1.6 ± 0.8

N/A

0.133

AIRg

707 ± 121

632 ± 255

N/A

0.502

DI

11.25 ± 5.72

11.44 ± 8.54

N/A

0.811

Urine AUCg
(g/dL•min)

(mU/mL•min)

SI

(L•min-1•mU-1)
× 10–4

Sg

( min-1)
× 10–2

(mU•min•L-1)

(× 10-2)
a-c

effect

Established
FSIGTT

For variables with significant (P < 0.05) treatment effects, mean values with different

superscripts differ significantly, as determined by use of an ANOVA and via comparison
of least squares mean values by use of a Least Significant Difference adjustment.
N/A = Not applicable; minimal model analysis was not performed.
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Linear regression calculated from the urinary glucose concentrations during the
linear phase revealed that the projected time for urinary glucose spillover to cease was
53.7 min, 27.6 min and 44.8 min, respectively for the tests evaluated. Mean ± SD %
urinary glucose loss relative to the mass of glucose administered intravenously for two
horses undergoing the additional urine collection procedure was 10.11 ± 1.51 %, 2.66 ±
0.58 % and 4.97 ± 2.14 %, respectively for the established FSIGTT, new FSIGTT and
CGIT (Table 3.4).

3.4

Discussion
The present study demonstrated that increasing the dosage of dextrose

administered during the FSIGTT caused parallel increases in AUCg, AUCi and AIRg
values. A plateau was registered for the AUCg values when the glucose dosage reached
200 mg/dL. Increasing the insulin dosage, however, only influenced the AUCg and left
minimal model and AUCi values unchanged.

Marked urinary glucose spilling was

apparent when the established FSIGTT was performed in horses. The new FSIGTT,
which is performed by infusing 100 mg/kg dextrose and 20 mU/kg insulin, provided
sufficient data for minimal model analysis while minimizing urinary glucose loss.
In the first phase of the study, AUCg increased in parallel with the increase in
dextrose dosage, however, a plateau was reached with dextrose dosages of 200 mg/kg or
above. Although no urinary glucose measurements were performed in this phase of the
study, we assume that this plateau resulted from increased urinary glucose loss. The
sudden decline in blood glucose concentrations immediately following the peak after 200,
250, and 300 mg/kg dextrose was administered may have been a result of immediate
urinary glucose loss, as well as mixing within the body glucose space. The same factors
were implicated for the steep decrease in blood glucose concentrations following the peak
after intravenous glucose boluses were administered in two studies performed in dogs
(Kaneko et al. 1978; Rottiers et al. 1981).

Additionally, increased blood glucose

concentrations are expected to facilitate glucose disposal by their mass effect. This
ability of glucose per se to normalize its concentration through actions on glucose
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Table 3.4 – Net glucose mass infused, total urine volume, urine glucose concentration,
net urinary glucose loss and glucose lost (%) registered in two horses during the
established FSIGTT, new FSIGTT and CGIT.
Horse

Established
FSIGTT

New
FSIGTT

CGIT

Net glucose mass
administered
(g/horse)

A

163.6

54.5

81.8

B

155.5

51.8

77.7

Total urine
volume
(mL)

A

750

630

570

B

960

480

455

Urine glucose
concentration
(mg/dL)

A

1973.1

265.9

495.9

B

1809.9

242.5

1107.5

Net urinary
glucose loss
(g)

A

14.8

1.7

2.8

B

17.4

1.2

5

Glucose lost
(%)

A

9

3.1

3.5

B

11.2

2.3

6.5
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production and utilization, independent of insulin, is represented by the parameter Sg in
the minimal model (Pacini et al. 1998). Indeed, Sg values appeared to be higher in the
third phase of the study for the established FSIGTT when 300 mg/kg dextrose was
administered, compared with the new FSIGTT when 100 mg/kg dextrose was infused,
although the difference was not significant. Our finding of a strong linear relationship
between glucose dosage and AUCg is in agreement with the work of Rottiers et al.
(1981). This group demonstrated that administration of five progressively increasing
glucose loads caused significantly higher successive post-infusion plasma glucose
concentrations in dogs (Rottiers et al. 1981). In the study reported here, AUCi and AIRg
also increased as the dextrose dosage increased. Since AIRg provides a measure of
insulin secretion over the first 10 minutes following glucose administration (Tiley et al.
2007) it was expected that changes in AIRg would mirror the changes in AUCi. Several
studies have demonstrated that total insulin secretion, which is represented by AIRg in
the minimal model, increases as the glucose dosage increases, which is an observation
that is similar to the increasing AUCi values registered in our experiment (Lerner and
Porte 1971; Rottiers et al. 1981).
It was interesting to note that insulin secretion occurred as a single phase response
in horses included in this study. Attributes of biphasic insulin secretion, including a nadir
and a second insulin peak were absent in the horses studied here. Our findings are
consistent with those of Giraudet et al. (1994).

This group found that insulin

concentrations abruptly increased and then gradually decreased in horses that received
0.33 g/kg bwt glucose intravenously (Giraudet et al. 1994). In humans and rats, the
sudden, sustained increase in plasma glucose concentration triggers biphasic insulin
secretion, characterized by a rapid increase with a peak, an interpeak nadir and a
subsequent slower increasing phase (Caumo and Luzi 2004; Henquin et al. 2002). The
first phase of the insulin response comes from the readily releasable pool granules located
adjacent to the cell membrane of the pancreatic β-cells (Bratanova-Tochkova et al. 2002).
For the second phase to occur, replenishment of the readily releasable pool from the
reserve pool is necessary (Bratanova-Tochkova et al. 2002).

Second phase insulin

secretion also requires the augmenting action of glucose, and the magnitude of the second
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phase response increases with the concentration of glucose administered (Henquin et al.
2002). Indeed, prolonged elevation of glucose concentration during the hyperglycemic
clamp facilitated clearer determination of the second phase insulin response than the
intravenous glucose tolerance test (Caumo and Luzi 2004).
Species differences have been also described for biphasic insulin secretion
(Henquin et al. 2002). Second phase insulin response to glucose in isolated Islets of
Langerhans from rats usually increase above the first phase peak, whereas the second
phase of glucose-induced insulin secretion is often flat and lower than the first phase peak
in mice (Henquin et al. 2002). Administration of glucose to dogs at different dosages has
also failed to elicit biphasic insulin secretion (Kaneko et al. 1978; Rottiers et al. 1981).
Furthermore, secondary plasma insulin peaks registered in human subjects undergoing
glucose tolerance tests correspond to exogenous insulin administration or injection of the
insulin secretagogue tolbutamide (Bergman et al. 1987; Katz et al. 2000). In the first
phase of the study reported here, dextrose was administered as a single bolus and blood
glucose concentrations were not sustained, neither was any insulin or insulin
secretagogue administered following the glucose infusion, which may explain the
absence of a distinct second phase of insulin secretion.
During the second phase of the study, AUCg decreased as the insulin dosage
increased, however, no significant differences were registered for AUCi, SI, Sg, AIRg
and DI.

Our inability to detect significant differences in AUCi values in spite of

administering markedly different dosages of exogenous insulin was an unexpected
finding. In retrospect, high variance of AUCi values provides a plausible explanation for
the lack of significant difference between treatments. The higher coefficient of variation
values encountered when plasma insulin concentrations were measured, relative to those
obtained for plasma glucose, may be partially responsible for the high variance observed
for AUCi.

Additionally, individual differences in stress-induced cortisol responses

(Ralston 2002) can influence the insulin response, and by doing so introduce further
variability into AUCi values. The absence of a dosage effect on minimal model variables
may indicate that even small insulin doses are sufficient to facilitate cellular glucose
uptake. Indeed the original FSIGTT design did not include administration of exogenous
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insulin; this was introduced later to facilitate minimal modeling in diabetic patients
(Pacini et al. 1998). Previous studies performed in horses used insulin dosages for the
FSIGTT that ranges from 1.5 mU/kg bwt (Treiber et al. 2005a) to 30 mU/kg bwt
(Hoffman et al. 2003).
In the third phase of the study, our primary goal was to compare the newly
developed FSIGTT procedure with the established FSIGTT and CGIT with respect to
urinary glucose spillover. A dextrose dosage of 100 mg/kg bwt was selected for the new
FSIGTT because measurements of blood glucose during the first phase of the study
suggested that this dosage could eliminate urinary glucose spillover.

Additionally,

administration of a lower dextrose dosage than the 300 mg/kg bwt used during the
established FSIGTT facilitates rapid administration via the IV catheter. Rapid infusion of
dextrose is advantageous because the minimal model assumes that the glucose is supplied
to the system with a pulse width of zero (personal communication; Ray Boston 2008).
The insulin dosage used in the new FSIGTT was selected (20 mU/kg bwt) with the aim of
facilitating glucose disposal in horses, without causing clinical hypoglycemia.

This

insulin dosage was also recommended by other investigators after completion of a study
involving the established FSIGTT (Treiber et al. 2005a).
Analysis of uAUCg revealed that urinary glucose spillover was significantly
lower during the new FSIGTT, when compared with the established FSIGTT or CGIT,
but was not completely abolished. Increased urine production was also detected during
the established FSIGTT, suggesting that osmotic diuresis was occuring as a result of
glucose spilling into the urine. On average, more than 10 % of glucose administered
during the established FSIGTT was lost to the urine, compared with less than 3 % for the
new FSIGTT.

These results are in agreement with previous findings in dogs

demonstrating that urinary glucose excretion varies directly with the size of glucose load
(Kaneko et al. 1978). Regression analysis of urinary glucose concentration demonstrated
that cessation of urinary glucose spilling occurred the earliest with the new FSIGTT, and
the latest with the established FSIGTT. Although glucose was still apparent in the urine
beyond the time suggested by the regression analysis, this was most likely a result of
inadequate clearance of glucose-containing urine from the bladder. Incomplete emptying
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of the bladder would be expected to affect subsequent samples. Glucose is normally
freely filtered at the glomerulus and most of the filtered glucose is reabsorbed in the
proximal tubules with a smaller percentage in the more distal segments of the nephron
(Brodehl et al. 1987).

Urine typically contains only minimal amounts of glucose,

however, it has been reported that glucosuria develops when blood glucose
concentrations exceed 160 to 180 mg/dL in horses (Carlson 2002), which is when the
resorptive capacity of the renal tubules is exceeded (Brodehl et al. 1987).
Minimal model variables obtained for the new and established FSIGTT did not
differ significantly. Mean SI values for the new and established FSIGTT were 2.02 × 10-4
L·min-1·mU-1 and 1.64 × 10-4 L·min-1·mU-1, respectively and these values compare
favorably with results of previous studies (Hoffman et al. 2003; Treiber et al. 2005b). In
these studies mean SI values of 2.1 × 10-4 L·min-1·mU-1 and 1.9 × 10-4 L·min-1·mU-1 were
registered for 46 horses (Treiber et al. 2005b) and in 4 non-obese thoroughbred geldings
(Hoffman et al. 2003), respectively. However, higher (3.0 and 2.9 × 10-4 L•min-1•mU-1)
mean SI values were detected in a previous study of sixteen mares performed by our
group (Toth et al. 2008). Lower mean SI values of 0.39 × 10-4 L·min-1·mU-1 and 0.08 ×
10-4 L·min-1·mU-1 were also measured in healthy ponies and in ponies with history of
laminitis, respectively (Treiber 2005). However, there is evidence to suggest that ponies
have lower insulin sensitivity than horses (Rijnen and van der Kolk 2003).
Glucose effectiveness values measured in the present study compared favorably
with results obtained in previous studies (Hoffman et al. 2003; Toth et al. 2008; Treiber
et al. 2005b).

Mean Sg values registered for non-obese and moderately obese

thoroughbred geldings were 1.43 × 10-2 min-1 and 1.59 × 10-2 min-1, respectively
(Hoffman et al. 2003).
When the minimal model is applied, AIRg is estimated from serum insulin
concentrations measured during the first 10 minutes following exogenous glucose
administration (Tiley et al. 2007), therefore the high correlation between AUCi and AIRg
recorded throughout the study was expected. Conversely, it was surprising that AIRg
values did not differ significantly between the new FSIGTT and established FSIGTT,
despite the significant difference registered for AUCi when the two tests were compared.
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This latter finding may be explained by the fact that different exogenous insulin dosages
administered at 20 min contributed to the significant difference in AUCi between the two
tests. In contrast, only insulin concentrations measured during the first 10 minutes of the
FSIGTT, prior to exogenous insulin administration, are included in the minimal model
when AIRg is estimated. Mean AIRg values previously detected in 16 mixed breed
(Quarter Horse / Tennessee Walking Horse) mares (Toth et al. 2008) were 503 and 520
mU·min·L-1 and these values are consistent with results obtained in the current study.
However, AIRg values measured in non-obese, moderately obese, and obese
Thoroughbred horses were 211, 221, and 408 mU·min·L-1, respectively (Hoffman et al.
2003), which are lower than those reported here.
The CGIT was completed in each horse without complications during the third
phase of the study. After its initial description by Eiler et al. (2005), the CGIT has been
used in several studies to identify horses with IR, and to establish glucose and insulin
dynamics (Frank et al. 2005a; Frank et al. 2006). In the study reported here, the mean ±
SD AUCg value registered during the CGIT was 15.7 ± 1.2 × 103 mg/dL•min, which
compares favorably to 12.7 × 103 mg/dL•min registered in eight healthy mares (Frank et
al. 2005a) and to the median value of 15.5 × 103 mg/dL•min reported for obese horses
with IR (Frank et al. 2006). In contrast the mean AUCi value of 18.3 × 103 μU/mL•min
measured in this study was somewhat higher than the range of 10.6 – 13.2 × 103
μU/mL•min reported for 5 nonobese horses (Frank et al. 2006) but lower than 25 × 103
μU/mL•min demonstrated in 8 healthy mares.

Serum insulin and blood glucose

concentrations were measured more frequently during the CGIT in this study than
recommended in the original report (Eiler et al. 2005). Calculation of AUCg and AUCi
from a larger number of samples should increase accuracy, and this may explain why our
results differed from those of previous studies.
In conclusion, results of this study indicate that glucose dosages equal to or higher
than 200 mg/kg bwt result in AUCg plateau, which suggests that the 300 mg/kg bwt
dosage used in the established FSIGTT is too high. Furthermore, profuse urinary glucose
spilling was detected during the established FSIGTT. Although we were unable to
demonstrate significant difference in minimal model values between the new and
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established FSIGTT procedures because of high variability, it is likely that urinary
glucose loss confounds minimal model analysis results, since one assumption of the
model is that glucose exiting the blood stream is used by peripheral tissues. A new
FSIGTT was developed for use in horses to minimize urinary glucose loss. In addition,
the smaller dextrose dosage used in the new FSIGTT facilitates more rapid
administration, which may also improve the accuracy of minimal model analysis.
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CHAPTER 4
Evaluation of C-peptide dynamics and clearance in horses
using a double antibody human C-peptide radioimmunoassay
4.1

Introduction
Insulin is a peptide hormone containing A and B chain that is synthesized by the

β-cells of the pancreatic islets of Langerhans (Wahren et al. 2000; Wilcox 2005). Upon
translation of the insulin mRNA, pre-proinsulin is generated and this molecule is
comprised of a signal peptide, the B chain, the connecting peptide (C-peptide) and the A
chain (Wilcox 2005). Proinsulin is synthesized by removal of the signal peptide from
pre-proinsulin in the ribosomes of the rough endoplasmic reticulum of β-cells. Proinsulin
is then transported to the Golgi apparatus, where it forms soluble, zinc containing
hexamers. Enzymes acting outside the Golgi convert proinsulin to insulin by cleaving the
C-peptide from the molecule during the formation of immature storage vesicles. Cpeptide has an important role in insulin synthesis by linking the A and B chains of insulin
in a manner that facilitates folding and interchain disulfide bond formation (Wahren et al.
2000). Proteolytic removal of C-peptide from proinsulin allows the carboxy terminal of
the B-chain of the insulin molecule to assume a conformation which facilitates interaction
with the insulin receptor. Insulin and C-peptide are cosecreted in equimolar amounts
when mature granules release their contents into the portal circulation (Wilcox 2005).
Until recently, C-peptide was generally accepted to possess little or no biological
activity.

Lately, however, specific binding of C-peptide to cell surfaces has been

demonstrated, suggesting the presence of G-protein coupled membrane receptors for this
protein (Wahren et al. 2000).

C-peptide has been shown to elicit concentration-

dependent stimulation of Na+-K+ ATPase in proximal segments of nephrons obtained
from rats (Ohtomo et al. 1996). Indeed, patients suffering from type I diabetes mellitus
(DM) frequently develop glomerular hyperfiltration early in the course of their disorder,
which can be significantly decreased by infusion of exogenous C-peptide (Johansson et
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al. 1992). Addition of C-peptide to the treatment regime of type I diabetic human
subjects significantly decreased urinary albumin excretion, when compared with insulin
treatment alone (Wahren et al. 2000). Through its stimulatory effect on Na+-K+ ATPase,
C-peptide has also been suggested to ameliorate nerve dysfunction in type I diabetes
(Wahren et al. 2000).
Compensatory hyperinsulinemia associated with insulin resistance typically
predates the development of type II DM in human subjects (Brunton et al. 2006).
Similarly, horses suffering from decreased insulin sensitivity triggered by endotoxemia or
obesity exhibit an augmented pancreatic insulin response to exogenous glucose
challenge, indicated by higher acute insulin response to glucose (AIRg) values (Hoffman
et al. 2003; Toth et al. 2008). In humans, overproduction of insulin by pancreatic β-cells
eventually induces β-cell exhaustion, impaired insulin secretion, and relative insulin
deficiency (Brunton et al. 2006).

As glucose levels rise, β-cell function further

deteriorates, with diminishing sensitivity to glucose, ultimately resulting in the
development of type II DM (Wilcox 2005). Insulin-resistant horses and ponies rarely
develop pancreatic β-cell insufficiency and usually maintain a state of compensated IR
(Johnson et al. 2005; Treiber et al. 2005b). Nevertheless, DM has been described in a
Spanish Mustang in association with IR (Johnson et al. 2005) and hyperglycemia was
also registered in 2 ponies suffering from insulin resistance, which indicates failed
compensation (Treiber et al. 2006b). Thus, estimation of the ability of pancreatic β-cells
to secrete insulin is important for the accurate assessment of glucose homeostasis.
During minimal model analysis of the frequently sampled intravenous glucose
tolerance test (FSIGTT), serum insulin concentrations measured during the first 10
minutes after exogenous glucose administration provide an estimate for AIRg (Tiley et
al. 2007). The AIRg reflects the ability of pancreatic β-cells to secrete insulin after
glucose challenge. However, it has been demonstrated in humans that approximately 60
percent of insulin secreted into the portal vein is removed by the liver (Wilcox 2005), so
serum insulin concentrations measured in peripheral blood provide only a crude estimate
of pancreatic function (Hovorka et al. 1998; Kjems et al. 2000). It is therefore preferable
to measure serum C-peptide concentrations when assessing pancreatic function, because
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this peptide is not extracted by the liver (Hovorka et al. 1998; Kjems et al. 2000). Higher
AIRg values have been associated with IR in horses (Hoffman et al. 2003; Toth et al.
2008), but it has not been determined whether this occurs as a result of increased
pancreatic insulin secretion or reduced hepatic insulin extraction.

This could be

investigated by simultaneously measuring insulin concentrations in blood samples
obtained from both the portal vein and hepatic vein, but the measurement of C-peptide
concentrations from peripheral blood samples is a more practical alternative.
A literature search revealed only one report describing C-peptide measurements in
horses; but the authors did not state whether the test was validated for the horse (Johnson
et al. 2005). Characteristics of C-peptide dynamics in horses, including clearance rate
and plasma half life have not been reported to date. C-peptide metabolism has been
established in dogs by blocking endogenous C-peptide secretion using a somatostatin
infusion (Polonsky et al. 1983).

Exogenous C-peptide was then administered to

investigate hepatic metabolism and metabolic clearance rate of C-peptide.
The aims of the study reported here were 1) to measure C-peptide concentrations
in equine serum using a human double antibody C-peptide radioimmunoassay (RIA), 2)
to establish clearance rate of C-peptide, and 3) to describe C-peptide dynamics during the
FSIGTT in horses. We hypothesized that the human double antibody C-peptide RIA
would be able to detect equine C-peptide and that concentrations would increase as the
pancreas responds to exogenous glucose during the FSIGTT.

4.2

Materials and Methods
Horses – Six mares from the University of Tennessee teaching and research herd

were evaluated during the study period (Oct 2006 to March 2007). Horses were admitted
to the teaching hospital in pairs and housed separately in 3.7-m × 3.7-m stalls. To
eliminate differences attributable to sex, only mares were selected. Horses were 6 to 13
years of age (mean age, 9.3 years; median, 9 years); breeds included Quarter horse /
Tennessee Walking horse crossbreds (n = 3), Quarter horse (2) and Standardbred (1).
Horses were weighed at the time of admission and weights ranged from 461 kg to 523 kg
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(mean weight, 497 kg; median, 501 kg). Body condition score (on a scale of 1 to 9)
ranged from 4 to 6 (Henneke et al. 1983). Daily physical examinations were performed
throughout the study period. Grass hay and water were provided ad libitum, and each
horse was acclimated to its new environment for approximately 72 h before experiments
started. The study protocol was approved by the University of Tennessee Institutional
Animal Care and Use Committee.
Experimental design – The study reported here comprises two phases performed
three months apart. The aim of the first phase was to evaluate C-peptide clearance in
horses after suppression of pancreatic insulin secretion by somatostatin, while the second
phase involved measurement of C-peptide concentrations in equine sera obtained during
the FSIGTT in the same six horses.
C-peptide dynamics – On the first day of the study, a 14-gauge polypropylene
catheter 1 was inserted into each jugular vein. Patency of IV catheters was maintained by
infusion of 5 mL of saline solution containing heparin (4 U/mL) every 6 hours. Tests
were performed 24 h after catheter insertion. At –90 min relative to C-peptide infusion,
each horse was administered a 500 μg bolus of (D-Trp8)-somatostatin-14 2 followed by a
continuous rate infusion (CRI) of 500 μg/h somatostatin for 330 min through one of the
intravenous catheters. Blood samples were collected at –100, –95, –90, – 75, – 60, – 45,
– 30, – 15, – 10, – 5, 0 min using an injection cap and infusion set 3 (length, 30 cm;
internal diameter, 0.014 cm) attached to the contralateral intravenous catheter. At 0 min,
a 50 nmol bolus of biosynthetic human C-peptide 4 was administered intravenously.
Further blood samples were collected at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24,
25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 210, and 240 min (n = 43
samples). At each time point, 3 mL of blood was withdrawn from the catheter and
discarded. A 4-mL blood sample was subsequently collected then the catheter was
flushed with 5 mL of saline solution containing heparin. Blood was transferred to a tube
without anticoagulant. Samples were allowed to clot at 22 oC for 1h and then serum was

1

Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, Ill
Bachem Americas, Inc. 3132 Kashiwa Street, Torrence, CA 90505
3
Butterfly, Abbott Laboratories, North Chicago, Ill.
4
GenScript Co., 120 Centennial Ave., Piscataway, NJ 08854
2
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harvested via low-speed (1,000 × g) centrifugation. Serum samples were stored at –20oC
until analyzed.
FSIGTT procedure – This procedure was performed during the second phase of
the study. Each horse was weighed and a 14-gauge polypropylene catheter was inserted
into the left jugular vein one day before the FSIGTT. Patency of the IV catheter was
maintained by infusion of 5 mL of saline solution containing heparin into the catheter
every 6h. During tests, horses were allowed access to grass hay and water ad libitum.
An injection cap and infusion set (length, 30 cm; internal diameter, 0.014 cm) were
attached to the catheter. The FSIGTT procedure first described for use in horses by
Hoffman et al. (2003) was followed. Briefly, a 300 mg/kg bolus of 50% (wt/vol)
dextrose 5 solution was administered to each horse via the infusion line and catheter,
followed by infusion of 20 mL saline solution containing heparin. Blood samples were
collected via the catheter immediately before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and
19 min after infusion of dextrose.

At 20 min, regular insulin 6 (30 mU/kg) was

administered followed by another infusion of 20 mL saline solution containing heparin.
Blood samples were subsequently collected via the catheter at 22, 23, 24, 25, 27, 30, 35,
40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min after the dextrose bolus infusion. At
each time point, 3 mL of blood was withdrawn from the infusion line and discarded. A
6-mL blood sample was then collected, followed by infusion of 5 mL of saline solution
containing heparin. Half the volume of the blood sample was transferred to a tube
containing sodium heparin, which was immediately cooled on ice and then refrigerated.
The remaining blood was transferred to a tube containing no anticoagulant.

These

samples were allowed to clot at 22 oC for 1 hour and then serum was harvested via lowspeed (1,000 × g) centrifugation. Plasma and serum samples were stored at –20oC until
further analyzed.
C-peptide RIA – Serum concentrations of C-peptide were measured using a
human, double antibody RIA kit 7 previously used, but not validated in horses (Johnson et
al. 2005). Samples were assayed in duplicate in accordance with instructions provided
5

Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill.
Humulin R, Eli Lilly and Co, Indianapolis, Ind.
7
Siemens Medical Solutions Diagnostics, 5210 Pacific Concourse Dr., Los Angeles, CA 90045-6900
(formerly: Diagnostics Products Co.)
6
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by the manufacturer.
parallelism.

The accuracy of the assay was assessed by recovery and

Dilutional parallelism was evaluated by diluting three aliquots of six

separate equine serum samples to 1:2, 1:4 and 1:8 dilutions of their initial concentration
using sterile nanopure water. Once the concentration for the undiluted sample was
obtained, expected (E) concentrations were calculated according to the dilutions used.
Observed (O) concentrations were compared with expected values and a ratio was
calculated, which was expressed as a percentage (%O/E). Spiking and recovery was
assessed by adding 50 μL solutions containing 195.3, 71.2, and 21.8 ng/mL human Cpeptide to 950 μL of three aliquots of six different equine serum samples. Expected
values were calculated by calculating the contribution of the added human C-peptide plus
the initial value for horse serum alone. For each spiked sample, observed concentrations
were compared with expected values and %O/E was calculated. Since human antibody
RIA was used in this study, results are expressed as human equivalents (HE) of
immunoreactive (ir) C-peptide.

C-peptide values were converted from ng/mL to

pmol/mL using a conversion factor of 0.333.
Serum insulin concentrations – Insulin concentrations were determined by use
of a radioimmunoassay 8 previously validated for equine insulin (Freestone et al. 1991).
Each sample was assayed in duplicate and intra-assay coefficients of variation of less
than 10% were required for acceptance of assay results. Insulin values were converted
from μU/mL to pmol/mL using a conversion factor of 6.945 × 10–3.
Statistical analysis – Serum C-peptide concentrations were measured and
clearance was calculated using commercially available software. 9 Statistical analysis was
performed according to a randomized blocked design, blocked on horse. Serum Cpeptide concentrations measured before, and during the first 90 min of the somatostatin
CRI were averaged for each horse and compared using mixed model analysis of variance
(one-tailed test). Mixed model analysis of variance with repeated measures was used to
compare C-peptide concentrations measured before and after dextrose administration

8

Coat-A-Count insulin, Siemens Medical Solutions Diagnostics, 5210 Pacific Concourse Dr., Los Angeles,
CA 90045-6900 (formerly: Diagnostics Products Co.)
9
WinNonlin 5.1, Pharsight, Mountain View, CA
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using statistical software. 10

During the FSIGTT, C-peptide-to-insulin ratios were

averaged in each horse for the 3 baseline samples and for samples obtained between 1
and 19 min (n = 13 samples) and subsequently compared using mixed model analysis of
variance.

No comparisons were made after the 19 min time point because of the

confounding effect of exogenous insulin. Square root or log transformation was used to
correct for non-normally distributed data.

Significance was defined at a value of P <

0.05.

4.3

Results:
Experimental procedures remained well tolerated throughout the study with no

abnormalities registered during daily physical examinations.

Evaluation of baseline

insulin concentrations and insulin sensitivity (SI) values revealed that one horse included
in the study suffered from IR. The mean resting insulin concentration for this horse was
58.3 μU/mL and mean SI was determined to be 0.23 × 10–4 L•min-1•mU-1. Data from this
horse were therefore handled separately.
Mean ± SD percent O:E ratio for the 6 serially diluted samples was 119 ± 25%
(Table 4.1) and parallelism was observed. Observed-to-expected spike and recovery
ratios for 6 samples with 3 spiking concentrations ranged from 112 to 136% with a mean
± SD of 123.09 ± 8.02% (Table 4.2).
Due to malfunction of the intravenous fluid pump, delivery of somatostatin failed
in one horse, so mean C-peptide clearance rate was calculated using data obtained from
four horses. Mean ± SD ir-C-peptide HE concentration measured before (0.23 ± 0.12
pmol/mL) and during the first 90 min (0.11 ± 0.06 pmol/mL) of the somatostatin CRI
differed significantly (P = 0.030; one-tailed test). Mean ir-C-peptide HE concentration
(2.96 ± 0.67 pmol/mL) peaked 1 min after intravenous administration of 50 nmol
biosynthetic human C-peptide and remained significantly (P = 0.003 at 50 min) elevated
for 50 min (Figure 4.1) relative to baseline. Mean ± SD clearance rate of ir-C-peptide
HE was calculated to be 1.74 ± 0.74 mL/min/kg bwt.
10

PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC.
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Table 4.1 – Dilutional parallelism of human equivalents of immunoreactive C-peptide as
measured in six different equine serum samples using a human double antibody Cpeptide radioimmunoassay kit.
Observed

Expected

(ng/mL)

(ng/mL)

1 in 1
1 in 2
1 in 4
1 in 8

0.9
0.41
0.26
0.11

NA
0.45
0.23
0.11

NA
91 %
116 %
97 %

B

1 in 1
1 in 2
1 in 4
1 in 8

1.47
0.71
0.47
0.11

NA
0.73
0.37
0.18

NA
98 %
128 %
60 %

C

1 in 1
1 in 2
1 in 4
1 in 8

0.78
0.42
0.30
0.14

NA
0.39
0.19
0.10

NA
108 %
153 %
146 %

D

1 in 1
1 in 2
1 in 4
1 in 8

1.37
0.75
0.45
0.24

NA
0.69
0.34
0.17

NA
109 %
132 %
141 %

E

1 in 1
1 in 2
1 in 4
1 in 8

1.23
0.69
0.34
0.17

NA
0.61
0.31
0.15

NA
112 %
111 %
113 %

F

1 in 1
1 in 2
1 in 4
1 in 8

1.29
0.77
0.45
0.25

NA
0.65
0.32
0.16

NA
119 %
139 %
161 %

Sample

Dilution

A

O/E %

O/E = ratio of observed (O) concentration to expected (E) concentration
NA = not applicable
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Table 4.2 – Recovery of human equivalents of immunoreactive C-peptide as measured
from six different equine serum samples spiked with biosynthetic human C-peptide using
a human double antibody C-peptide radioimmunoassay kit.
Spiking
Sample

concentration
(ng/mL)

Observed

Expected

(ng/mL)

(ng/mL)

O/E %

A

0
195.2
71.2
21.8

0.9
14.2
6.0
2.5

NA
10.6
4.4
2.0

NA
134 %
136 %
128 %

B

0
195.2
71.2
21.8

1.5
12.6
5.8
2.8

NA
12.0
5.0
2.5

NA
113 %
117 %
112 %

C

0
195.2
71.2
21.8

0.8
13.2
5.6
2.3

NA
10.5
4.3
1.8

NA
125 %
131 %
124 %

D

0
195.2
71.2
21.8

1.4
14.0
6.2
2.7

NA
11.1
4.9
2.4

NA
127 %
128 %
112 %

E

0
195.2
71.2
21.8

1.2
12.5
6.00
2.6

NA
10.9
4.7
2.3

NA
114 %
126 %
114 %

F

0
195.2
71.2
21.8

1.3
13.0
6.4
2.9

NA
11.0
4.8
2.3

NA
118 %
133 %
125 %

O/E = ratio of observed (O) concentration to expected (E) concentration
NA = not applicable
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Figure 4.1 – Mean ± SE concentration of human equivalents of immunoreactive Cpeptide in serum collected from horses (n = 4) after administration of 50 nmol
biosynthetic human C-peptide at 0 min. Endogenous C-peptide secretion was suppressed
by infusion of 500 μg biosynthetic human somatostatin at –90 min followed by 500 μg/h
for 330 min.
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Measurements of ir-C-peptide HE were successfully performed from blood
samples collected during the FSIGTT from all five horses. For 100 min after intravenous
glucose administration, ir-C-peptide HE concentrations remained significantly elevated
(P = 0.042 at 100 min) relative to baseline (Figure 4.2). Mean ± SD ir-C-peptide HE-toinsulin ratio was 3.6 ± 1.95 preceding glucose administration, and this ratio significantly
decreased (P = 0.004) to 1.03 ± 0.18 during the first 20 min following dextrose
administration (Figure 4.3).
In the horse with preexisting IR, the resting concentration (0.24 pmol/mL) and
clearance rate (1.62 mL/kg/min) of ir-C-peptide HE were both similar to those registered
in healthy horses. However, mean ir-C-peptide HE-to-insulin ratio values for the three
baseline samples and those from the first 20 min of the FSIGTT appeared to be lower
relative to healthy mares (0.66 ± 0.16 and 0.48 ± 0.09, respectively; Figure 4.4).

4.4

Discussion
Serum C-peptide concentrations were successfully measured in equine serum, and

the release of C-peptide and insulin from the pancreas were suppressed in horses by
intravenously administering somatostatin. This enabled determination of the C-peptide
clearance rate in horses. Administration of dextrose during the FSIGTT was associated
with higher concentrations of ir-C-peptide HE relative to baseline and a lower C-peptideto-insulin ratio.
Somatostatin is a peptide hormone that has two biologically active isoforms
somatostatin-14 and somatostatin-28 containing 14 and 28 amino acid, respectively
(Ludvigsen 2007). This peptide hormone is present in the brain, and is also secreted by
the enteroendocrine D cells and δ-cells of the pancreas. Pancreatic somatostatin secretion
is influenced by changes in blood glucose concentrations, and hormonal effects are
exerted in an autocrine or paracrine fashion through binding to one of five somatostatin
receptor subtypes (Low 2004). In mice, somatostatin receptor subtype 5 is responsible
for the inhibition of insulin secretion from the β-cells and somatostatin receptor subtype
2, present on the α-cells, is essential for inhibition of glucagon secretion (Low 2004). In
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Figure 4.2 – Mean ± SE concentrations of human equivalents of immunoreactive Cpeptide measured during the frequently sampled intravenous glucose tolerance test in 5
horses. Dextrose (300 mg/kg) was infused intravenously at time = 0 followed by 30
mU/kg insulin after 20 min
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Figure 4.3 – Mean ± SE concentrations of human equivalents of immunoreactive Cpeptide (solid squares) and insulin (open circles) as measured from three baseline
samples and samples collected during the first 19 min of the frequently sampled
intravenous glucose tolerance test in 5 horses.
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Figure 4.4 – Concentrations of human equivalents of immunoreactive C-peptide (solid
squares) and insulin (open circles) as measured from three baseline samples and samples
collected during the first 19 min of a frequently sampled intravenous glucose tolerance
test in a horse suffering from insulin resistance
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humans, however, somatostatin inhibits insulin secretion by binding to somatostatin
receptor subtype 2 (Low 2004).
Successful suppression of C-peptide secretion in horses was evident by the
significantly lower ir-C-peptide HE concentrations detected after initiation of the
somatostatin CRI. However, detection of trace amounts of ir-C-peptide HE during the
same period suggests that suppression was incomplete. These findings are consistent
with previous observations in humans, as intravenous administration of somatostatin, or
its analogue octreotide, resulted in only partial suppression of C-peptide release to 48%
and 27% of baseline concentrations, respectively (Hwu et al. 2001). In dogs, however,
an intravenous bolus of 50 μg somatostatin followed by a CRI of 800 ng/kg/min,
suppressed C-peptide concentrations below the detection limit of the assay (Polonsky et
al. 1983). Complications associated with somatostatin infusion such as gastrointestinal
discomfort, diarrhea or fainting observed in human subjects (Hwu et al. 2001) were not
detected in this study.
The resting mean ir-C-peptide HE concentration measured in this study (0.23 ±
0.12 pmol/mL) corresponds well with those reported previously for samples obtained
from the femoral artery (0.24 ± 0.04 pmol/mL) and hepatic vein (0.33 ± 0.06 pmol/mL)
of fasted dogs (Polonsky et al. 1983) or from fasted human subjects (range: 0.14 to 0.35
pmol/mL; Faber et al. 1978). Our results compare favorably with plasma C-peptide
concentrations of 0.18 pmol/mL and 0.64 ± 0.17 pmol/mL registered in one diabetic
Spanish Mustang and five healthy horses, respectively (Johnson et al. 2005).
Mean clearance rate for ir-C-peptide HE measured in this study (1.74 ± 0.74
mL/min/kg) was lower than the values of 4.4 mL/min/kg and 4.7 mL/min/kg detected in
healthy and diabetic human subjects, respectively (Faber et al. 1978), and an even higher
endogenous C-peptide metabolic clearance rate of 11.5 ± 0.8 mL/kg/min has been
detected in dogs (Polonsky et al. 1983). In humans, C-peptide is metabolized by the
kidney and partially excreted into the urine (Zavaroni et al. 1987). In the basal state,
renal C-peptide metabolism is characterized by a high fractional extraction of
approximately 26 % and very low urinary clearance of only 14 % (Zavaroni et al. 1987).
These values indicate that most of the C-peptide taken up by the kidneys is metabolized
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by renal tissues. Differences in kidney function may therefore explain the wide variation
in C-peptide clearance rate registered in different species.
Concentrations of ir-C-peptide HE increased and remained significantly higher
than baseline for 100 min during the FSIGTT. This observation was expected because
insulin and C-peptide are co-secreted from the pancreas in equimolar amounts, and
increased insulin concentrations are routinely demonstrated during the FSIGTT in horses
(Hoffman et al. 2003; Hovorka et al. 1998). Similar observations were made in dogs
during a 60 min intravenous glucose infusion, with elevated C-peptide and insulin
concentrations detected (Polonsky et al. 1983). When intravenous glucose tolerance tests
(IVGTT) are performed in humans, higher C-peptide concentrations are detected after
glucose infusion (Kjems et al. 2001).
Characteristic biphasic C-peptide secretion occurs in humans following glucose
infusion (Kjems et al. 2001), but this was not observed in this study. The most likely
explanation for this finding is that glucose concentrations are not sustained during the
FSIGTT in horses, so concentrations may not remain high enough to stimulate second
phase insulin secretion. It has been suggested that the second phase insulin secretion
requires the augmenting action of glucose (Henquin et al. 2002). Indeed, prolonged
elevation of glucose concentration during the hyperglycemic clamp facilitates clearer
determination of the second phase insulin response than the intravenous glucose tolerance
test (Caumo and Luzi 2004). For this reason, the hyperglycemic clamp is considered the
gold standard method for the assessment of biphasic insulin response in vivo (Caumo and
Luzi 2004).

Furthermore, tolbutamide is often administered to humans during the

IVGTT to trigger the insulin/ C-peptide response at t = 20 min (Kjems et al. 2001),
whereas only insulin is administered during the FSIGTT performed in horses (Hoffman et
al. 2003; Toth et al. 2008). Tolbutamide is a first generation sulfonylurea drug that
stimulates pancreatic insulin secretion (Krentz and Bailey 2005). Finally, the second
phase insulin/ C-peptide response may blend with the first phase in horses, resulting in a
secretory pattern similar to that demonstrated in mice (Henquin et al. 2002). In isolated
mouse pancreatic islets, second phase insulin response to glucose is flatter and lower than
the first phase (Henquin et al. 2002).
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One of the most intriguing findings of this study was the significant decrease in
C-peptide-to-insulin ratio from a baseline of 3.6 ± 1.9 to 1.0 ± 0.2 after dextrose
administration during the FSIGTT. Similar results have been obtained in human subjects
as the C-peptide-to-insulin molar ratio decreased from a fasting level of 5.0 to values
between 2.0 and 3.0 following β-cell stimulation (Faber et al. 1978). The authors of that
study hypothesized that the lower C-peptide-to-insulin ratio was due to the longer halflife of C-peptide. In dogs, the C-peptide-to-insulin molar ratio remained unchanged after
initiation of a glucose infusion lasting 60 min (Polonsky et al. 1983). One possible
explanation for this change in proportions is that hepatic insulin extraction decreases
following glucose challenge in horses, causing the peripheral blood C-peptide-to-insulin
ratio to approach 1:1 after stimulation of pancreatic β-cells. It is unlikely that increased
hepatic extraction of C-peptide contributes to the shift in ratio, since very little or no
hepatic C-peptide extraction has been demonstrated in dogs (Polonsky et al. 1983) or
humans (Polonsky et al. 1986). Reduced hepatic insulin extraction may be a normal
physiological response to dextrose infusion if it results in more insulin being left in
circulation to act on insulin-sensitive tissues that store glucose. Alternatively, renal
clearance of C-peptide might increase in response to dextrose, which would lower serum
concentrations and alter the C-peptide-to-insulin ratio. In human subjects, renal uptake,
renal clearance and fractional extraction of C-peptide markedly increased when elevated
plasma C-peptide concentrations were induced by the consumption of amino acids
(Zavaroni et al. 1987).
One interesting observation from this study was that a horse suffering from
preexisting insulin resistance exhibited a lower C-peptide-to-insulin ratio than that
registered in healthy horses, both during the resting period and following dextrose
administration. This difference was attributed to higher insulin concentrations because
C-peptide concentrations did not appear to be affected. These findings suggest that
higher concentrations of insulin detected in horses and ponies with IR are a consequence
of reduced insulin clearance rather than enhanced secretion (Hoffman et al. 2003; Toth et
al. 2008; Treiber et al. 2006b). However, caution must be exercised when interpreting
this result because data were only collected from a single insulin-resistant horse.
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One of the weaknesses of the study reported here is our inability to measure
equine specific C-peptide, due to the lack of a species-specific C-peptide RIA or
biosynthetic equine C-peptide. However, amino acid sequences of equine and human Cpeptide are homologous, differing only in seven residues (Wahren et al. 2000), which
suggests a high potential for cross reactivity. Another limiting factor of this study was
the small number of horses evaluated, which was compounded by the exclusion of one
horse because of pre-existing IR and malfunction of the infusion pump. Nevertheless,
detection of statistical significance was still possible.
Measurement of ir-C-peptide HE may provide an additional tool for the
assessment of glucose and insulin dynamics in horses, facilitating precise reconstruction
of the prehepatic insulin secretion profile. Evaluation of C-peptide concentration during
IVGTT has been used to accurately assess prehepatic insulin secretion in healthy subjects
and people suffering from type II diabetes (Kjems et al. 2000; Kjems et al. 2001). The
use of the C-peptide minimal modeling of the insulin modified IVGTT was also
demonstrated to correctly assess β-cell function in 15 healthy human subjects (Toffolo et
al. 1999).
Estimation of pancreatic insulin secretion is important in horses because
decreased insulin sensitivity and hyperinsulinemia have been associated with laminitis
(Bailey et al. 2007; Carter et al. 2009; Treiber et al. 2006b). Insulin concentrations
higher than 32 mU/L predict incipient pasture-associated laminitis in ponies before
exposure to pastures rich in non-structural carbohydrates (Carter et al. 2009).
Development

of

laminitis

in

ponies

undergoing

experimental

induction

of

hyperinsulinemia (1,036 ± 55 μU/mL) as euglycemia was being maintained provides
evidence that insulin plays a role in the pathogenesis of laminitis (Asplin et al. 2007b).
Insulin resistance, established from increased insulin concentrations via the proxy
measure, reciprocal of the square root of insulin, was one of the criteria used to identify
ponies suffering from prelaminitic metabolic syndrome; a condition associated with a 10fold increase in the incidence of pasture-associated laminitis (Treiber et al. 2006b). In
the same study, euglycemia was registered in all but 2 horses suffering from IR,
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indicating that increased insulin secretion managed to sustain insulin-mediated glucose
disposal in spite of the decreased insulin sensitivity (Treiber et al. 2006b).
Decompensation develops when increased pancreatic insulin secretion is unable
to offset reduced insulin sensitivity and hyperglycemia develops (Treiber et al. 2006b).
Increased expression of matrix metalloproteinases 2 and 9 has been described in horses
suffering from laminitis (Souza et al. 2006) and in endothelial cells and macrophages
exposed to high glucose concentrations (Death et al. 2003). These findings suggest that a
connection exists between the hyperglycemia associated with decompensation and
laminitis. Hence, accurate description of prehepatic insulin secretion based on peripheral
C-peptide concentration will likely enhance our understanding and treatment of IR and
comorbid conditions in horses.
In conclusion, we demonstrated that C-peptide can be detected and quantified in
equine serum using a double antibody human C-peptide RIA. Changes in the proportions
of ir-C-peptide HE and insulin were demonstrated in association with dextrose infusion
suggesting that hepatic insulin extraction may be influenced by changes in blood glucose
levels. Precise quantification of C-peptide concentration from equine serum along with
further studies investigating the relationship between serum C-peptide levels and
pancreatic insulin release are required to facilitate accurate evaluation of β-cell function
in horses. More insulin-resistant horses must be evaluated in the future to confirm or
refute our observation that higher insulin concentrations detected in one horse with IR
were a result of reduced insulin clearance rather than enhanced pancreatic secretion.
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CHAPTER 5
Effects of pretreatment with dexamethasone or levothyroxine
sodium on endotoxin-induced insulin resistance in horses
5.1

Introduction
Insulin resistance (IR) is a state in which normal concentrations of insulin fail to

elicit the expected physiologic response (Kahn 1978). Development of IR in horses has
previously been associated with endotoxemia (Toth et al. 2008; Vick et al. 2008), obesity
(Hoffman et al. 2003), pituitary pars intermedia dysfunction (PPID; Keen et al. 2004)
and dexamethasone administration (Tiley et al. 2007). The importance of decreased
insulin sensitivity (SI) is underscored by its purported role in the development of
laminitis (Asplin et al. 2007b; Bailey et al. 2008; Treiber et al. 2006b), osteochondrosis
(Pagan 2001) and decreased fertility (Sessions et al. 2004).
Previous studies have demonstrated that ponies predisposed to laminitis suffer
from decreased insulin sensitivity (Bailey et al. 2008; Treiber et al. 2006b). Treiber et al.
(2006b) showed that 25% of ponies with preexisting IR, but no clinical evidence of
laminitis in March developed clinical laminitis by May. The appearance of clinical
laminitis in these ponies coincided with a significantly higher starch content measured
within pasture grass in May relative to March (Treiber et al. 2006b).

Excessive

consumption of non-structural carbohydrates including starches can lead to rapid
fermentation within the equine hindgut causing intraluminal acidosis, Gram-negative
bacterial death, and increased intestinal permeability (Longland and Byrd 2006; Weiss et
al. 1998).

Studies specifically examining hindgut bacterial populations during the

development of carbohydrate-induced laminitis revealed that proliferation of bacteria
belonging to the Streptococcus bovis/equinus complex consistently preceded the
development of laminitis, implicating these specific microorganisms in the pathogenesis
of alimentary laminitis (Milinovich et al. 2007; Milinovich et al. 2006). Horses grazing
on pastures rich in soluble carbohydrate may therefore develop laminitis as a result of
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intestinal events caused by carbohydrate overload, exacerbation of preexisting IR, or both
problems occurring concurrently.
Endotoxin is a heat stable lipopolysaccharide (LPS) found in the outer membrane
of Gram-negative bacteria, which is released upon bacterial death and during bacterial
multiplication (Rietschel et al. 1994). Under physiological circumstances, only a small
amount of endotoxin enters the bloodstream, and it is subsequently removed by the
Kupffer cells of the liver (Hardie and Kruse-Elliott 1990a).

Clinically apparent

endotoxemia develops when the liver is unable to clear all of the circulating endotoxin, or
when excessive amounts of endotoxin enter the blood (Hardie and Kruse-Elliott 1990a;
Morris 1991). In horses, endotoxemia most commonly results from compromise of the
gastrointestinal mucosal barrier, which allows endotoxin to move from the intestinal
lumen to the bloodstream (Morris 1991). Other conditions associated with endotoxemia
include Gram-negative bacteremia, pleuropneumonia, and metritis (Morris 1991;
Werners et al. 2005).
Endotoxemia may contribute to the development of laminitis in horses. Elevated
endotoxin concentrations were detected in 85% of horses developing Obel Grade 3
laminitis after experimental carbohydrate overload (Sprouse et al. 1987). In a previous
study, we demonstrated that transient IR develops after LPS administration (Toth et al.
2008), which leads to the hypothesis that endotoxin-induced alterations in glucose and
insulin dynamics contribute to the development of laminitis in horses. It has also been
recognized that hospitalized horses suffering from endotoxemia have 5 times the odds of
developing laminitis than horses with no evidence of endotoxemia (Parsons et al. 2007).
This finding supports the role of endotoxemia in the development of laminitis and also
raises the question of whether stress induced by stall confinement (Harewood 2005; Mal
1991) increases the risk of disease.
Chronic IR in pastured ponies and stress associated with hospitalization are preexisting factors that may exacerbate the reduction in insulin sensitivity induced by
endotoxemia. If this is the case, ponies and horses affected by these conditions may
undergo exaggerated responses to endotoxin that lower insulin sensitivity even further
and raise the likelihood of laminitis. This may enhance the negative impact of minor
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intestinal events occurring in grazing ponies if endotoxemia develops in these animals.
We therefore hypothesized that differences in resting insulin sensitivity affect the
magnitude of changes in glucose and insulin dynamics induced by endotoxin
administration.
Dexamethasone (DEX) and levothyroxine sodium (L-T4) treatments were
administered to alter resting insulin sensitivity prior to endotoxin administration in this
study. It has previously been demonstrated that SI decreases when DEX is administered
to horses (Tiley et al. 2007). Insulin sensitivity significantly decreased in healthy adult
horses when DEX was administered orally at a dosage of 0.08 mg/kg, IV, q 48h for 21
days (Tiley et al. 2007). In contrast, we have previously shown that SI increases in
healthy adult mares treated with L-T4 for 8 or 48 weeks (Frank et al. 2008; Frank et al.
2005b).

The mechanisms responsible for this improvement in SI have not been

determined in horses, but it may be the result of increased glucose transport through the
cell membrane in both intra and extrahepatic sites (Haber et al. 1995; Romero et al. 2000;
Weinstein et al. 1994). Thyroid hormone has been shown to increase glucose transporter
4 (GLUT4) gene expression as well as translocation of glucose transporters to cell
membranes (Romero et al. 2000; Weinstein et al. 1994).

5.2

Materials and methods

Horses – Twenty-four adult mares from the University of Tennessee teaching and
research herd were included in the study. The study was performed over the course of
five months between September 2007 and January 2008. Horses were admitted to the
University of Tennessee Veterinary Teaching Hospital in groups of four and remained
hospitalized for 22 days. At the conclusion of the study, horses were returned to the
research herd. To eliminate differences attributable to gender only mares were selected.
Mean ± SD weight of horses upon admission was 519 ± 36 kg. The age of horses ranged
from 5 to 16 years (mean ± SD: 10.4 ± 3.6 years) and breeds included Quarter horse (11),
Quarter horse / Tennessee Walking horse crossbred (10), Tennessee Walking Horse (1),
Standardbred (1) and Thoroughbred (1). Body condition scores (on a scale from 1 to 9)
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ranged from 4 to 6 (Henneke et al. 1983). The study protocol was approved by the
University of Tennessee Institutional Animal Care and Use Committee.
Experimental design – Using a completely randomized design, horses were assigned to
one of the three treatment groups, each containing eight horses. The treatment groups
included:
Control group (n = 8)

horses receiving 200g of oats and no other medications

L-T4 group (n = 8)

horses receiving 48 mg of L-T4 powder 1 mixed with 200g
of oats once daily

DEX group (n = 8)

horses were administered 20 mg dexamethasone 2 (2
mg/mL solution) orally using a syringe and 200g of oats
once daily

Horses were weighed and physical examinations were performed on the first day (Friday)
of the study, then each horse was housed separately in 3.7-m X 3.7-m stalls within the
veterinary teaching hospital. Grass hay was fed in amounts equivalent to two percent of
body weight (bwt) and ad libitum water was provided, and each horse was acclimated to
its new environment for approximately 72h. On the fourth day of the study (Monday) a
14G intravenous catheter 3 was inserted into the left jugular vein and left in place for
approximately 24h. A baseline frequently sampled IV glucose tolerance test (FSIGTT)
was performed on the fifth day (Tuesday) starting at 9:00 AM.

Treatments were

administered each morning for 15 days, starting on the sixth day (Wednesday). On the
twentieth day (Wednesday) horses were weighed, and intravenous catheters were inserted
and left in place for approximately 48h. The post-treatment FSIGTT procedure was
performed on day 21 (Thursday) starting at 0900.

On this day, treatments were

administered at 1200, after completion of the FSIGTT. Additionally, at 1300 all horses
received an intravenous LPS infusion, and 20h later horses underwent the post-LPS
FSIGTT starting again at 0900 AM. Horses in the DEX and L-T4 groups received

1

Thyro L, Lloyd Inc, Shenandoah, IA
Dexamethasone, VetOne, Bimeda-MTC Animal Health Inc., Cambridge, ON, Canada
3
Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, IL.
2
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tapering doses of their respective treatments for another 6 days after the conclusion of the
study.
Lipopolysaccharide administration – Escherichia coli O55:B5 LPS 4 was mixed with
30 mL of sterile saline (0.9% NaCl) solution under a fume hood with the investigator
wearing gloves and a respirator to minimize exposure. The LPS solution (20 ng/kg) was
infused via the IV catheter during a 15-minute period. Horses were observed for signs of
colic and physical examination variables, including rectal temperature, heart rate,
respiratory rate, mucous membrane color, and capillary refill time were recorded every
30 min for the first 3h, then every hour for the following 3h, and then every 2h for 6h.
Complete blood count (CBC) analysis – To evaluate individual responses to endotoxin,
CBC analyses were performed in each horse. Blood was collected from the indwelling
jugular catheter into tubes containing EDTA before the LPS infusion was initiated and 2h
(ie, 1h 45 min after completing the LPS infusion).

Samples were immediately

transported to the clinical pathology laboratory for CBC analysis.
FSIGTT procedure – One day preceding the FSIGTT, a 14-gauge polypropylene
catheter was inserted into the left jugular vein. During tests, horses were allowed access
to grass hay and water. Patency of the IV catheter was maintained before the test by
infusion of 5 mL of saline solution containing heparin (4 U/mL) into the catheter every 6
hours. During the FSIGTT, an injection cap and infusion set 5 (length, 30 cm; internal
diameter, 0.014 cm) were attached to the catheter. The FSIGTT procedure first described
by Hoffman (Hoffman et al. 2003) and modified by our research group (Chapter 3) was
used. Briefly, a bolus (100 mg of glucose/kg) of a 50% (wt/vol) dextrose solution 6 was
administered to each horse via the infusion line and catheter, followed by injection of
saline solution containing heparin. Blood samples were collected via the catheter 10, 5
and 1 min before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of

4

Sigma Chemical Co., St Louis, MO
Butterfly, Abbott Laboratories, North Chicago, IL.
6
Dextrose 50% injection, Abbott Laboratories, North Chicago, IL.
5
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dextrose. At 20 min, regular insulin 7 (20 mU/kg) was administered followed by another
infusion of saline solution containing heparin.

Blood samples were subsequently

collected via the catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120,
150, and 180 min relative to the dextrose infusion. At each time point, 3 mL of blood
was withdrawn from the infusion line and discarded. A 6-mL blood sample was then
collected, followed by infusion of 5 mL of saline solution containing heparin. Half of the
volume of blood was transferred to a tube containing sodium heparin, which was
immediately cooled on ice and then refrigerated. The remaining blood was transferred to
a tube containing no anticoagulant. Those samples were allowed to clot at 22oC for 1h
and then serum was harvested via low-speed (1,000 × g) centrifugation. Plasma and
serum samples were stored at –20oC until further analyzed.
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations
were measured by use of a colorimetric assay 8 on an automated discrete analyzer. 9
Serum insulin concentrations were determined by use of a radioimmunoassay 10 that has
been validated for use in horses (Freestone et al. 1991). Each sample was assayed in
duplicate and intra-assay coefficients of variation < 5% or < 10% were required for
acceptance of glucose and insulin assay results, respectively.
Interpretation of FSIGTT data by use of the minimal model – Values of SI, glucose
effectiveness (Sg), acute insulin response to glucose (AIRg), and disposition index (DI)
were calculated for each FSIGTT in accordance with the minimal model (Bergman et al.
1981) by use of commercially available software 11,12 and previously described methods
(Hoffman et al. 2003). Disposition index was calculated via multiplication of AIRg by
SI.

7

Humulin R, Eli Lilly and Co, Indianapolis, IN.
Glucose, Roche Diagnostic Systems Inc, Somerville, NJ.
9
Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ.
10
Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, CA.
11
MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA.
12
Stata 9.2, Stata Corporation, College Station, TX.
8
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Statistical analysis – To evaluate the effects of LPS administration on physical
parameters and white blood cell (WBC) count, measurements obtained before and after
endotoxin administration were compared using mixed model analysis of variance. In
each horse, area under the curve for glucose (AUCg) and for insulin (AUCi) were
calculated for all three FSIGTT procedures (baseline, post-treatment and post-LPS) from
the glucose and insulin concentrations measured during the FSIGTT, by use of the
trapezoidal method and commercially available computer software. 13 To determine the
effects of treatments and time (baseline, post-treatment and post-LPS) on Sg, SI, AIRg,
DI, AUCi and AUCg mixed model analysis of variance was used. If data was nonnormally distributed or unequal variance was encountered, square root or log
transformation was applied. When a significant treatment × time effect was detected,
protected Least Significant Difference mean separation method was used. Significance
was defined at a value of P < 0.05.

5.3

Results
Mean ± SD body weight of horses receiving L-T4 (n = 8) decreased significantly

(P < 0.001) relative to baseline (528.9 ± 25.3 kg) by the end of the 15-day pretreatment
period (511 ± 28 kg), whereas mean body weight remained unchanged in the DEX and
control groups.
Mean ± SE baseline SI values did not differ significantly (P = 0.942) between
groups (Table 5.1), but one horse within the L-T4 group had a low baseline SI value
(0.59 ×10–4 L•min-1•mU-1) at the beginning of the study that was judged to be an outlier
(studentized residual of 2.14), so data from this animal were excluded from the analysis
of treatment and time effects on glucose and insulin dynamics.

Insulin sensitivity

significantly decreased (P < 0.001) over time in all groups across the 15-day pretreatment
period. Mean SI values decreased by 47%, 52%, and 78% relative to baseline for control,
L-T4 and DEX groups, respectively. A significant (P = 0.021) treatment × time effect
was detected; mean SI for the DEX group was significantly (P = 0.032) lower than
13

PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC
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control group by the end of the pretreatment period. Significant treatment × time effects
were also detected for AUCg (P = 0.001) and AUCi (P < 0.001).

Mean AUCg

significantly increased (P < 0.001) over time in the DEX group, but did not change in the
control (P = 0.626) and L-T4 (P = 0.878) groups relative to baseline. Mean AUCi
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Table 5.1 – Mean ± SD minimal model variables and AUCi and AUCg registered in
horses undergoing 15 days of control, levothyroxine sodium (L-T4) or dexamethasone
treatment followed by intravenous administration of 20 ng/kg LPS. Measurements were
taken on day 5 (after acclimation; baseline), before LPS administration (pre LPS) and 20h
after LPS infusion (post LPS). Respective treatments (control/L-T4/dexamethasone) were
also administered on day 21 preceding the LPS administration.
Treatment

SI
(L•min-1•mU-1)
× 10–4
Sg
(min-1)
× 10–2

AIRg
(mU•min•L-1)

DI
× 10-2

AUCi
(mU/mL•min)

AUCg
(g/dL•min)

Control
(n = 8)

L-T4
(n = 7)

Dexamethasone
(n = 8)

baseline

3.24 ± 1.7 a

3.48 ± 1.35a

3.34 ± 1.82a

Pre LPS

1.72 ± 1.25b

1.67 ± 1.16b,c

0.73 ± 0.63c,d

Post LPS

0.63 ± 0.59

1.48 ± 1.2

b,c,d

0.21 ± 0.23

2.02 ± 0.99

2.29 ± 1.36

2.68 ± 1.31

Pre LPS

2.48 ± 1.06

2.39 ± 1.12

1.65 ± 0.88

Post LPS

2.29 ± 1.7

1.41 ± 1.06

1.53 ± 0.98

baseline

516 ± 263

434 ± 162

416 ± 221

Pre LPS

664 ± 428

545 ± 191

884 ± 263

Post LPS

1190 ± 1150

712 ± 108

1635 ± 741

baseline

14.9 ± 9

14.6 ± 7.4

11.7 ± 4.1

Pre LPS

8.8 ± 4.1

7.9 ± 6

6.9 ± 6.9

Post LPS

5.5 ± 5.4

9.6 ± 6.7

2.4 ± 3.1

baseline

5.12 ± 1.33a,b

5.81 ± 2.3a,b,c

4.85 ± 1.85a

Pre LPS

10.2 ± 4.91c

9.1 ± 7.49a,b,c

23.23 ± 20.74d

d

0.288

0.099

0.103

26.9 ± 33.32

baseline

17.27 ± 0.94a,b,c

16.65 ± 1.52a

15.83 ± 1.02a

Pre LPS

16.92 ± 1.27a,b

16.77 ± 2.72a

19.57 ± 2.39c,d

19.87 ± 3.52

b,c,d

18.67 ± 2.63

< 0.001

e

Post LPS

d

9.61 ± 4.5

b,c

0.021

e

baseline

Post LPS
a-c

d,e

Trt × time
P

57.25 ± 47.35

0.001

e

22.43 ± 3.38

For variables with significant (P < 0.05) treatment × time effects, mean values with

different superscripts differ significantly, as determined by repeated measures ANOVA
and comparison of least squares means using Least Significant Difference adjustment.
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increased over this 15-day period in the control (P = 0.001) and DEX (P < 0.001) groups,
but remained unchanged in the L-T4 group (P = 0.153). No significant changes in Sg,
AIRg, or DI were detected.
All horses included in this study responded to LPS by exhibiting colic signs, and
leukopenia defined by a WBC count < 5.4 × 103 WBCs/µL (Smith 2002) that was
detected 2h after LPS administration (Table 5.2). One horse had a baseline WBC count
of 5.1 × 103 cells/µL which further decreased to 2.4 × 103 cells/µL following endotoxin
administration. Heart rate, respiratory rate and rectal temperature increased (P < 0.001)
and WBC count decreased (P < 0.001) in all treatment groups following LPS
administration. Horses in the DEX group had significantly higher maximal heart rates
after LPS administration than L-T4 (P < 0.001) and control (P = 0.006) group animals,
and maximal respiratory rates were higher in DEX group, compared with the control
group during the same period (P = 0.006).
Insulin sensitivity significantly decreased after LPS administration in control (P =
0.002) and DEX (P = 0.015) groups, but remained unaffected (P = 0.695) in the L-T4
group. Additionally, mean AUCi (P < 0.001) and AUCg (P < 0.001) values were
significantly higher in the DEX and control groups after LPS administration, compared
with values obtained beforehand (Figure 5.1 and 5.2). Mean AUCg increased (P =
0.016) over time in the L-T4 group, but AUCi remained unchanged (P = 0.329) relative to
values obtained before LPS administration.

Mean SI measured 20h after LPS

administration was significantly (P = 0.002) higher in the L-T4 group than the DEX
group, and there was a trend (P = 0.075) towards higher SI values in the L-T4 group
relative to control group. No significant treatment × time effects were detected for Sg,
AIRg, or DI.

5.4

Discussion
In the present study, SI decreased significantly across the 15-day pretreatment

period in all treatment groups, which was an unexpected finding. Possible explanations
for this finding include stress associated with hospitalization, changes in exercise, or
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Table 5.2 – Mean ± SD maximal heart rate (HR), maximal respiratory rate (RR),
maximal rectal temperature (T) and white blood cell (WBC) count measured in horses
undergoing 15 days of control, levothyroxine sodium (L-T4) or dexamethasone treatment,
followed by intravenous administration of 20 ng/kg LPS. Measurements of WBC were
performed on day 20 immediately before LPS administration (Pre LPS) and 2h after the
initiation of the LPS infusion (Post LPS). Physical examinations were performed on day
20 before LPS administration (Pre LPS) and within 12h after the initiation of the LPS
infusion (Post LPS).

Respective treatments (control/L-T4/dexamethasone) were also

administered on day 20 preceding the LPS administration.
Treatment

HR
bpm
RR
b/min
T
ºC
WBC
×103/μL
a-c

Control
(n = 8)

L-T4
(n = 8)

Dexamethasone
(n = 8)

Pre LPS

32.6 ± 7 a

38.8 ± 5.1 a

39.3 ± 5.2 a

Post LPS

64.3 ± 16.4 b

55 ± 6.8 b

79.8 ± 16.1 c

Pre LPS

17.6 ± 5.9 a

17.3 ± 3.5 a

17.5 ± 6.7 a

Post LPS

38 ± 7.1 b

53.3 ± 20.4 c,b

59.8 ± 16.2 c

Pre LPS

37.3 ± 0.3 a

37.4 ± 0.3 a

37.3 ± 0.3 a

Post LPS

38.6 ± 0.3 b

38.9 ± 0.4 b

39.2 ± 0.6 b

Pre LPS

7.26 ± 1.35 a

6.94 ± 0.71 a

7.38 ± 0.82 a

Post LPS

3.04 ± 0.89 b

3.03 ± 0.86 b

2.94 ± 0.90 b

For variables with significant (P < 0.05) treatment × time effects, mean values with

different superscripts differ significantly, as determined by ANOVA for repeated
measures and comparison of least squares mean values by use of a Least Significant
Difference adjustment.
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Figure 5.1 – Mean ± SE plasma glucose concentration during the FSIGTT in horses
undergoing 15 days of control (panel A), L-T4 (panel B) or dexamethasone (panel C)
treatment followed by intravenous administration of 20 ng/kg LPS.

Testing was

performed on day 5 at baseline (solid squares), day 21 before LPS administration (empty
circles), and on day 22 after LPS infusion (solid triangles).
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Figure 5.2 – Mean ± SE serum insulin concentration, during the FSIGTT in horses
undergoing 15 days of control (panel A), L-T4 (panel B) or dexamethasone (panel C)
treatment followed by intravenous administration of 20 ng/kg LPS.

Testing was

performed on day 5 at baseline (solid squares), day 21 before LPS administration (open
circles) and day 22 after LPS infusion (solid triangles).
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alterations in diet. At the end of the pretreatment period, the lowest mean SI value was
detected in the DEX group. Administration of LPS exacerbated IR causing an additional
71.2 % and 63.4 % decrease in SI in the DEX and control groups, respectively.
However, the degree of change did not differ between these groups, so our hypothesis
that resting insulin sensitivity influences the magnitude of endotoxin-induced IR was not
supported. Nevertheless, mean SI after LPS administration was less than 0.5 × 10–4
L•min-1•mU-1 in the DEX group, indicating an additive effect. In contrast to our
expectations, pretreatment with L-T4 did not increase SI, but did prevent endotoxininduced exacerbation of IR. After endotoxin infusion, horses receiving L-T4 treatment
had significantly higher SI values than horses undergoing dexamethasone treatment, and
there was a trend towards higher insulin sensitivity in the L-T4 group, when compared
with control results.
Two methods were used to evaluate glucose and insulin dynamics and estimate
insulin sensitivity. One of these methods was minimal model analysis, which partitions
glucose disposal into glucose- and insulin-mediated parts by fitting a nonlinear model to
data obtained from the FSIGTT (Kronfeld et al. 2005a). Although the repeatability of
this method was shown to be lower than the euglycemic-hyperinsulinemic clamp (EHC)
in one study (Pratt et al. 2005), this technique is preferred because it is technically
simpler and provides estimates of Sg, AIRg and DI as well as SI. The second method
involved calculation of area under the curve values for glucose and insulin concentrations
during the FSIGTT. It has previously been demonstrated that horses suffering from IR
have significantly higher AUCi and AUCg than their healthy counterparts (Frank et al.
2006).
Dexamethasone and L-T4 treatments alter insulin sensitivity in horses (Frank et al.
2008; Frank et al. 2005b; Tiley et al. 2007). In a previous study, insulin sensitivity
significantly increased when horses were treated with L-T4 for 8 weeks. These changes
were paralleled by significant decreases in plasma triglyceride, total cholesterol and very
low density lipoprotein concentrations (Frank et al. 2005b). When the duration of L-T4
treatment was extended to 48 weeks, increased insulin sensitivity persisted throughout the
study and was accompanied by significant weight loss (Frank et al. 2008).

It is
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speculated that SI improves in response to L-T4 treatment because weight loss in induced,
but thyroid hormones may also exert direct effects on glucose uptake (Frank et al. 2008).
However, SI did not increase across the 15-day pretreatment period in the study reported
here. On the contrary, insulin sensitivity was significantly lower by the end of the 15d
pretreatment period. Since identical changes were noted in the control group, it was
assumed that insulin sensitivity decreased because of factors common to all treatment
groups.
Before enrollment in the study, horses were kept on pasture without additional
feed provided. During the study however, horses were moved into stalls, exercise was
restricted, and only grass hay was fed. It has previously been demonstrated that shortterm exercise training increases SI in both obese and lean horses (Powell et al. 2002), and
skeletal muscle GLUT4 content increases 2- to 3-fold after 6 weeks of exercise
(McCutcheon et al. 2002). Sedentary behavior is often implicated in the development of
IR in humans (Muoio and Newgard 2008), so this is one possible explanation for the
reduction in SI across the pretreatment period. Alternatively, stress associated with stall
confinement during hospitalization (Harewood 2005; Mal 1991) may have contributed to
the decrease in SI. It has been previously demonstrated that minor perturbations in
housing conditions, such as removal of a horse from its accustomed environment, are
sufficient to alter the normal circadian rhythm of cortisol concentrations, which would
raise total cortisol secretion across a 24-hour period (Irvine and Alexander 1994).
Mean insulin sensitivity significantly decreased to 0.73 ± 0.63 × 10–4 L•min-1•mU-1
in horses that received dexamethasone for 15d relative to baseline, which compares
favorably with the mean value of 0.53 ± 0.13 × 10–4 L•min-1•mU-1 detected in horses that
received 0.08 mg/kg bwt dexamethasone intravenously every other day for 21 days (Tiley
et al. 2007).

Dexamethasone induces IR by altering insulin signaling pathways in

adipocytes (Kawai et al. 2002) and skeletal muscle (Ruzzin et al. 2005) and liver (Saad et
al. 1993) tissues. Phosphorylation of phosphoinositol-3-kinase, a central molecule in
insulin signal transduction, significantly decreased in rat liver following dexamethasone
treatment (Saad et al. 1993).

In skeletal muscle, glucocorticoid-induced IR is

accompanied by reduced insulin-mediated phosphorylation of protein kinase B, which in
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turn leaves the enzyme glycogen synthase kinase-3 in its unphosphorylated active form.
Active glycogen synthase kinase-3 phosphorylates and thereby inactivates glycogen
synthase, which inhibits glycogen synthesis and contributes to the development of IR
(Ruzzin et al. 2005).

Protein kinase Cβ appears to play an important role in

glucocorticoid-induced IR in adipocytes (Kawai et al. 2002). In horses, treatment with
dexamethasone for 21 days impairs insulin-mediated phosphorylation of glycogen
synthase kinase-3 in skeletal muscle but does not alter the expression of GLUT4 or protein
kinase B, or affect insulin-stimulated phosphorylation of protein kinase B (Tiley et al.
2008).
All horses included in the study exhibited characteristic signs of endotoxemia after
LPS administration, including leukopenia, elevated rectal temperature, heart rate and
respiratory rate.

These findings are in agreement with previous observations of

endotoxemic horses (Barton et al. 2004; MacKay et al. 1999). It was surprising however,
that clinical signs of endotoxemia were not ameliorated by dexamethasone treatment. On
the contrary, horses in the DEX group had significantly higher heart and respiratory rates
than horses in the control group. It has previously been demonstrated that dexamethasone
pretreatment suppresses LPS-induced interleukin-1β and interleukin-6 responses in rats
(O'Connor et al. 2003). These mediators play a central role in the development of the
LPS-induced inflammatory reaction (Morris 1991). Nevertheless, the same study also
showed that exposure to an acute stressor preceding dexamethasone administration
eliminates the inhibitory effect of this drug on proinflammatory cytokine production and
release (O'Connor et al. 2003). In ponies, dexamethasone administration 5 min 3, 9 and
24h after endotoxin infusion did not prevent the endotoxin-induced reduction in WBC
count (Ewert et al. 1985).
In the study reported here, SI was lower twenty hours after LPS administration in
horses undergoing control and dexamethasone treatments, but remained unaffected in the
L-T4 group. Results of two independently conducted studies, including one performed by
our research group, have established that SI decreases in response to LPS infusion in
horses (Toth et al. 2008; Vick et al. 2008). In humans, assessment of glucose and insulin
dynamics in response to LPS revealed a biphasic response with an initial increase in
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glucose utilization followed by a progressive decrease in SI (Agwunobi et al. 2000).
Endotoxin-mediated IR involves hepatic, skeletal muscle and adipose tissues (McCowen et
al. 2001; Song et al. 2006). Lipopolysaccharide-induced activation of Toll-like receptor 4
in 3T3-L1 adipocytes stimulated the expression of inflammatory cytokines and provoked
IR (Song et al. 2006). In rats, sustained endotoxemia adversely affected the early steps of
the insulin signaling pathway by inhibiting tyrosine phosphorylation of the insulin receptor
substrate-1 molecule in skeletal muscle and hepatocytes (McCowen et al. 2001).
Both SI and AUCi remained unchanged 20h following LPS infusion in horses
receiving L-T4. This finding was attributed to the effects of thyroid hormone on glucose
transport at both hepatic and extrahepatic sites (Haber et al. 1995; Romero et al. 2000;
Weinstein et al. 1994). In 3T3-L1 adipocytes, treatment with tri-iodothyronine (T3) was
shown to increase GLUT1 and GLUT4 content and favor partitioning to plasma
membranes, which would facilitate transmembrane glucose transport into cells (Romero et
al. 2000). These changes were observed in both the presence and absence of insulin
(Romero et al. 2000). An in vivo study performed in rats treated with L-thyroxine yielded
similar results, demonstrating that insulin-stimulated glucose transport increased in
association with higher GLUT1 and GLUT4 content and functional activity (Matthaei et
al. 1995). Thyroid supplementation has been shown to increase both basal and insulinstimulated glucose uptake in skeletal muscle, with the change being proportional to the
increase in GLUT4 content (Weinstein et al. 1994). In liver-derived ARL-15 cells, T3
stimulates glucose transport by increasing GLUT1 content and enhancing its partition to
the cell surface (Haber et al. 1995).
In conclusion, results of this study indicate that thyroid supplementation protects
against endotoxin-induced IR when administered to horses for 15 days beforehand. It was
also demonstrated that horses receiving dexamethasone treatment developed exacerbated
IR following LPS administration, which may explain why hospitalized horses with
endotoxemia are more likely to develop laminitis. These animals may have higher cortisol
concentrations as a result of stress and confinement. Insulin sensitivity may also be lower
in these animals because exercise is restricted during hospitalization. It can also be
hypothesized that chronically insulin-resistant horses grazing on pasture experience minor
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intestinal events resulting in endotoxemia that exacerbates IR and contributes to the
development of laminitis. Although the single endotoxin dose used in this study was
sufficient to exacerbate IR, none of the treated horses developed laminitis. However, a
bolus infusion is only a crude approximation of the clinical condition because
endotoxemia is more severe and persists for longer in affected animals. Further studies are
required to explain why L-T4 treatment failed to prevent the decrease in SI that occurred
across the pretreatment period, yet protected horses against endotoxin-induced IR.
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CHAPTER 6
Effects of endotoxemia on the development of laminitis and
glucose and insulin dynamics in horses
6.1

Introduction
Endotoxemia, carbohydrate overload, and insulin resistance (IR) are important

risk factors for laminitis in horses and these conditions can occur concurrently (Garner et
al. 1975; Parsons et al. 2007; Treiber et al. 2006b; van Eps and Pollitt 2006). An
association between carbohydrate overload, endotoxemia, and laminitis was first
described by Sprouse et al. in 1987 (Sprouse et al. 1987). This group detected elevated
plasma endotoxin concentrations in 85% of horses that developed laminitis following
carbohydrate overload (Sprouse et al. 1987).

Alterations in the mucosal barrier,

occurring after carbohydrate overload may enable endotoxin absorption during the
prodromal stages of laminitis (Weiss et al. 1998). An association between endotoxemia
and IR has recently been established, based upon results of two independently conducted
studies in which endotoxemia was experimentally induced in healthy horses (Toth et al.
2008; Vick et al. 2008). Insulin sensitivity significantly decreased 24 h after intravenous
administration of exogenous endotoxin to healthy horses in both reports, suggesting that
this disturbance is a component of the systemic inflammatory response induced by
endotoxemia. Results of these studies suggest that intestinal carbohydrate overload leads
to endotoxemia, which induces IR. However, no studies have been performed to date to
determine whether pre-existing endotoxemia increases the likelihood or severity of
experimentally-induced laminitis in horses.
Endotoxemia frequently develops in horses suffering from gastrointestinal
disturbances, metritis, pleuropneumonia or Gram-negative sepsis (Morris 1991; Werners
et al. 2005). The absorption of lipopolysaccharide (LPS) into circulation is a prolonged
process in most clinical cases of endotoxemia, yet most experimental models involve the
administration of a single bolus infusion of LPS with dosages ranging from 0.02 μg/kg to
200 μg/kg (Barton et al. 2004; Bottoms et al. 1981; Doherty et al. 2003; Toth et al.
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2008). There are only few reports describing the administration of exogenous endotoxin
to horses as a continuous rate infusion (CRI) (Duncan et al. 1985; Kindahl et al. 1991;
MacKay et al. 1991). Infusion rates ranged from 0.03 μg/kg/h to 1 μg/kg/h in these
studies, resulting in cumulative doses that exceed the amount administered as a bolus
infusion in other studies. In humans, however, 100 times lower dosages of 0.75 ng/kg/h
LPS have been used to model low-grade inflammation (Taudorf et al. 2007). Lower LPS
dosages may therefore represent a model for endotoxemia associated with minor
intestinal events if they occur when horses and ponies are grazing on pasture grass rich in
soluble carbohydrate.
The association between pasture-associated laminitis and IR is supported by
results of a study by Treiber et al. (2006b).

This group demonstrated that ponies

suffering from prelaminitic metabolic syndrome, a condition characterized by lower
resting insulin sensitivity, have an odds ratio of 10 to develop clinical laminitis.
Laminitis became apparent in these ponies in the month of May when pasture grass
contained significantly more starch than in March (Treiber et al. 2006b). When starches
are abundant, the digestive capacity of the equine small intestine is exceeded and this
carbohydrate enters the hindgut and undergoes rapid bacterial fermentation, resulting in
the proliferation of lactic acid-producing bacteria, and a concomitant decrease in Gramnegative bacteria (Garner et al. 1978; Longland and Byrd 2006). Analysis of hindgut
bacterial populations during the development of carbohydrate-induced laminitis revealed
that bacteria belonging to the Streptococcus bovis/equinus complex, predominantly
Streptococcus lutetiensis (formerly known Streptococcus infantarius ssp. coli) proliferate
(Milinovich et al. 2007; Milinovich et al. 2006).

This alteration precedes the

development of lameness, which implicates these specific microorganisms in the
pathogenesis of alimentary laminitis. Additionally, damage to the intestinal mucosa,
triggered by high intraluminal levels of lactic acid and endotoxin, may compromise the
mucosal barrier, and thereby facilitate absorption of endotoxin (Garner et al. 1978). If
these intestinal events occur at a minor level, subclinical endotoxemia may contribute to
the development of clinical laminitis in horses and ponies grazing on pasture. This could
occur through exacerbation of preexisting IR or as a result of sustained inflammatory
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reaction (Toth et al. 2008). The significance of endotoxemia in the development of
laminitis has been further emphasized by the work of Parsons et al. (2007). This group
demonstrated that hospitalized horses suffering from clinical endotoxemia have 5-fold
higher odds of developing laminitis than horses without endotoxemia.
One method for experimentally inducing laminitis in horses involves the
administration of oligofructose (OF) at dosages ranging from 5 g/kg to 12.5 g/kg (French
and Pollitt 2004b; Kalck et al. in press; van Eps and Pollitt 2006). In this model, higher
OF dosages are associated with more severe laminitis and greater loss of
hemidesmosomes between the lamina densa of the basement membrane and the
epidermal basal cells (French and Pollitt 2004b). Development of laminitis in the OF
model is also associated with altered glucose and insulin dynamics (Kalck et al. in press;
van Eps and Pollitt 2006) as well as clinical signs suggestive of a systemic inflammatory
response (van Eps and Pollitt 2006).
It was therefore hypothesized that the IR associated with alimentary carbohydrate
overload would be significantly greater in horses pretreated with endotoxin, and that the
severity of laminitis would increase when endotoxin and OF treatments were combined.
Specific aims of this study were (1) to use low-dose endotoxin CRI as an experimental
model for minor intestinal events occurring in horses grazing on pasture, (2) to determine
whether LPS infusion alone induced IR and/or laminitis, and (3) to investigate whether
pre-treatment with LPS would accentuate IR and/or laminitis induced by intestinal
carbohydrate overload. An OF dosage of 5g/kg bwt was selected for this study because
our research group has recently determined that this dosage induces mild laminitis that
horses can successfully recover from (Kalck et al. in press)

6.2

Materials and methods

Horses – Twenty-four adult mares from the University of Tennessee research and
teaching herd were included in the study. Mean ± SD bodyweight (bwt) was 495 ± 43 kg
(range from 403 – 559 kg) with the body condition score ranging from 4 to 6 (Henneke et
al. 1983). Mean ± SD age of the horses were 11.2 ± 3.8 (range: 6 – 16); breeds included
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Quarter Horse/Tennessee Walking horse crossbred (n = 8), Quarter Horse (n = 11),
Tennessee Walking Horse (n = 4), and Thoroughbred (n = 1).
Experimental design – Procedures were performed between the months of January and
June 2008. Three treatments were compared using a completely randomized design with
eight repetitions (horses) per treatment. Treatment groups consisted of:
LPS group (n = 8)

Endotoxin CRI for 8h followed by administration of 4L
water via nasogastric intubation

OF group (n = 8)

Saline (0.9% NaCl) CRI for 8h followed by 5g/kg bwt OF
dissolved in 4L water

LPS/OF group (n = 8)

Endotoxin CRI followed by 5g/kg bwt OF dissolved in 4L
water.

Horses were brought into the teaching hospital in groups of three and one horse was
assigned to each treatment group. Each horse was individually housed in a 3.7-m ×3.7-m
stall and fed grass hay in amounts equivalent to 2% of bwt and ad libitum water.
Upon admission (Friday), horses were weighed and physical examinations were
performed. An intravenous catheter was inserted into the jugular vein 24h prior to the
baseline frequently sampled intravenous glucose tolerance test (FSIGTT). The baseline
FSIGTT was then performed at 0800 on day four (Monday). A CRI of either LPS or
0.9% NaCl solution was initiated at 0800 on day five (Tuesday) and continued until 1600.
At 0800 on day six (Wednesday; 16h after completion of the CRI), each horse received
either 5 g/kg OF dissolved in 4L of water or 4L water alone via nasogastric intubation. A
post-treatment FSIGTT was performed 24h later, starting at 0800 on day seven
(Thursday).

Horses were evaluated for the presence of laminitis for 48h after the

administration of water or OF using the Obel grading system (Taylor et al. 2002). Horses
that developed laminitis remained hospitalized and were treated with phenylbutazone
until clinical signs of laminitis resolved or euthanasia was performed. The study protocol
was approved by the University of Tennessee Institutional Animal Care and Use
Committee.
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Lipopolysaccharide administration – Escherichia coli O55:B5 LPS 1 was mixed with
1L 0.9% NaCl with the investigator wearing protective attire.

Lipopolysaccharide

solution was infused intravenously at a dosage of 7.5 ng/kg/h for 8h using an infusion
pump set at a rate of 100 mL/h. Horses enrolled in the OF group received 800 mL 0.9%
NaCl intravenously at the same rate. Horses were observed for signs of colic and
physical examination parameters were monitored, including rectal temperature, heart rate
and respiratory rate, for 72h after the initiation of the CRI. Data were recorded hourly
during the 8-hour CRI, then every 2h for 8h, and finally every 4h for 56h.
Oligofructose administration – Oligofructose 2 was administered to horses at a dosage
of 5 g/kg bwt.

Powder was mixed with 4L warm water until dissolved and then

administered via nasogastric intubation. Horses in the LPS group received 4L water
alone by the same route.
Complete blood count (CBC) analysis – To evaluate the individual response to
endotoxin, CBC analysis was performed in each horse on three occasions. Blood was
collected from the indwelling jugular catheter into tubes containing EDTA before the
CRI was initiated, 2 hours after initiation of the CRI, and finally at the end of the 8-hour
infusion. Samples were immediately transported to the clinical pathology laboratory
within the teaching hospital for CBC analysis.
FSIGTT procedure – A 14-gauge polypropylene catheter 3 was inserted into the left
jugular vein the day before procedures were initiated and an injection cap and infusion
set 4 (length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter during
each test. The FSIGTT first described by Hoffman (Hoffman et al. 2003) and further
refined by our research group (Chapter 4) was used. Briefly, a rapid (< 1 min) bolus
infusion (100 mg of glucose/kg) of 50% (wt/vol) dextrose solution 5 was administered to
1

Sigma Chemical Co., St Louis, MO,
Orafti P95 BENEO-Orafti Inc. 2740 Route 10 West, Morris Plains, NJ 07950
3
Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, IL.
4
Butterfly, Abbott Laboratories, North Chicago, IL.
5
Dextrose 50% injection, Abbott Laboratories, North Chicago, IL.
2
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each horse via the infusion line and catheter, followed by 20 mL infusion of saline
solution containing heparin (4 U/mL).

Blood samples were then collected via the

catheter 10, 5, and 1 min prior to, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after
infusion of dextrose. At 20 min, regular insulin 6 (20 mU/kg) was infused, followed by
another infusion of 20 mL saline solution containing heparin. Blood samples were
subsequently collected via the catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90,
100, 120, 150, and 180 min relative to the dextrose bolus infusion. At each time point, 3
mL of blood was withdrawn from the infusion line and discarded. A 6 mL blood sample
was then collected, followed by infusion of 5 mL of saline solution containing heparin.
Half of the volume of blood was transferred to a tube containing sodium heparin, which
was immediately cooled on ice and then refrigerated.

The remaining blood was

transferred to a tube containing no anticoagulant. These samples were allowed to clot at
22oC for 1h and then serum was harvested via low-speed (1,000 × g) centrifugation.
Plasma and serum samples were stored at –20oC until further analyzed.
Laminitis scoring – Obel grading was performed as previously described (Taylor et al.
2002) and horses were assessed before LPS or saline was infused intravenously on day
four. Obel grades were also determined every 4h for 56h after OF or water was
administered. Horses that developed laminitis were subsequently monitored every 12h
until lameness resolved (n = 6) or euthanasia was performed (n = 1).
Phenylbutazone administration – Treatment for laminitis was initiated as soon as Obel
grade ≥ 2 laminitis was detected. Phenylbutazone 7 was administered at an initial dosage
of 4.4 mg/kg IV or PO q12h.

The dosage was then gradually reduced over time,

according to the response shown by each individual horse.
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations
were measured by use of a colorimetric assay 8 on an automated discrete analyzer 9.
6

Humulin R, Eli Lilly and Co, Indianapolis, IN.
Equi-Phar, Vedco, Inc., St. Joseph, MO.
8
Glucose, Roche Diagnostic Systems Inc, Somerville, NJ.
7
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Serum insulin concentrations were determined by use of a radioimmunoassay 10 that has
previously been validated for use in horses (Freestone et al. 1991). Each sample was
assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were
required for acceptance of glucose and insulin assay results, respectively.
Interpretation of FSIGTT data by use of the minimal model – Values of insulin
sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and
disposition index (DI) were calculated for each FSIGTT in accordance with the minimal
model (Bergman et al. 1981) by use of commercially available software 11,12 and
previously described methods (Hoffman et al. 2003). Disposition index was calculated
via multiplication of AIRg by SI.
Statistical analysis – White blood cell, neutrophil and lymphocyte counts obtained at 0,
2h, and 8h relative to the initiation of the LPS infusion were compared between horses
receiving endotoxin (LPS and LPS/OF) versus saline control (OF group) using a mixed
model analysis of variance with repeated measures. Heart rate, respiratory rate and rectal
temperature measurements were compared among treatment groups using mixed model
analysis of variance with repeated measures. Fisher’s Exact Test was used to evaluate
the relationship between development of laminitis and treatment groups. In each horse,
area under the curve for glucose (AUCg) and for insulin (AUCi) were calculated for both
FSIGTT procedures (baseline, post-treatment) from the glucose and insulin
concentrations measured, by use of the trapezoidal method, using commercially available
computer software. 13 To determine the effects of treatments and time (baseline, posttreatment) on Sg, SI, AIRg, DI, AUCi and AUCg mixed model analysis of variance with
repeated measures was used. Two outliers, an SI value with a studentized residual of
4.79 and an AIRg value with a studentized residual of 3.22, were eliminated from the
final analysis. When a significant treatment × time effect was detected, protected Least
9

Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ.
Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, CA.
11
MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA.
12
Stata 9.2, Stata Corporation, College Station, TX.
13
PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC
10
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Significant Difference mean separation method was used to compare groups at different
time points. Significance was defined at a value of P < 0.05.

6.3

Results
Horses that received LPS exhibited signs of abdominal pain, including pawing,

stretching and occasional attempts to roll during the first 4h of the LPS infusion.
Transient diarrhea was noted 16 to 24h following OF administration when horses
received this treatment. At the initiation of the study, none of the horses exhibited signs
of laminitis (Obel grade 0). Laminitis developed in 7 horses 28 to 36h following OF
administration and all affected animals recovered after treatment with phenylbutazone,
with one exception. This horse from the LPS/OF group developed Obel grade 4 laminitis
and remained lame despite treatment with phenylbutazone. Euthanasia was performed
and pathological examination revealed marked rotation of the third phalanx in all four
feet, compatible with severe laminitis.
Significant time × treatment effects (P < 0.001) were registered for WBC,
neutrophil, and lymphocyte counts (Table 6.1 and Figure 6.1). Two hours following the
initiation of the LPS infusion, neutrophil, WBC and lymphocyte counts significantly
decreased in LPS and LPS/OF groups relative to baseline values, and compared to horses
receiving 0.9 % NaCl treatment (OF group). Neutrophil and WBC counts significantly
increased whereas lymphocyte counts further decreased 8 h following the commencement
of the LPS infusion in LPS and LPS/OF groups, relative to baseline or control (OF group)
values.
With respect to physical examination findings, significant treatment × time effects
were registered for rectal temperature (P < 0.001), heart rate (P < 0.001) and respiratory
rate (P = 0.004). A biphasic response for rectal temperature and heart rate was observed
in horses from the LPS/OF group, with peaks apparent approximately 2 to 8h after
commencement of the LPS infusion and again 24h after nasogastric intubation with OF.
Single peaks were observed approximately 2 to 8h after the initiation of the LPS infusion
and at 24 h after OF administration in the LPS and OF groups, respectively (Figure 6.2).
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Table 6.1 – Mean ± SD white blood cell, neutrophil, and lymphocyte counts registered
at 0, 2 and 8 h relative to the initiation of an 8-hour lipopolysaccharide (LPS and LPS/OF
groups) or saline (OF group) continuous rate infusion.
Treatment

WBC
(× 103/µL)

Neutrophils
(× 103/µL)

Lymphocytes
(× 103/µL)

a-c

LPS and LPS/OF
(n = 16)

OF
(n = 8)

0h

7.32 ± 1.35 a

6.98 ± 1.60 a

2h

3.05 ±1.18 b

7.28 ± 1.81 a

8h

8.81 ± 2.30 c

7.20 ± 1.48 a

0h

4.24 ± 1.26 a

4.02 ± 1.01 a

2h

1.54 ± 1.00 b

4.17 ± 1.41 a

8h

7.89 ± 2.34 c

4.09 ± 1.07 a

0h

2.68 ± 0.59 a

2.50 ± 0.84 a

2h

1.39 ± 0.36 b

2.63 ± 0.87 a

8h

0.80 ± 0.39 c

2.66 ± 0.78 a

Treatment
× time
P

< 0.001

< 0.001

< 0.001

For variables with significant (P < 0.05) treatment × time effects, mean values with

different superscripts differ significantly, as determined by ANOVA for repeated
measures and comparison of least squares mean values by use of a Least Significant
Difference adjustment.
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Figure 6.1 – Mean ± SE white blood cell (panel A), neutrophil (panel B), and
lymphocyte (panel C) counts registered at 0, 2 and 8 h relative to initiation of the LPS
(open columns; LPS and LPS/OF groups) or saline (solid columns; OF group) continuous
rate infusion. Columns with different superscripts differ significantly at the P < 0.05
level.
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Figure 6.2 – Mean rectal temperature (panel A), heart rate (panel B) and respiratory rate
(panel C) registered in horses receiving lipopolysaccharide (LPS; solid squares),
oligofructose (OF; open circles), or LPS followed by OF (open triangles).
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Mean ± SD Obel laminitis grade was zero, 0.4 ± 0.7, and 1.7 ± 1.5 for LPS, OF
and LPS/OF groups, respectively. Laminitis was not observed in the LPS group. Two
horses in the OF group developed Obel grade 1 (n = 1) or 2 (n = 1) laminitis and five
horses in the LPS/OF group developed Obel grade 2 (n = 2), 2.5 (n = 1), 3 (n = 1), and 4
(n = 1) laminitis. The Fisher’s exact test revealed a significant (P = 0.021) association
between treatment groups and development of Obel grade > 2 laminitis with 0, 12.5 and
62.5 % of horses developing Obel grade > 2 laminitis of in LPS, OF and LPS/OF groups,
respectively. Individual comparisons between treatment groups using the Fisher’s exact
test demonstrated that horses in the LPS/OF group were significantly (P = 0.013; onetailed test) more likely to develop laminitis of Obel grade > 2 than horses in the LPS
group. A trend (P = 0.060; one-tailed test) towards increased likelihood of developing
laminitis of Obel grade > 2 in horses receiving both LPS and OF versus OF alone was
also detected. It was noted that 4 of 5 cases of laminitis registered in the LPS/OF group
occurred during the months of February and March, when horses were kept on pasture
and fed primarily hay in round bales.
Although post-treatment SI was significantly decreased over time compared to
baseline in LPS (P = 0.006), OF (P < 0.001), and LPS/OF (P = 0.018) groups, the
treatment × time effect was not statistically significant (P = 0.224; Table 6.2).
Conversely, a significant treatment × time effect (P = 0.037) was detected for AIRg, as
the pancreatic insulin response increased significantly over time in the LPS (P = 0.005)
and LPS/OF (P < 0.001) groups, but remained unchanged (P = 0.104) in the OF group.
Disposition index remained unchanged over time for LPS (P = 0.293) and LPS/OF (P =
0.160) groups, but significantly decreased after OF (P = 0.011) administration, which
resulted in a significant treatment × time effect (P = 0.022). No significant alterations in
Sg were registered.
Mean post-treatment AUCg and AUCi were significantly higher than pretreatment baseline values in all three groups. A significant treatment × time effect was
registered for AUCg (P < 0.001), but not AUCi (P = 0.093).
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Table 6.2 – Mean ± SD glucose and insulin variables values registered before (pre) and
after (post) treatment in horses from lipopolysaccharide (LPS), oligofructose (OF), and
LPS/OF groups.
Treatment

Treatment

SI
(L•min-1•mU-1)
× 10–4
Sg
(min-1)
× 10–2
AIRg
(mU•min•L-1)

DI
× 10-2

AUCi
(mU/mL•min)

AUCg
(g/dL•min)
a-c

Pre

× time

LPS

OF

LPS/OF

3.59 ± 1.62 a,b

5.1 ± 2.28 a

3.61 ± 2.09 a

c

c

1.31 ± 0.71

1.85 ± 2.15

P

b,c

Post

1.21 ± 0.93

Pre

2.44 ± 0.56

3.24 ± 1.59

2.1 ± 0.9

Post

2.09 ± 1.75

2.85 ± 1.45

2.85 ± 1.09

Pre

469 ± 316 a

490 ± 386 a,b

346 ± 114 a

0.224

0.320

b,c

861 ± 456

Pre

13.5 ± 4.8 a,b,c

18.6 ± 5.9 a,b

15.4 ± 9.8 a,b,c

Post

9.6 ± 7.0 b,c

8.2 ± 6.0 c

20.8 ± 18.2 a

6.29 ± 3.01 a,b,c 5.66 ± 2.64 a,b
d

Pre

16.00 ± 1.41 a 16.43 ± 1.40 a,b 16.18 ± 1.14 a

Post

18.25 ± 2.64

23.36 ± 2.67

8.11 ± 3.52

b,c

12.18 ± 3.80

d

0.038

0.023

4.46 ± 1.43 a

Post

b,c

8.04 ±3.08

c

1046 ± 602

c

Post

Pre

702 ± 449

a,b,c

19.92 ± 1.67

c

0.093

< 0.001

For variables with significant (P < 0.05) treatment × time effects, mean values with

different superscripts differ significantly, as determined by ANOVA for repeated
measures and comparison of least squares mean values by use of a Least Significant
Difference adjustment.
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6.4

Discussion
Administration of LPS, OF, or both treatments lowered insulin sensitivity, but the

magnitude of change did not differ between groups, so our hypothesis that pretreatment
with LPS would exacerbate the insulin resistance induced by OF was not supported.
Nevertheless, significant association between treatments and the incidence of Obel grade
> 2 laminitis was demonstrated, with the highest incidence of laminitis observed in the
LPS/OF group.

Results suggest that endotoxemia is an important determinant of

laminitis severity in the OF experimental model, but lipopolysaccharide does not induce
the condition when administered alone for 8h. Furthermore, physical examination and
complete blood count results indicate that continuous infusion of LPS at a rate of 7.5
ng/kg/h is sufficient to induce a systemic inflammatory response. This provides an
experimental model for systemic inflammation and results help to explain why
endotoxemia is an important risk factor for laminitis in horses.
Alterations in WBC, neutrophil, and lymphocyte counts were induced by
endotoxemia in this study. Previous studies investigating the effects of endotoxemia on
blood leukocytes in horses have yielded variable results (Kelmer et al. 2008; MacKay et
al. 1999; Morris et al. 1990). Intravenous administration of 30 ng/kg Escherichia coli
O55:B5 endotoxin significantly decreased the WBC count between 60 and 300 min after
endotoxin infusion (MacKay et al. 1999). Morris et al. (1990) used the same endotoxin
dosage and detected a significantly lower WBC count 1.5 and 2 h following endotoxin
infusion, with counts returning to baseline 2.5 to 8h after LPS administration. In the
study reported here, the initial leukopenia registered at 2 h was followed by a rebound
leukocytosis recorded at 8 h, with the WBC count significantly higher than baseline. The
rebound leukocytosis was most likely due to the significant increase in neutrophil count
registered 8 h after initiation of the LPS infusion. This latter finding is consistent with
results reported by Kelmer et al. (2008). This group detected a significantly higher mean
polymorphonuclear cell count 6h after 0.2 μg/kg LPS was administered intravenously to
horses. The higher neutrophil count detected 8h after initiation of the endotoxin CRI in
our study is likely to be a consequence of enhanced granulocyte production and release
from the bone marrow (Morris 1991).

This was likely to have been triggered by
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endotoxin-induced secretion of granulocyte colony stimulating factor, keratinocytederived chemokine, and macrophage inflammatory protein-2 (Morris 1991; Zhang et al.
2005). Elevated plasma cortisol concentrations have been detected in humans following
endotoxin administration and this would provide an explanation for the progressive
lymphopenia registered during the endotoxin CRI if the same alteration occurs in horses
(Richardson et al. 1989). Unfortunately, blood cortisol concentrations were not measured
in this study.
Alterations in physical examination parameters have previously been associated
with exogenous endotoxin administration in horses (Barton et al. 2004; Clark and Moore
1989; Kelmer et al. 2008; Moore et al. 2007). Administration of LPS to horses at
different dosages (20 to 200 ng/kg) significantly increased heart rate and rectal
temperature with peak values registered between 60 – 120 min and 120 – 180 min after
bolus infusion, respectively (Barton et al. 2004; Kelmer et al. 2008; Morris et al. 1990).
In horses, physical examination findings have also been significantly altered by OF
administration (Kalck et al. in press; van Eps and Pollitt 2006). Administration of 10g
OF/kg bwt significantly increased rectal temperature and heart rate, with the highest
values demonstrated at 20 and 32 h relative to OF administration (van Eps and Pollitt
2006). These findings correspond well with the alterations in physical examination
parameters detected in this study, and provide an explanation for the biphasic response
observed in horses receiving OF sixteen hours after completion of the LPS infusion
(LPS/OF group).
Endotoxemia has previously been shown to influence glucose and insulin
dynamics in horses. Our research group demonstrated that intravenous administration of
20 ng/kg Escherichia coli O55:B5 lipopolysaccharide significantly lowered SI and DI,
and raised AIRg when administered to healthy horses (Toth et al. 2008). Endotoxemiainduced IR has also been detected in horses by Vick et al. (2008). This group used the
euglycemic hyperinsulinemic clamp and showed that insulin sensitivity significantly
decreased 24h after the administration of 0.045 μg/kg LPS. These findings correspond
well with results of the current study, which also show that SI significantly decreased
from the baseline mean value of 3.59 × 10–4 L•min-1•mU-1 to the post-treatment value of
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1.21 × 10–4 L•min-1•mU-1 in horses receiving LPS. Additionally, the significantly higher
AUCg and AUCi detected in horses treated with LPS provides further evidence of
reduced insulin sensitivity.
It has previously been shown that administration of 7.5 to 12.5 mg/kg OF via
nasogastric intubation alters blood glucose and insulin concentrations in horses (van Eps
and Pollitt 2006). Nasogastric intubation with 10 g/kg OF significantly increased plasma
glucose concentrations from 12 to 48 h after its administration, relative to saline treated
controls. A similar trend was noted for serum insulin concentrations as well, although
significant differences were only registered at 12, 40, and 44h (van Eps and Pollitt 2006).
Results of a recent study performed by our research group indicate that intestinal
carbohydrate overload induced by OF significantly alters glucose dynamics in horses.
Higher AUCg values for the FSIGTT were detected 24 and 48 h after administration of 5
g OF/kg bwt, when compared with controls (Kalck et al. in press). Minimal model
analysis results from the same study indicated lower insulin sensitivity 24 and 48 h after
OF administration relative to controls, but this difference was not statistically significant
because of wide variability in results between and within horses.
In the study reported here, horses in the LPS, OF and LPS/OF groups
demonstrated a significant decrease in SI, accompanied by significant increases in AUCg
and AUCi. Changes in AUCg were greatest in horses receiving the OF treatment alone,
indicated by the significant time × treatment interaction. Consistent with these findings
Kalck et al (in press) also demonstrated that AUCg values increased 34 and 32% when
measured 24 and 48h, respectively after oral administration of 5g/kg OF to horses.
Higher AUCg values registered following OF administration are more likely to be a
consequence of decreased insulin sensitivity than fructan absorption from the small
intestine, because only a small amount of this carbohydrate is absorbed in the proximal
gastrointestinal tract of the horse (Bailey et al. 2007). Administration of LPS followed
by OF had no additive effect on SI or AUCi in this study and AUCg was more
profoundly affected when OF was administered alone. This suggests that prior exposure
to endotoxin reduces the effect of intestinal carbohydrate on glucose metabolism.
Development of early endotoxin tolerance, characteristic of repeated endotoxin exposure,
149

may explain the absence of an additive effect of LPS/OF treatment on glucose and insulin
dynamics. Higher maximum TNFα concentrations and earlier, more sustained serum
TNFα activity was detected following the first infusion when two endotoxin infusions
were administered to horses 24h apart (Allen et al. 1996), indicating that early phase
endotoxin tolerance develops in horses. Nevertheless, the biphasic response detected for
physical examination variables is not consistent with endotoxin tolerance. Alternatively,
LPS infusion alone may have maximally lowered SI in the LPS/OF group.
Increased AIRg successfully compensated for lower SI in horses receiving LPS
and LPS/OF treatments, as demonstrated by DI values being statistically the same before
and after treatment in these groups.

It is thought that pancreatic insulin secretion

increases to sustain insulin-mediated glucose disposal when insulin sensitivity decreases,
and this represents an efficient compensatory mechanism in the horse (Treiber et al.
2006b). In contrast, humans with IR more commonly develop pancreatic exhaustion in
association with type II diabetes mellitus (Brunton et al. 2006; Kaiser et al. 2003).
Equine pancreatic β-cells maintain high basal insulin concentrations and euglycemia,
which makes type II DM a rare condition in the horse (Treiber et al. 2005b).
Nevertheless, excessive compensation characterized by elevated circulating insulin
concentrations may be a precursor of metabolic disorders, such as laminitis (Treiber et al.
2005a). Horses in the OF group, however, suffered from uncompensated IR, as indicated
by the lower post-treatment mean DI value. Decompensation develops when increased
insulin secretion can no longer be sustained. Decompensated insulin resistance
characterized by hyperglycemia has been described in horses suffering from laminitis
(Treiber et al. 2006b).
In the study reported here, a significant association existed between treatment and
the incidence of laminitis, with 0 of 8, 1 of 8, and 5 of 8 horses developing Obel grade >
2 laminitis in the LPS, OF and LPS/OF groups, respectively. The highest incidence of
laminitis occurred in the LPS/OF group and this indicates that endotoxemia plays an
important role in the development of this condition. This finding is supported by the
previous observation that hospitalized horses suffering from clinical endotoxemia have an
odds ratio of five to develop laminitis (Parsons et al. 2007). Endotoxemia may contribute
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to the development of laminitis by inducing digital vasoconstriction mediated by 5hydroxytryptamine and thromboxane B2 (Menzies-Gow et al. 2004).

Alternatively,

endotoxemia may enhance cyclooxygenase-2 mRNA expression in vascular smooth
muscle cells (Rodgerson et al. 2001) or activate the coagulation cascade (Pernerstorfer et
al. 1999; Weiss et al. 1994). It has recently been shown that horses exhibit a strong
innate immune response during the developmental stages of laminitis, and a mixture of
innate and adaptive immune responses at the onset of lameness, which suggests that
lamellar inflammation plays an important role in laminitis (Belknap et al. 2007).
Although measurements of inflammatory cytokines were not performed in the study
reported here, clinical examination and CBC findings were suggestive of a systemic
inflammatory response following the lipopolysaccharide CRI and again after
administration of OF. These inflammatory responses provide a plausible explanation for
the high incidence of laminitis in horses that received LPS followed by OF.
Although endotoxemia has long been suspected to contribute to the development
of laminitis (Elliott and Bailey 2006) and LPS has been demonstrated in the blood of
horses subjected to carbohydrate overload to induce laminitis (Sprouse et al. 1987),
convincing evidence connecting these two conditions has been lacking. Therefore, the
ability of endotoxin pretreatment to increase the incidence of Obel grade ≥ 2 laminitis,
demonstrated in this study, is of great clinical importance. Our findings indicate that
endotoxemia associated with colitis, strangulating intestinal obstruction, metritis or
pleuropneumonia (MacKay 2001; Morris 1991) requires aggressive treatment in order to
prevent laminitis. Furthermore, if minor intestinal events occur in horses grazing on
pasture (Longland and Byrd 2006), they may result in subclinical endotoxemia that could
trigger laminitis. Ponies suffering from IR are predisposed to pasture-associated laminitis
(Carter et al. 2009; Treiber et al. 2006b), so endotoxin-mediated exacerbation of
preexisting IR may be an important trigger for laminitis when susceptible horses and
ponies are grazing on pasture. Lower insulin sensitivity associated with endotoxemia
(Toth et al. 2008; Vick et al. 2008) may contribute to the development of laminitis
through the induction of vasoconstriction (Kim et al. 2006) or activation of matrix
metalloproteinases (Treiber 2005).
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At the same time, it is important to note that none of the horses receiving the LPS
infusion as the only treatment (LPS group) developed laminitis. This finding is in
agreement with results of previous studies in which laminitis failed to develop after
experimental administration of endotoxin alone (Barton et al. 2004; Kelmer et al. 2008;
MacKay et al. 1999). Only one study reports the development of clinical signs consistent
with laminitis in 6 of 7 horses following endotoxin administration (Duncan et al. 1985).
This study by Duncan et al. (1985) involved 24-hour infusion of endotoxin into the portal
vein at a rate of 1 μg/kg/h.
Laminitis of Obel grade 1 or 2 developed in two horses from the OF group that
did not receive LPS beforehand. Nasogastric intubation with OF, using dosages ranging
from 5.0 to 12.5 g/kg has been successfully used to induce laminitis in previous studies
(Croser and Pollitt 2006; French and Pollitt 2004b; Kalck et al. in press; van Eps and
Pollitt 2006). Kalck et al. (in press) recently demonstrated that administration of 5 g/kg
OF induced clinically apparent laminitis in 3 of 8 horses, which corresponds well with
our findings.

A temporal progression of histopathologic changes consistent with

laminitis has previously been demonstrated when hoof biopsy samples were collected
every 6h for 36h following administration of 10 g/kg OF (Croser and Pollitt 2006).
Histopathologic examination of lamellar basal cells harvested from horses 48 h after
nasogastric intubation with 7.5, 10, and 12.5 g/kg OF revealed that the severity of
pathologic changes, including loss of hemidesmosomes, rounding of basal cell nuclei and
failure of the cytoskeleton, positively correlated with the OF dosage used (French and
Pollitt 2004b).

The authors hypothesized that OF administration induces laminitis

through activation of matrix metalloproteinases and glucose deprivation of basal cells
found within secondary epidermal lamellae (French and Pollitt 2004b). Nasogastric
intubation with 10 g/kg OF also induces profound changes in the hindgut bacterial
population by causing a shift from the predominantly Gram-negative flora to one
dominated by Gram-positive bacteria (Milinovich et al. 2006). Initial overgrowth of
bacteria belonging to the Streptococcus bovis/equinus complex, predominantly
Streptococcus lutetiensis followed by a rapid population decline were consistently
observed in horses developing laminitis after OF administration. These findings suggest
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the involvement of streptococci in the development of laminitis induced by OF overload
(Milinovich et al. 2007; Milinovich et al. 2006).
In this study, the incidence of laminitis decreased during the months of April and
May when pastures were growing rapidly.

It has been shown that the storage

carbohydrate content of pasture grass is highest during late spring (Longland and Byrd
2006; Treiber et al. 2006b), therefore adaptation of the intestinal flora to this higher
carbohydrate load may have prevented acute digestive disturbances associated with OF
administration.

Our results therefore indicate that horses are at greatest risk for

developing carbohydrate overload and laminitis when they are suddenly turned out on
pasture, instead of being gradually introduced to the new environment. Further studies
are required to determine whether adaptation to a high soluble carbohydrate diet helps
prevent laminitis induced by carbohydrate overload. For the purpose of the experimental
model, horses should be removed from pasture and fed grass hay for 4 weeks in order to
prevent adaptation.
In conclusion, findings of the study reported here indicate that endotoxemia is an
important determinant of laminitis severity. Laminitis developed in a greater number of
horses and was more severe when LPS was administered before induction of intestinal
carbohydrate overload. Results suggest that endotoxemia should be intensively managed
in horses suffering from colitis or strangulating obstructions to prevent the development
of laminitis. Minor intestinal events associated with grazing on pasture may also result in
endotoxemia, which would be expected to raise the risk of laminitis in pastured horses
and ponies.
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CHAPTER 7
General Summary and Future Directions
Studies reported here aimed to investigate glucose and insulin dynamics in horses
and their relationship to endotoxemia and laminitis.
Our results provide substantial evidence of an association between endotoxemia
and insulin resistance (IR) in horses. However, the specific alterations in insulin signal
transduction induced by endotoxemia must still be elucidated in the horse. Accurate
characterization of mediators involved in the development of endotoxin-mediated IR may
provide new targets for pharmacological interventions aimed to restore normal insulin
sensitivity. Results of our study examining the effects of resting insulin sensitivity on the
magnitude of IR induced by endotoxemia suggest that pretreatment with levothyroxine
sodium days prevents the reduction in insulin sensitivity triggered by endotoxemia.
Studies must be performed in the future to determine the minimal duration of treatment
required to achieve this protection and investigate the exact mechanisms responsible for
this protective effect.

This work may lead to the development of new drugs for

preventing or treating IR.
Our observation that endotoxemia predisposes horses to laminitis corresponds
well with clinical experience, and confirms findings previously reported in a retrospective
study (Parsons et al. 2007). Nevertheless, the pathophysiological mechanism by which
endotoxemia facilitates the development of laminitis must still be identified.

The

systemic inflammatory response triggered by endotoxemia and IR are likely to play
important roles in the development of laminitis (Belknap 2007; Treiber et al. 2006a).
Induction of IR using a model other than endotoxemia, such as lipid infusion (Sessions et
al. 2004) or dexamethasone administration (Tiley et al. 2007), followed by challenge
with 5 g/kg oligofructose would provide a practical method for assessing the role of
altered insulin sensitivity in the development of laminitis. If a higher incidence of
laminitis were demonstrated in horses with experimentally-induced IR, it would suggest
that reduced insulin sensitivity is an independent risk factor for laminitis in horses.
Furthermore, mitigation of endotoxin-induced IR by pretreatment of horses with
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levothyroxine sodium preceding oligofructose administration would be an alternative
method to evaluate the role of endotoxin-induced IR in laminitis development. Temporal
measurements of inflammatory mediators in lamellar tissues harvested from horses
suffering from clinical endotoxemia with and without laminitis and comparison of these
results with healthy horses would help to determine the role of the endotoxin-induced
inflammatory response in the development of laminitis.
Minimal model analysis has been used throughout these studies to interpret
frequently sampled intravenous glucose tolerance test (FSIGTT) data and to assess
glucose and insulin homeostasis.

This procedure was selected because it not only

estimates insulin sensitivity (SI), but also acute insulin response to glucose (AIRg),
glucose effectiveness (Sg) and disposition index (DI). Technical difficulties associated
with the euglycemic hyperinsulinemic clamp (EHC) also contributed to the selection of
the FSIGTT method. However, our studies also showed that minimal model analysis
increased variance, which reduced the likelihood of attaining statistical significance.
Thus, to further characterize glucose and insulin dynamics, area under the glucose
(AUCg) and insulin (AUCi) curves were calculated in two studies included in this thesis,
and between-horse variability was lower for these values. A study should be performed
in the future to investigate the relationship between area under the curve values and
minimal model analysis estimates using the statistical method of regression. Area under
the curve values alone or AUCg-to-AUCi ratios may provide an alternative method for
estimating insulin sensitivity in the future.
C-peptide-to-insulin ratios in horses undergoing the FSIGTT suggest that hepatic
insulin extraction decreases following dextrose challenge. Furthermore, the basal Cpeptide-to-insulin ratio appeared to be lower in a horse with IR, when compared with
horses with normal insulin sensitivity, and this ratio further decreased following dextrose
administration during the FSIGTT. This lower C-peptide-to-insulin ratio may indicate
that elevated resting insulin concentrations and higher AIRg values registered in horses
with IR are a result of reduced hepatic insulin extraction. Further studies are required to
compare C-peptide-to-insulin ratios in horses with IR to healthy control animals.
Comparing insulin and C-peptide concentrations in blood collected from the portal and
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jugular vein in normal and insulin resistant horses would also allow hepatic insulin
clearance to be quantified. Development and validation of an equine specific C-peptide
radioimmunoassay kit would provide more accurate measurement of C-peptide
concentrations and facilitate further evaluation of pancreatic function in horses.
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